WO 00/50639

Continued

8 of 12

troxy-5,11- nethyl-6H- ido[4,3- arbazolium mide	hydroxy-5,11- dimethyl-6H- pyrido[4,3- b]carbazolium bromide Marketed 8,8'- [carbonylbis[imino- 3,1- phenylenecarbonylimi no(4-methyl-3,1- phenylene)carbonyli

0.144110

onine; onine hloride; GD V V 63 fen dide; PA	(Talpha, 2alpha, 8beta, 8abeta)]-octahydro- 1,2,8-indolizinetriol 1 chrome-8-acetic acid		infection HIV infection;
ionine shloride; GD V			HIV infection;
03 fen dide; PA 635			HIV infection;
03 fen dide; PA 635			
fen dide; PA 635			cancer
dide; PA 635			Cancer
535			
			retinonother concern
tBCEU Preclinical	4-tert-butyl-[3-(2-		concernity, cancer
		•	calicel
	benzene		
TER 286 Preclinical			cancer
	glutamyl-3-[[2-		
	[[bis[bis(2-		
	chloroethyl)amino]ph		
	osphinyl]oxy]ethyl]su		
	lfonyl]-L-alanyl-2-		
	phenyl-glycine	-	

SD-14411

thaliblastine; taliblastine;	Phase III	[S-(R*,R*)]-9-[4,5-dimethoxv-2-	cancer
thalicarpine; (+)- thalicarpine: TBL:	-	[(1,2,3,4-tetrahydro-	
thalicarpin; NSC		methyl-1-	
68075		isoquinolinyl)methyl]	
		phenoxy]-5,6,6a,7-	
		tetrahydro-1,2,10-	
-		unnetnoxy-6-metnyi- 4H-	
		dibenzo[de,g]quinolin	
thrombopoietin	Discontinued		cancer.
mimetic, Axys			thrombocytonenia
TJ 14026	Discontinued		cancer
transforming growth	Preclinical		cancer
factor beta receptor			
inhibitors, Affymax			
triacetyluridine	Phase I		cancer
triciribine; NSC	Preclinical	1,5-dihydro-5-	HIV infection;
154020; TCN		methyl-1-beta-D-	cancer
		ribofuranosyl-	
		1,4,5,6,8-	
		pentaazaacenaphthyle	
TDIEENIC		n-3-amine	
INITEINS	Preclinical		diarrhea;
			gastrointestinal
			disorder; sickle cell
			anemia; cancer
79 11	Discontinued	5-fluoro-2'-	cancer
		deoxyuridine 5'-	
		tetradecylphosphate	

01.144110

	ſ		
tucaresol; BWA	Phase II	4-[(2-formyl-3-	sickle cell anemia;
BW 589C; 589C		nydroxypnenoxy)met hyl]benzoic acid	viral infection; HIV infection; cancer;
tumor suppressor genes, oncology, Onyx	Preclinical		cancer
tumor suppressor genes, Onyx	Preclinical		cancer
U 77863	Discontinued	trans-3-(2'- methylphenyl)-2-	cancer
		propene-1- carboxamide	
UBC 10 inhibitors,	Preclinical		cancer
UK 21	Preclinical	N-(1-0x0-2-	cancer
		propylpentyl)glycine triester with 5-	
V 489	Phase I	olimi moroni	100100
VA 5	ical	K-(7 S-	cancer
		o-(2,3- dimethoxyphenyl)- 2,3-	heart failure; cancer
		dihydroimidazo[2,1- b]thiazole	
ariolin B	Discontinued		cancer; viral
/Dacac	Preclinical		infection
	Declinical		cancer; contraception
observed by 19076			cancer; contraception
'elaresol; BW 12C/9; Suspended 2 C		5-(2-formyl-3-	cancer; sickle cell
7		nydroxyphenoxy)- pentanoic acid	anemia
/G 18563	Preclinical	-	anemia; cancer

SD-144110

	cancer	cancer						ancer	Cancer						cancer							cancer	cancer	cancer				cancer	Cancer	7101
	<u>ੱ</u>	j	<u> </u>						3 8						Ca	-						cai	Cal	Cal				Car	Car	
	-	N-[[1-[[2-	(diethylamino)ethyl]a	mino]-9-oxo-9H-	thioxanthen-4-	yl]methyl]-	methanesulfonamide		(+,-)-3-[4-[2-	(dimethylamino)-1-	methylethoxy]phenyl]	-1H-pyrazolo[3,4-	b]pyridine-1-acetic	acid	6-[4-[[5-(1H-	imidazol-1-	yl)pentyl]oxy]phenox	y]-2,2-	dimethylhexanoic	acid ethyl ester	monohydrochloride			N-[[4-[bis(2-	iodoethyl)amino]phen	oxy]carbonyl]-L-	glutamic acid		5,6-0-((RS)-	
Preclinical		Discontinued						Preclinical	Discontinued						Phase I							Preclinical	Preclinical	Phase I			7	Preclinical	Suspended	
vitamin B12 growth	blockers, Receptagen	WIN 33377						XK 469	Y 25510		-				YM.534						000 1111	r w 200		ZD 2767P				ZD 9063P	zilascorb; ZOXXOZ	

011771 03

zinostatin stimalamer; Marketed drug delivery system.	, Marketed	zinostatin stimalamer		cancer
neocarzinostatin;		-		
neocarzinostatin				
delivery system; YM			<u>-</u>	
7K 119010	Description			
	riecimical	2-(4-nydroxypnenyl)-		cancer
		D-incury 1-1-[0-(1- pyrrolidinyl)hexyl]-		
		1H-indol-5-ol		
ZYN 176	Suspended			Cancer
ZYN-LINKER	Preclinical			Cancer
conjugated				Carlock
thiocolchicine				
analogues			-	
epristeride; SKF	Discontinued	17beta-[[(1,1-	5 alpha reductase	benign prostate
7056 ONO 5/ cocor		dimethylethyl)amino] inhibitor	inhibitor	hypertrophy; cancer;
		carbonyl]androsta-		alopecia; acne
		3,5-diene-3-		
_				
^	Marketed		5 alpha reductase	cancer; benign
MIN USUO; Y M 152;			inhibitor	prostate
FROSCAK;		3-oxo-4-azaandrost-1-		hypertrophy;
FINASPROS;		ene-17-carboxamide		alopecia; acne
CHIBRO-				
FRUSCAK;				
FINASTID;	-			
PROSTIDE; EUTIZ;				-
PRODEL;				
PROPECIA				
1 23	Discontinued		5 alpha reductase	cancer; acne;
				nirsutism

A 63162	Preclinical	N-hydroxy-N-[1-[4- 5 lipoxygenase	5 lipoxygenase	cancer
-		(phenylmethoxy)phen inhibitor	inhibitor	
		yl]ethyl]acetamide		
masoprocol; CHX	Marketed		5 lipoxygenase	skin disease; cancer;
100; ACTINEX		dimethyl-1,4-	inhibitor	psoriasis
		butanediyl)bis-1,2-		
		benzenediol		
SC 41661A	Discontinued		5 lipoxygenase	cancer
KBR 8498	Preclinical	(1alpha, 2alpha, 4beta) 5HT agonist	5HT agonist	cancer
		4-[[2-(1-	:	
		piperazinyl)-4-		
		quinazolinyl]oxy]-1		
		,2-cyclopentanediol		
EF 7412	Preclinical	N-3-[4-[4-	5HT antagonist;	neurodegeneration;
	•	(tetrahydro-1,3-	5HT1A antagonist;	depression; cancer
			glutamate release	
		pyrrolo[1,2-	inhibitor	
		c]imidazol-2(3H)-		
		yl)butyl]-1-		
		piperazinyl]phenyl]et		
		hanesulfonamide		
adecypenol; OM 3223 Preclinical		5-(7,8-dihydro-8-	adenosine deaminase	cancer
		[4,5-	inhibitor	
	-	d][1,3]diazepin-	-	
	-	3(4H)-yl)-3-		
		(hydroxymethyl)-3-		
	-	cyclopentene-1,2-diol		
		A		

pentostatin; 2'-	Marketed	(R)-3-(2-deoxy-heta.	(R)-3-(2-deoxy-heta_ ladenosine deamings	
deoxycoformycin;		D-erythro-	inhibitor	calical
covidarabine; CI 825;	•••	pentofuranosyl)-		
81565: CI. 67310465	- .	3,4,7,8-		
YK 176; NIPENT; COFORIN		-d][1,3]diazepin-8-ol		
adenosine allosteric	Preclinical.			
modulators Medeo			auenosme regulating	cardiovascular
modarators, Micaco			agent	disease; cancer;
OCT 1003	Preclinical	3-nitrosobenzamide	ADPRT ligand	Suloke
OCT 1004	Preclinical	1	ADPRT ligand	cancer
6. 6				
fortenimex; forthenicinal: BE 121	Discontinued	mino-3-	hosphatase	bacterial infection;
re-prioritation, Dr. 121		Inydroxy-4-	inhibitor;	cancer
		(hydroxymethyl)benz immunostimulant	immunostimulant	
1				•
ambamustine; PTT	Phase III	,	alkylating agent	cancer
119; BLASIOF		nino]-		-
		N-(4-fluoro-L-		
		phenylalanyl)-L-		
		phenylalanyl]-L-		
	~	methionine, ethyl		
		ester		
	Preclinical	8	alkylating agent	cancer
77779;	Phase I			cancer
167C 0 15291		nino-		
		1H-indole-5,2-		
	•	diylcarbonyl)]bis[8-		
		(chloromethyl)-		
		3,6,7,8-tetrahydro-1-	-	
		methylbenzo[1,2-		
		0:4,3-b dipyrrol-4-ol		

alkylating agent cancer)	yl-5-)carbo	1,2-	-1]- [lút	-9	2-	oxami		Discontinued [4-[3-(2-chloroethyl)- alkylating agent cancer				₩W	-tyl-	ide	alkylating agent cancer		[2.2.1]		
N-[2-[[1-	(chloromethyl)-1,6-	dihydro-8-methyl-5-	[[(phenylamino)carbo	nyl]oxy]benzo[1,2-	b:4,3-b']dipyrrol-	3(2H)-yl]carbon	1H-indol-5-yl]-6-	(diethylamino)-2-	benzofurancarboxami	qe	4-[3-(2-chloroet	1-(benzyl)-2-	mazenyl]-1,4-	dioxobutyl-beta-	alanyl-tryptophyl-	methionyl-aspartyl-	phenylalaninamide	1,4-bis(2-	chloroethyl)-1,4-	diazoniabicyclo[2.2.1	heptane ((Z)-2-	Ly tomodia attended
Phase II		•				•					Discontinued			- -					.		,1	
carzelesin; U 80244 Phase II											CBS 5							DABIS maleate; NSC Preclinical	762666			

drug delivery system, Marketed	. Marketed		alkylating agent	
carmustine			The Street Comme	Calicol
biodegradable				
implant; drug delivery	_>			
system, sustained	 ,	· :		
release BCNU;			. -	
BIODEL BCNU				
implant; carmustine		2 2		
delivery system;		2000 2000 2000 2000 2000 2000 2000 200		
prolifeprosan 20,				
carmustine implant;		- : = -		
GLIADEL;				
GLIADEL WAFER				-
electrophilic	Preclinical		alkvlating agent	Canoer
alkylating agents			ant rains again	Calicei
BioNumerik				
EO 9; NSC 382459	Phase II	(E)-5-(1-aziridinyl)-3-alkylating agent	alkylating agent	cancer
		(hydroxymethyl)-2-	•	
		(3-hydroxy-1-		
		propenyl)-1-methyl-		
		1H-indole-4,7-dione		
estramustine analoguePhase II	Phase II		alkylating agent	cancer
famide; D	Phase I		alkylating agent	cancer
19575		H		
		odiamidate]-beta-D-		
		glucopyranose		-
glutathione S-	Discontinued		alkylating agent	cancer
transferase-activated				
toxins, Telik	÷			
isopropyl pyrrolizine derivative; IPP	Discontinued		alkylating agent	cancer
KF 22678	Preclinical		alkylatino agent	Concer
				valicei

SD-144110

mafosfamide; mefosfamide; ASTA Z 7557; NSC 345842; ASTA Z 7654; Z 7557	Discontinued	cis-(+,-)-2-[[2-[bis(2-alkylating agent chloroethyl)amino]tet rahydro-2H-1,3,2-oxazaphosporin-4-yl]thio]ethansulfonic acid P-oxide	alkylating agent	cancer
melphalan + A-MSH; Discontinued F1K	Discontinued		alkylating agent	cancer
melphalan + L-amino Preclinical oxidase	Preclinical		alkylating agent	cancer
OCX 177; OCX 0177 Preclinical	Preclinical		alkylating agent	cancer
porfiromycin;	Phase III	[1aS-	alkylating agent	cancer
porfiromycine; N-		a.a		
ENT 50825; NSC		ipna.,60.aipna.)]-0- amino-8-		
56410; U 14743;	٠	[[(aminocarbonyl)oxy	·	
PROMYCIN]methyl]-	-	
		1,1a,2,8,8a,8b-		
		hexahydro-8a-		
		methoxy-1,5-	:	
		dimethyl-		
		azirino[2',3':3,4]pyrro		
		lo[1,2-a]indole-4,7-		
SBR 11170; SBR 170 Preclinical			alkylating agent	cancer
temozolomide;	Marketed	3,4-dihydro-3-	alkylating agent	cancer
methazolastone; SCH		0[5,1-)	
52365; CCRG 81045;		d]-1,2,3,5-tetrazine-8-		
NSC 362856; M&B		carboxamide		
39831; TEMODAL				
treosulfan;	Marketed		alkylating agent	cancer
OVASTAT;		dimethanesulfonate		1
TITOSOFT VIA				

DNII 150540	101			
040601 011	rnase 1	(/S-cis)-9-acetyl-7-	alkylating agent; DNA cancer	cancer
		[[3-(1-aziridinyl)-	intercalator	•
		2,3,6-trideoxy-4-0-		
		(methylsulfonyl)-		
•		alpha-L-lyxo-		
		hexopyranosyl]oxy]-	-	
		7,8,9,10-tetrahydro-		
		6,9,11-trihydroxy-		
		5,12-		•
mitological.	N (1 . 4 . 3	naphthacenedione		
ninolacioi; bromoalcohol;	Marketed	1,6-dibromo-1,6- dideoxygalactitol	alkylating agent;	cancer
dibromodulcitol;				
DBD; NSC 104800; MITOL A CTOL:				
METHOI ACTOLE	- p			
ELOBROMOL				
bisaziridinylspermine; Preclinical	Preclinical		alkylating agent;	cancer
BAS			polyamine analogue	
	- -	nine		
dializiumyispermine; Precimical	Preclinical		alkylating agent;	cancer
JASPM		aziridinyl)propyl]-	polyamine analogue	
O6-benzylguanine	Phase I			
	1) Carrier 1		alkyliransierase	cancer
-			nunonor; chemosensitizer	
	Marketed	(OC-6-21)-[[[1,2-	Ä	cancer; pain;
exidronam; Sm 153-		ethanediylbis[nitrilobilradiotherapeutic		rhenmatoid arthritis
EDTMP; samarium		s(methylene)]tetrakis[
53-EDTMP;		phosphonato]](8-)-	-,	
samarium EDTMP;		N,N',OP,OP',OP",OP"	-	
CYI 424;]-samarate(5-)-	-	
KONDAME!		1535m		

abiraterone; piraterone; CB 7630;	Phase I	(3beta)-17-(3- pyridinyl)-androsta-	androgen synthesis inhibitor	cancer
CB /398		5,16-dien-3-ol		
cancer therapy,	Preclinical		androgen synthesis	cancer
Research			inhibitor	
cancer therapy,	Preclinical		androgen synthesis	cancer
Saarbrucken University			inhibitor	
GI 111924	Suspended		androgen synthesis	cancer
			inhibitor	
VN 851	Preclinical	÷	synthesis	cancer
			inhibitor	
VN 871	Preclinical		androgen synthesis	cancer
YM 116	Phase I	2-(1H-imidazol-4-	androgen synthesis	cancer
	•	ylmethyl)-9H-	inhibitor	
		carbazole	-	
YM 53789	Preclinical	2-(6,7-dihydro-5H-	androgen synthesis	cancer
		рупою[1,2-	inhibitor	
		c]imidazol-7-yl)-9H-		
20000		carbazole		
Y IM 55208	Preclinical	2-[1-(1H-imidazol-1- androgen synthesis yl)ethyl]-9H-:	androgen synthesis inhibitor	cancer
		carbazole	-	
rapy, cancer,	Preclinical		angiogenesis inducer;	cancer
Genetix			biotechnology; gene	
			therapy	
2-methyl-2-	Preclinical		angiogenesis inhibitor	cancer
phthalimidino-		-		
giutaric acid				

9alpha-	Preclinical	(6-alpha)-17-	angiogenesis inhibitor cancer	cancer
fluoromedroxyprogest	- 	(acetyloxy)-9-fluoro-		
erone acetate; FMPA		6-methyl-pregn-4-		
ANG 453; ZD 6126	Preclinical	210000000000000000000000000000000000000	angiogenesis inhibitor cancer	Cancer
angiogenesis	Preclinical		angiogenesis inhibitor cancer	cancer
inhibitor, Boston Life		-	migrofericals innivitor	calicel
Sciences				
	Phase I		angiogenesis inhibitor cancer	cancer
inhibitor, Merck				
KGaA; EMD 121974				
angiogenesis inhibitors,	Preclinical		angiogenesis inhibitor cancer	cancer
AstraZeneca				
angiogenesis inhibitors,	Preclinical		angiogenesis inhibitor cancer	cancer
Nanodesign				
angiogenesis inhibitors,	Preclinical		angiogenesis inhibitor cancer	cancer
Novartis/Schering AG				
angiogenesis	Preclinical		anoiogenesis inhibitor cancer retinocathu	Cancer retinonother
pligen			10110111111 11101101 1111101101	cancer, remopanis
CT 3577	Discontinued		angiogenesis inhibitor cancer	cancer
				Carroor

FCE 26644; PNU	Preclinical	7.7	angiogenesis inhibitor cancer	cancer
151484	-	[carbonylbis[imino(1-		
		methyl-1H-pyrrole-		
-		-7,4		
		diyl)carbonylimino(1-		
		4,2-		
		diyl)carbonylimino]]b		
		is-1,3-		
		naphthalenedisulfonic		
		acid tetrasodium salt		
FCE 27164; PNU	Preclinical	7,7'-	angiogenesis inhibitor cancer	cancer
165897		[carbonylbis[imino(1-		
		methyl-1H-pyrrole-		
-		4,2-		
	•	diyl)carbonylimino(1-		
		methyl-1H-pyrrole-		
		4,2-		
		diyl)carbonylimino]]b		
		is-1,3,5-		
-		naphthalenetrisulfonic		
		acid hexasodium salt		
gene discovery, tumor Preclinical epithelium	rPreclinical		angiogenesis inhibitor cancer	cancer
greenstatin	Preclinical		angiogenesis inhibitor cancer	cancer
irsogladine;	Marketed		angiogenesis inhibitor gastrointestinal	gastrointestinal
irsogladine maleate;		dichlorophenyl)-s-)	ulcer: cancer
isaglidole; MN 1695;		triazine		
GASLON;			2	
GASLON-N			-	-
RG 8803; RG	Preclinical		angiogenesis inhibitor	cancer
8803B11; RG 1009				

Sanalamine	Dhace I	12hate 5016 7016 240		
- <u>-</u>)-3-[[3-[(4-)-3-[[3-[(4-	viral infection; cancer; retinopathy
		aminobutyl)amino]pr		
		opyl]amino]cholestan e-7-24-diol 24-		
		(hydrogen sulfate)	٠	
SR 25989	Discontinued		angiogenesis inhibitor	cancer
SU 301	Discontinued		angiogenesis inhibitor cancer	cancer
SU 302	Discontinued		angiogenesis inhibitor cancer	cancer
suradista	Phase I		angiogenesis inhibitor	cancer
TAN 1120	Preclinical	8-acetyl-7,8,9,10-	_	cancer
		8,11-		
		trihydroxy-1-		
-		methoxy-10-		
		[[octahydro-5-		
		hydroxy-2-(2-		
		hydroxypropyl)-4,10-		
		dimethylpyrano[3,4-		
		d]-1,3,6-dioxazocin-		-
		8-yl]oxy]-5,12-		
T7 03	10000	парптпасепедіопе		
7/10	Discondinged		anglogenesis inhibitor	cancer
v E-cadnern-2	Preclinical		angiogenesis inhibitor k	cancer
antagonists, ImClone Systems				
VEGF receptor	Preclinical		angiogenesis inhihitor cancer	ancer
modulators,				
Pharmacopeia				
INGN 401	Preclinical		angiogenesis inhibitor; cancer	ancer
			antiproliferative agent	
soluble Tie-2	Preclinical		angiogenesis inhibitor; cancer	ancer
			olotechnology	

				i
angiogenesis inhibitor, Bio-	Preclinical		angiogenesis inhibitor; cancer	cancer
Technology General;			procedurology, populae	
plasminogen-related				
peptide Bio-				
gy General				
SU 6668	Phase I		angiogenesis inhibitor; cancer	cancer
			growth factor	
			modulator	
AE 941;	Phase III		angiogenesis inhibitor; cancer; psoriasis;	cancer; psoriasis;
NEOVASTAT;			NSAID	rheumatoid arthritis;
NEOKETNA;				eve disease:
PSOVASCAR;		•		retinopathy
ARTHROVAS				
FR 111142; WF	Discontinued	4,5-dihydroxy-2-	angiogenesis inhibitor; cancer; rheumatoid	cancer; rheumatoid
Z015A		hexenoic acid 5-	NSAID	arthritis; retinopathy
		methoxy-4-[2-methyl-		
		3-(3-methyl-2-	·	
		butenyl)oxiranyl]-1-		
•		oxaspiro[2.5]oct-6-yl		
		ester		
heparanase inhibitors, Preclinical InSight	Preclinical		angiogenesis inhibitor; cancer; inflammation	ancer; inflammation
ıge	Preclinical		angiogenesis inhibitor; cancer; rheumatoid	ancer; rheumatoid
			NSAID; biotechnologylarthritis: eve disease	urthritis: eve disease
nesis	Discontinued	-	angiogenesis inhibitor; cancer; restenosis	ancer; restenosis
ys			peptide	
XMP 300	Preclinical		angiogenesis inhibitor; inflammation; cancer	nflammation; cancer
			peptide	
ENDOSTATIN	Preclinical		angiogenesis inhibitor; cancer	ancer
			peptide; biotechnology	

thrombospondin 1	Preclinical		angiogenesis inhibitor. cancer. diagnosis.	cancer. diagnosis.
inhibitor, InKine;			platelet antiaggregant; thrombosis	thrombosis
TSP-1 inhibitor,			radiodiagnostic;	
Inkline			contrast medium	
tecogalan sodium; DS Phase I	Phase I	sulfated	angiogenesis inhibitor: cancer	cancer
4152; SP PG		polysaccharide	polysaccharide sulfate	
		peptidoglycan		
SU 5416	Phase II	3-[(4,5-dimethyl-1H-	3-[(4,5-dimethyl-1H- angiogenesis inhibitor; cancer	cancer
	-	pyrrol-2-	tyrosine kinase	
		yl)methylene]-1,3-	inhibitor; signal	
		dihydro-2H-indol-2-	transduction inhibitor	
1		OIIC		
rubiginone B1	Discontinued		angucyclinone;	cancer
aclarubicin;	Marketed	methyl(1R.2R.4S)-2-	ine.	recorder
aclambicin				
hydrochloride		,	antibiotic; DNA	
of of managers		nexanydro-2,5,7-	intercalator	
aciacinomycin A;		trihydroxy-6,11-		
NSC 208734; MA	-	dioxo-4-[[2,3,6-		
144A1; JACLACIN;		trideoxy-4-0-[2,6-	-	
ACLAPLASTIN;		dideoxy-4-0-		
ACLACINOMYCIN;		[(2R,6S)-tetrahydro-		
ACLACINON		6-methyl-5-oxo-2H-		
		pyran-2-yl]-alpha-L-		
		lyxo-hexopyranosyl]-		
		3-(dimethylamino)-		
		alpha-L-lyxo-hexo-		
		pyranosyl]oxy]-1-		
		naphthacenecarboxyla		
		te		

drug delivery system, Phase II	Phase II		anthracycline;	cancer
liposome		:	antibiotic: DNA	!
anthracycline;			intercalator	
anthracycline				
liposome; AR 522;			-	
ANNAMYCIN		: : :		
IT 62B	Discontinued		anthracycline;	cancer; bacterial
		· · · · · · · · · · · · · · · · · · ·	antibiotic; DNA	infection
SO 07501			Ilicicalator	
1XC/0.0c	Freclinical		anthracycline;	bacterial infection;
			antibiotic; DNA	cancer
			intercalator	
bisantrene; bisantrene Phase III	Phase III	bis[(4,5-dihydro-1H-	anthracycline: DNA	cancer
hydrochloride; CL			intercalator: antibiotic	
216942; NSC		yl)hydrazone]-9,10-		
337766; ADCA;	•	anthracenedicarhoxal		
CYABIN		dehyde		
daunoform	Preclinical		anthracycline; DNA	cancer
			intercalator; antibiotic	
doxotorm	Preclinical	- 3 %		cancer
			intercalator; antibiotic	
	Preclinical		anthracycline; DNA	cancer
micellar doxorubicin;			intercalator; antibiotic	
doxorubicin micelles				
epidoxoform	Preclinical		anthracycline; DNA	cancer
			intercalator; antibiotic	

100	1			
memorubicin; FCE	Phase II		anthracycline; DNA	cancer
23762		[8alfa,10alfa(R*)]]-	intercalator; antibiotic	
		7,8,9,10-tetrahydro-		
		6,8,11-trihydroxy-8-		
	-	(hydroxyacetyl)-1-		
		methoxy-10-[[2,3,6-		
		trideoxy-3-(2-	-	
		methoxy-4-morpho		
		linyl)-alfa-L-lyxo-		
		hexopyranosyl]oxy]-		
		5,12-		
		naphthacenedione		
ZYN 191	Suspended		anthracycline; DNA	cancer
			intercalator; antibiotic	
D 26232; AN 207	Preclinical	(2S-cis)-6-[N6-[5-[2 - anthracycline; DNA	anthracycline; DNA	cancer
		[1,2,3,4,6,11-	intercalator; antibiotic;	
		5,12-	gonadorelin agonist;	
		trihydroxy-7-	peptide	-
		methoxy-6,11-dioxo-		
		4-[[2,3,6-trideoxy-3-		
		(2,3-dihydro-1H-		
		pyrrol-1-yl)-alpha-L-		•
		lyxo-		
		hexopyranosyl]oxy]-		•
		2-naphthacenyl]-2-		
		oxoethoxy]-1,5-	.*	
		dioxopentyl]-D-		
		lysine]-luteinizing		• •
		hormone-releasing		
٠		factor (swine)		
AN 1006	Discontinued		anthraquinone	cancer

anthraquinone	Discontinued		anthraquinone;	cancer
prodrugs, De Montfort University			radiosensitizer	
antiandrogen.	Discontinued		the state of the s	
prostatic carcinoma			annanuogen	cancer
bicalutamide: Zeneca	Marketed	(+-)-N-[4-cyano 3	ontion dropes	
176334: ICI 176334·			annanden	penign prostate
CASODEX		(d.m.delensy)pnen yl]-3-[(4-		hypertrophy; cancer
		fluorophenyl)sulfony		
		l]-2-hydroxy-2-		
ICI 192779	Suspended		antiandrogen	Cancer
LGD 1331	Preclinical		antiandrogen	cancer; benign
			,	prostate
				hypertrophy; acne;
	•		,	alopecia
milutamide; KU 23908; RU 23908-10;	Marketed	5,5-dimethyl-3-[4-	antiandrogen	cancer
ANANDRON;		(trifluoromethy))phen		
NILANDRON		yl]-2,4-		
Т		ımıdazolidinedione		-
oj.			antiandrogen	benign prostate
acciale, 12F 4238; HIPROS	registration	chloro-2-oxapregna- 4.6-diene-3-20-dione		hypertrophy; cancer;
rone; WIN	Phase II	T	antiandrogen	benign prostate
49596		H		hypertrophy; cancer
		pregn-20-yno[3,2- c]pyrazol-17-ol		
albacarcin; virenomycin M, V	Discontinued		antibiotic	cancer

		Γ		
ankinomycin	Discontinued		antibiotic	caricer
		dideoxy-alfa-L-sorbo-		
		2,3-oxiranosyl)-11-		
		hydroxy-5-methyl-10-		
		[2,3,6-trideoxy-3-		
		(dimethylamino)-3-C-		
		methyl-alfa-L-lyxo-		
		hexopyranosyl]-4H-	_	
		anthra[1,2-b]pyran-		
		4,7,12-trione	-	
antibiotic, Sagami	Preclinical	-9"	antibiotic	cancer
		dideoxy-alpha-L-		
		lyxo-		
		hexopyranosyl)oxy]-	-	
		9-(fluoroacetyl)-		
•	•	7,8,9,10-tetrahydro-		
15		6,9,11-trihydroxy-		
		5,12-		
- 4		naphthacenedione		
anticancer, Chugai	Discontinued	3'-deoxytalopiericidin antibiotic	antibiotic	cancer
		A1 (DTPA)		
AT 2433A1	Discontinued	d ·	antibiotic	cancer
		[2,4-dideoxy-4-		
		(methylamino)-alpha-		
		D-threo-pento		
		pyranosyl]-4-0-		
		methyl-beta-D-		
_		glucopyranosyl]-		
		12,13-dihydro-6-5H-i		
		ndolo[2,3-		
		a]pyrrolo[3,4-	-	
		c]carbazole-5,7(6H)-		
		dione		

azamitosenes	Preclinical		antibiotic	Cancer
BE 124064		Т	o in the second	carrect
W00471 77	Discontinued		antibiotic	cancer
		mannopyranosyl)oxy]		
		-1-hydroxy-10-	<u>.</u>	
		methoxy-8-methyl-		
	·-	-Н9		
		benzo[d]naphtho[1,2-		
		b]pyran-6-one		
betaclamycin B; BCMA	Preclinical		antibiotic	cancer
CC 1065	Discontinued	(7bR)-7-[[1,6-	antibiotic	bacterial infection:
	•	dihydro-4-hydroxy-5-		Cancer
•		methoxy-7-[(4,5,8,8a-		100100
		tetrahydro-7-methyl-	-	
		4		
		oxocyclopropa[c]pyrr	a.	
		olo[3,2-e]indol-		
-		Z(1H)-		
		yl)carbonyl]benzo[1,2		
		-b:4,3-b']dopyrrol-		
		3(2H)-yl]cabonyl-1,6-		
		dihydro-4-hydroxy-5-		
		methoxybenzo[1,2-		
		b:4,3-b']dipyrrole-		
	- 1	3(2H)-carboxamide		
collismycin A; SF	Discontinued		antibiotic	cancer
Z/38A		(methylthio)-[2,2'-		
		bipyridine]-6-		
		carboxaldehyde		
		oxime		

antibiotic antibiotic	Disconti	nued	Discontinued (Z)-4-methoxy-5-	antibiotic	cancer
antibiotic L- antibiotic -L- 1-(E)- 2- 1-L- 1-L- 1-LLLLLLL-	(methy bipyrid carbox:	(methy bipyrid carbox	(methylthio)-[2,2'-bipyridine]-6-carboxaldehyde		
-L- antibiotic	Discontinued			antibiotic	cancer
-!-L- -!-CB)- -2- -!-L- -L- -L- -yl-L- steinyl- steinyl- clic	Discontinued N,N-di	N,N-di	.5		bacterial infection;
ucyl-L- lehydro-2- sutanoyl-L- wutanoyl-L- dro-2- wutanoyl-L- inyl-L- alanyl-L- alanyl-L- inylglycyl-L- wutanoyl-L-	didehy	didehy	dro-2-		calicel
L-alanyl-(E)- lehydro-2- utanoyl-L- dro-2- utanoyl-Lalanyl-L- alanyl-L- alanyl-L- inylglycyl-L- E)-2,3- tro-2- utanoyl-L- wtanoyl-L- wtanoyl-L- mide cyclic mide cyclic -sulfide	aminol	amino	outanoyl-L-		
lehydro-2- outanoyl-L- dro-2- utanoyl-L- alanyl-L- alanyl-L- inylglycyl-L- wtanoyl-L- inylglycyl-L-	prolyl-	prolyl-	L-alanyl-(E)-		
utanoyı-L- dro-2- wtanoyl-L- inyl-L- alanyl-L- alanyl-L- inylglycyl-L- mide cyclic sulfide	2,3-did	2,3-did	ehydro-2-		
E)-2,3- Iro-2- utanoyl-Lalanyl-L- lanyl-L- lanyl-L- unylglycyl-L- nylglycyl-L- utanoyl-L- utanoyl-L- utanoyl-L- in-Cysteinyl- i-N-(2- ioethenyl)-L- mide cyclic sulfide	aminob	aminob	utanoyl-L-		-
alanyl-L- alanyl-L- alanyl-L- alanyl-L-valyl- lcyl-L- nylglycyl-L- ntanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- sulfide	prolyl-(prolyl-(.	E)-2,3-		
-alanyl-L- nyl-L- lanyl-L-valyl- lcyl-L- nylglycyl-L- iro-2- utanoyl-L- vl-L-cysteinyl- l-N-(2- oethenyl)-L- mide cyclic	aminob	aminob	utanoyl-L-		
nyl-L- lanyl-L-valyl- cyl-L- nylglycyl-L- nylglycyl-L- stanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- itanoyl-L- sulfide	valyl-L-	valyl-L-	alanyl-L-		
llanyl-L-valyl- ucyl-L- nylglycyl-L- !)-2,3- tro-2- utanoyl-L- vl-L-cysteinyl- i-N-(2- mide cyclic sulfide	glutami	glutami	nyl-L-		
ucyl-L- nylglycyl-L- s)-2,3- Iro-2- utanoyl-L- vl-L-cysteinyl- toethenyl)-L- mide cyclic sulfide	phenyla	phenyla	nlanyl-L-valyl-		
nylglycyl-L- 3)-2,3- Iro-2- utanoyl-L- yl-L-cysteinyl- toethenyl)-L- mide cyclic -sulfide	L-isole	L-isole	ucyl-L-		
!)-2,3- lro-2- utanoyl-L- yl-L-cysteinyl- 1-N-(2- toethenyl)-L- mide cyclic	glutami	glutami	nylglycyl-L-	•	
utanoyl-L- vl-L-cysteinyl- i-N-(2- mide cyclic sulfide	seryl-(E	seryl-(E	3)-2,3-		
utanoyl-L- yl-L-cysteinyl- i-N-(2- toethenyl)-L- mide cyclic -sulfide	didehyo	didehyo	lro-2-		
yl-L-cysteinyl- 1-N-(2- toethenyl)-L- mide cyclic -sulfide	aminob	aminob	utanoyl-L-		
I-N-(2- oethenyl)-L- mide cyclic sulfide	isoleucy	isoleucy	/l-L-cysteinyl-		
toethenyl)-L- mide cyclic -sulfide	L-leucy	L-leucy	1-N-(2-	-	
mide cyclic)-sulfide	mercap	mercap	toethenyl)-L-		
-sulfide	leucina	leucina	mide cyclic		
	(19-21	(19-21)-sulfide		

...

dioxamycin; BE	Preclinical	Calfa 3alfa 4aalfa 907 antihiotic	antihiotic	Concer. bostorial
16493	-	R*,3S*[1E(2S*,4S*,5		infection
		S*),3E,5E],6R*],12ba		TO DO TO TO
		Ifa]-(+)-2,4-dimethyl-		
		5-[7-0xo-7-		
		[[tetrahydro-2-		
		methyl-6-		
		(1,2,3,4,4a,7,12,12b-		
		octahydro-		
		2,3,4a,8,12b-		
		pentahydroxy-3-		
		methyl-1,7,12-		
		trioxobenz[a]anthrace		
		n-9-yl)-2H-pyran-3-		
		yl]oxy]-1,3,5-		
***	•	heptatrienyl]-1,3-		
		dioxolane-2-		
		carboxylic acid		
eponemycin; BMY 28647; BU 3862T	Discontinued	()	antibiotic	cancer
		(h:-[1-		
		(II) di Oxymetinyi)-2-		
		-711-111		
		(hydroxymethyl)oxira		
		nyl]carbonyl]-3-		
		methyl-3-		
		butenyl]amino]-2-	•	
		oxoethyl]-6-		
		methylheptanamide		
epoxomicin	Discontinued	-	antibiotic	cancer

esperamicin A1; esperamycin; esperamcin; BMY 28175; BBM 1675A1; BBM 1675	(1R*,4Z,8S*,12S*,13 E)]-4,5-dimethoxy-2- [(2-methoxy-1-oxo-2- propenyl)amino]benz		
esperamycin; esperamcin; BMY 28175; BBM 1675A1; BBM 1675	E)]-4,5-dimethoxy-2- [(2-methoxy-1-oxo-2- propenyl)amino]benz		
esperamcin; BMY 28175; BBM 1675A1; BBM 1675	[(2-methoxy-1-oxo-2-propenyl)amino]benz		
28175; BBM 1675 1675A1; BBM 1675	propenyl)amino]benz		
1675A1; BBM 1675	oic acid 3'(12) ector		
	יייייייייייייייייייייייייייייייייייייי		
	with methyl [8-[[4,6-		
	dideoxy2-O-[2,4-		
	dideoxy-3-0-methyl-		
	4-[(1-		
	methylethyl)amino]-		
	alfa-L-		
	threopentopyranosyl]-	•	
	4-[[(2,6-dideoxy-4-S-		
	methyl-4-thio-beta-D-		
	ribo-		
	hexopyranosyl)oxy]a		
	mino]-beta-D-		
	glucopyranosyl]oxy]-		
-	12-[(2,6-dideoxy-alfa-		
	L-lyxo-	_	
	hexopyranosyl)oxy]-		
	1-hydroxy-13-[2-		
	(methyltrithio)ethylid		
	ene]-11-		
	oxobicyclo[7.3.1]tride		
	ca-4,9-diene-2,6-		
	diyn-10-yl]carbamate		

	(hexahydro-2,4,6-		
	trioxo-5-		
	pyrimidinyl)octahydr		
	0-2-(2-		
	hydroxypropyl)-4,10-	•	
	dimethylpyrano[3,4-		
	d]-1,3,6-dioxazocin-		
	8-yl]oxy]-6,8,11-		
	trihydroxy-1-		
	methoxy-5,12-	-	
	naphthacenedione		
FCE 24366 Preclinical	8-acetyl-10-[[5-	antibiotic	cancer
	(hexahydro-1,3-		
	dimethyl-2,4,6-trioxo-		
	. 5-		
	pyrimidinyl)octahydr	-	
	0-2-(2-		
	hydroxypropyl)-4,10-		
	dimethylpyrano[3,4-	-	
	d]-1,3,6-dioxazocin-		
	8-yl]oxy]-7,8,9,10-		
	tetrahydro-6,8,11-		
	trihydroxy-1-		
	methoxy-5,12-		
	naphthacenedione		

rce 2430/	Prec Inno			
	10011111001	8-acetyl-10-[[5-	antibiotic	cancer
		(hexahydro-4,6-		
		dioxo-2-thioxo-5-		
		pyrimidinyl)octahydr		
		0-2-(2-		
		hydroxypropy1)-4,10-		
•		dimethylpyrano[3,4-		
		d]-1,3,6-dioxazocin-		
		8-yl]oxy]-7,8,9,10-		
		tetrahydro-6,8,11-		-
		trihydroxy-1-	_ ·	-
		methoxy-5,12-		
	-	naphthacenedione	-	
	Phase I		antibiotic	cancer
bicin	Preclinical	10-[(3-amino-2,3,6-	antibiotic	cancer
hydrochloride	٠	trideoxy-alpha-L-		
		lyxo-		
· -		hexopyranosyl)oxy]-	٠	
		8-(fluoroacetyl)-		
		7,8,9,10-tetrahydro-		
		6,8,11-trihydroxy-1-		
		methoxy-5,12-		
		naphthacenedione		

hatomamicin. VI	Draginian	ron		
0358MA		[2alfa,3alfa,6alfa[1R* (S*),2Z,4E(1alfaS*,7 alfaR*)]]]-6-[[4-(2,3- dihydrocyclopent[b]o xireno[c]pyridin- 7(1aH)-ylidene)-1-(1- hydroxypropyl)-3- methyl-2- butenyl]oxy]tetrahydr o-2-methyl-2H-pyran-		cancer
himastatin; BMY 40800	Discontinued		antibiotic	bacterial infection;
hydramycin		[4S- (4alfa,4aalfa,5alfa,5aa lfa,6alfa,12aalfa)]-4- (dimethylamino)- 1,4,4a,5,5a,6,11,12a- octahydro- 3,5,10,12,12a- pentahydroxy-6- methyl-1,11-dioxo-2- naphthacenecarboxam ide	antibiotic	cancer; bacterial infection
K 818B	Discontinued		antibiotic	cancer
kedarcidin	Discontinued		antibiotic	bacterial infection; cancer
KT 5432	Discontinued		antibiotic	cancer

nisamycin; antibiotic Preclinical	Preclinical	[1S-	antibiotic	bacterial infection:
106B		[1alfa,2beta,2(2E,4E,		cancer
		6E),4(2E,4E),6alfa]]-		
	-	7-[4-[(5-cyclohexyl-		
		1-0xo-2,4-		
		pentadienyl)amino]-		
		2-hydroxy-5-oxo-7-		
		oxabicyclo[4.1.0]hept		
		-3-en-2-yl]-2,4,6-		-
		heptatrienoic acid		
oligomycin E; MCI	Discontinued	26-hydroxy-28-	antibiotic	cancer
2225		oxooligomycin A		
oxaunomycin; D 788; Preclinical	Preclinical		antibiotic	cancer
R 20X2		(7alfa,8beta,10beta)]-		
•		10-[(3-amino-2,3,6-		
		trideoxy-alfa-L-lyxo-		
	-	hexopyranosyl)oxy]-	-	
		8-ethyl-7,8,9,10-		
		tetrahydro-1,6,7,8,11-		
		pentahydroxy-5,12-		
		naphthacenedione		
phenazinomycin; (-)- Preclinical	Preclinical	(2,2-	antibiotic	bacterial infection;
phenazinomycin		dimethyl-6-		cancer
		methylenecyclohexyl)		
-		-3-methyl-2-pent		
		enyl]-1(5H)-		
		phenazinone		

pyrindamycin A	Discontinued	(2R-trans)-8-	antibiotic	cancer
		(chloromethyl)-		
		1,2,3,6,7,8-		
		hexahydro-4-		
		hydroxy-2-methyl-1-		
		oxo-6-[(5,6,7-		
		trimethoxy-1H-indol-		
		-2		
•		yl)carbonyl]benzo[1,2		
		-b:4,3-b']dipyrrole-2-		
		carboxylic acid,		
		methyl ester		
pyrindamycin B	Discontinued	,	antibiotic	cancer
		hexahydro-4-		
		hydroxy-2-methyl-1-		
		oxo-6-[(5,6,7-		
		trimethoxy-1H-indol-		
		2-yl)carbonyl]-1H-		
		pyrrolo[3,2-		
	-	f]quinoline-2-		
		carboxylic acid,		
		methyl ester		
saintopin	Discontinued 1,3,8,10,11-		antibiotic	bacterial infection;
•		pentahydroxy-5,12-		cancer
		naphthacenedione		

saptomycin D	Discontinued		antibiotic	cancer: bacterial
				infection
•		trideoxy-3-		
		(dimethylamino)-3-C-		
-		methyl-alfa-L-lyxo-		
		hexopyranosyl]-11-		
	-	hydroxy-5-methyl-2-		
		[2-methyl-3-(1-		
		propenyl)oxiranyl]-		
		4H-anthra[1,2-		
		b]pyran-4,7,12-trione		
SPM VIII	Discontinued	_	antibiotic	cancer
		oxododecyl)amino]ac		
		etyl]amino]-N-1H-		
		purin-6-yl-L-glycero-		
		beta-L-manno-		
		heptopyranosylamine		
tetrazomine; Y	Preclinical	3-hydroxy-N-	antibiotic	bacterial infection;
09194L-B		[2a,3,4,5,6,6a,7,11b-		cancer
		octahydro-5-		
		(hydroxymethyl)-11-		
		methoxy-12-methyl-		
		3,6-imino-1H-2-oxa-		
		11c-azanaphth[1,2,3-		
		cd]azulen-10-yl]-2-		
		piperidinecarboxamid		-
		9		
UCA 1064B	Discontinued		antibiotic	cancer
vicenistatin	Discontinued		antibiotic	cancer

Y 05460MA	Preclinical	4-amino-4,5,6-	antibiotic	bacterial infection:
		trideoxy-N-[1-(3,4-		cancer
		dihydro-8-hydroxy-		
		1H-2-benzopyran-3-		
		yl)-3-methylbutyl]-5- methylbeyonamide		
drug delivery system, Discontinued	Discontinued		antibiotic. olloulating	100
mitomycin;			amout, anyianng	calicer
mitomycin			0	
Therapeutic Implant; MPI 5016				
HMAF	Phase II	(R)-6'-hvdroxv-3'-	antihiotic: alkylating	20020
			agent temene	Califor
		trimethylspiro[cyclop		
		ropane-1,5'-		
		[5H]inden]-7'(6'H)-		
		one		
AGM 1470; TNP 470 Phase I	Phase II	[3R-[3alfa, 4alfa	antibiotic;	cancer
			angiogenesis inhibitor	
	-	6beta]]-5-methoxy-4-		
		[2-methyl-3-(3-		
		methyl-2-		
		butenyl)oxiranyl]-1-		
		oxaspiro[2.5]oct -6-y1		•
		cal Daniel avid		
		cinoloacetyl ester		

AD 143	Preclinical	hexanedioic acid (2S- antibiotic:	antibiotic:	cancer
		cis)-mono[2-	anthracycline; DNA	
		[1,2,3,4,6,11-	intercalator	
		hexahydro-2,5,12-		
		trihydroxy-7-		
		methoxy-6,11-dioxo-		
•		4-[[2,3,6-trideoxy-3-		
		[(trifluoroacetyl)amin		
		o]-alfa-L-lyxo-		
		hexopyranosyl]oxy]-		
		2-naphthacenyl]-2-		
		oxoethyl] ester		
AD 198	Preclinical	l	antibiotic;	cancer
		cis)-2-[1,2,3,4,6,11-	anthracycline; DNA	
			intercalator	-
			•	
	•	methoxy-6,11-dioxo-		
-		4-[[2,3,6-trideoxy-3-		
		[(phenylmethyl)amin	_	
		o]-alpha-L-lyxo-		
		hexopyranosyl]oxy]-		
		2-naphthacenyl]-2-	•.	
anthracycline	Discontinued		antibiotic:	cancer
analogue, BioChem			anthracycline; DNA	
Pharma			intercalator	
B 880308	Suspended	7-0-(3-N-methyl-3-N-antibiotic;	antibiotic;	cancer
	·	(R)-glycidyl-alpha-L- anthracycline; DNA	anthracycline; DNA	
		daunosaminyl)-beta- intercalator	intercalator	
		rhodomycinone	-	

drug delivery system,	Preclinical		antibiotic;	cancer
release doxorubicin:			anthracycline; DNA	
doxorubicin			miter calatel	
ATRIGEL				
drug delivery system,	Discontinued		antibiotic;	cancer
doxorubicin;		·	anthracycline; DNA	
doxorubicin drug			intercalator	
delivery system; AD				
70; ADM OXD; GC				
1004				
drug delivery system,	Discontinued		antibiotic;	cancer
doxorubicin;			anthracycline; DNA	
doxorubicin drug			intercalator	
delivery system				
stem,	Preclinical		antibiotic;	cancer
doxorubicin;			anthracycline; DNA	
doxorubicin-tumor			intercalator	
homing peptide;				
THP-doxorubicin				
drug delivery system,	Discontinued		antibiotic;	cancer
doxorubicin;			anthracycline; DNA	
doxorubicin			intercalator	
Therapeutic Implant;		-	-	
MPI 5015				-
tem,	Phase I		antibiotic;	cancer
HPMA polymer-	•		anthracycline: DNA	
bound doxorubicin;			intercalator	
doxorubicin HPMA	÷.	•		
polymer-bound; PK 1				

dense delivery meters handed	N Contrate d			
linosome	IMAINCICA		antiblotic;	cancer
damonibicin:			anuracycine; DNA	
dennotation,			Intercalator	
daulorubicin				
hposome; VS 103;	-		,	
DaunoXome				
drug delivery system,	Discontinued		antibiotic;	cancer
liposome			anthracycline: DNA	
doxorubicin;			intercalator	
doxorubicin				
liposome; DOXOME				-
drug delivery system, Pre-	Pre-		antibiotic;	cancer
liposome	registration		anthracycline: DNA	
doxorubicin;			intercalator	
doxorubicin				
liposome; TLC D99;				
TLC DOX 99; DOX				
99; EVACET;				
LIPODOX				
drug delivery system, Clinicals	Clinicals		antibiotic;	cancer
liposome			anthracycline; DNA	
doxorubicin;			intercalator	
doxorubicin liposome				
drug delivery system, Phase III	Phase III		antibiotic;	cancer
liposome			anthracycline; DNA	
doxorubicin;			intercalator	
doxorubicin liposome				
drug delivery system, Preclinical	Preclinical		antibiotic:	cancer
micellar doxorubicin;			anthracycline; DNA	
doxorubicin micelles			intercalator	
	3	-		

drug delivery system, Phase I	Phase I		antibiotic	Cancer
nanosphere			anthracycline: DNA	
doxorubicin;			intercalator	
doxorubicin			_	
nanosphere				
drug delivery system, Discontinued	Discontinued		antibiotic;	cancer
ONCHOLAB			anthracycline: DNA	
aclarubicin;			intercalator	
aclarubicin			-	
ONCHOLAB				
drug delivery system,	Discontinued		antibiotic	cancer
ONCHOLAB AD 32;			anthracycline: DNA	Tooling.
AD 32 ONCHOLAB			intercalator	
drug delivery system,	Marketed		antibiotic;	cancer
STEALTH liposome	_		anthracycline; DNA	
doxorubicin;	٠	<u>.</u>	intercalator	
doxorubicin				
STEALTH; DOXIL;				
DOX-SL; S-DOX;			F	
CAELYX				
drug delivery system, Preclinical	Preclinical		antibiotic;	cancer
tetrapeptide		-	anthracycline: DNA	
doxorubicin;			intercalator	
doxorubicin		 	<u>.</u>	
tetrapeptide; Super-		:		
Leu-Dox				

epirubicin;	Marketed	(8S-cis)-10-[(3-	antibiotic:	cancer
pidorubicin; 4'-epi-	·	amino-2,3,6-trideoxy-anthracycline; DNA	anthracycline; DNA	
doxorubicin; IMI 28;		alfa-L-arabino-	intercalator	
MSC 256942; FI		hexopyranosyl)oxy]-		
7701;		7,8,9,10-tetrahydro-		
PHARMORUBICIN;		6,8,11-trihydroxy-8-		
FARMORUBICIN;		(hydroxyacetyl)-1-		
FARMORUBICINE		methoxy-5,12-		
		naphthacenedione	-	
FCE 27726	Discontinued	,	antibiotic;	cancer
		[[3-[bis(2-	anthracycline; DNA	
		chloroethyl)amino]-	intercalator	
		2,3,6-trideoxy-4-O-		
		(methylsulfonyl)-		
		alpha-L-lyxo-		
		hexopyranosyl]oxy]-		
		7,8,9,10-tetrahydro-	<u></u>	
		6,9,11-trihydroxy-		
		5,12-		
•	-	naphthacenedione		_
galarubicin; DA 125	Phase II		antibiotic;	cancer
	-		anthracycline; DNA	
-		alpha-L-talopyran	intercalator	
		osyl)oxy]-		
		1,2,3,4,6,11-		-
		hexahydro-2,5,12-		
		trihydroxy-7-	٠.	
		methoxy-6,11-dioxo-		
		2-naphthacenyl]-2-		
		oxoethyl ester beta-		
		alanine hydrochloride		
			T	

GPX 100	Phase I		antibiotic;	cancer
			anthracycline; DNA	
I-DOX	Phase I	4'-iodo-4'-		cancer
		deoxydoxorubicin	ie; DNA	
			intercalator	
idarubicin; IMI 30;	Marketed	9-acetyl-7-[(3-amino- antibiotic;	antibiotic;	cancer
NSC 256439; IMI 22;	-	2,3,6-trideoxy-alfa-L- anthracycline; DNA	anthracycline; DNA	
ZAVEDOS;		lyxo-	intercalator	
ZAVEDOSE;		hexopyranosyl)oxy]-		
ZAVIDOS;		7,8,9,10-tetrahydro-		
IDAMYCIN;		6,9,11-trihydroxy-	•	
DAUNOBLASTINA;		5,12-		
CERUBIDINE		naphthacenedione	-	
iododoxorubicin;	Phase II		antibiotic.	ancer
FCE 21954;		[2alfa(8S*,10S*),4bet		
TODODOX		a,5beta,6beta]]-10- intercalator	intercalator	
		[(4-aminotetrahydro-	-	
		5-iodo-6-methyl-2H-		
		pyran-2-yl)oxy]-		
		7,8,9,10-tetrahydro-		-
		6,8,11-trihydroxy-8-		
		(hydroxyacetyl)-1-		-
		methoxy-5,12-		
		naphthacenedione		

[7R-antibiotic; antibiotic; (7alfa,8beta,10beta)]- anthracycline; DNA 8-ethyl-7,8,9,10-
8-ethyl-7,8,9,10- ietrahydro-1,6,7,8,11-
pentahydroxy-10- [[2,3,6-trideoxy-3-(4-
morpholinyi)-alfa-L- lyxo-
hexopyranosyl]oxy]- 5,12-
naphthacenedione hydrochloride
heptanedioic acid,
mono[2-[4-[(2,6-
dideoxy-2-fluoro- alfa-L-
talopyranosyl)oxy]-
.,2,3,4,6,11-
hexahydro-2,5,12-
trihydroxy-7-
methoxy-6,11-dioxo-
2-naphthacenyl]-2-
oxoethyl] ester, (2S -
cis)-

71,144,170

menogarii; 7-OMEN; Phase III (2R,3S,4R,5R,6R,11 R,13R)-4- U 52047; TOMOSAR TAMOSAR TAMOSCIN-9,10-dione THERARUBICIN; THERARUBICIN; TAMORUBIN; TAMORUBIN; TAMOSCIN-19,10-tetrahydro-19,10-tetrahydro-10,10-	 antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator	cancer
본	3,5,8,10,13- methoxy-6,13- dimethyl-2,6-epoxy- 2H-naphthaceno[1,2- bloxocin-9,16-dione [8S- [8alfa,10alfa(S*)]]- 10-[[3-amino-2,3,6- trideoxy-4-O- (tetrahydro-2H-pyran- 2-yl)-alfa-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12-	3,5,8,10,13- methoxy-6,13- dimethyl-2,6-epoxy- 2H-naphthaceno[1,2- bloxocin-9,16-dione [8S- [8alfa,10alfa(S*)]]- 10-[[3-amino-2,3,6- trideoxy-4-O- (tetrahydro-2H-pyran- 2-yl)-alfa-L-lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12-

mino-2,3,6-trideoxy-anthracycline; DNA alpha-L-lyxo- hexopyranosyl)oxy], 2,3,4,6,11-hexahydro- 2,5,12-trihydroxy-7- methoxy-6,11-dioxo- 2,5,12-trihydroxy-7- methoxy-6,11-dioxo- 1-piperidinyloxy] piperidinyloxyl piperidinyloxyl hexahydro-2,5,12- methoxy-7- piperidinyloxyl hexahydro-2,5,12- methoxy-7- methoxy-7- piperidinyloxyl hexahydro-2,5,12- methoxy-7- methoxy-7- methoxy-7- methoxy-7- methoxy-1- methox-1- m	mihovvi	Dhogo 11			
alpha-L-lyxo-intercalator haxopyranosyl)oxy]1, 2,3,4,6,11-hexahydro- 2,5,12-trihydroxy-7- methoxy-6,11-dioxo- 2,5,12-trihydroxy-7- methoxy-6,11-dioxo- heramethyl-1- piperidinyloxyl nelhydrazono-2,2,6,6- tetramethyl-1- piperidinyloxyl hexahydro-2,5,12- methoxy-7- methoxy-7- methoxy-7- methoxy-7- methoxy-7- methoxy-7- methoxy-7- frihydroxy-7- methoxy-7- methoxy-7- methoxy-7- methoxy-11-dioxo- 4-[[2,3,4,6,11- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended mutbiotic; muthracycline; DNA intercalator muthracycline; DNA intercalator muthracycline; DNA intercalator muthracycline; DNA intercalator muthracycline; DNA intercalator; estrogen	, Current	11050 11	(23-CIS)-4-[[1-[4[(3-	antibiotic;	cancer
hexopyranosyl)oxy]1, 2,3,4,6,11-hexahydro- 2,5,12-trihydroxy-7- methoxy-6,11-dioxo- 2,5,12-trihydroxy-7- methoxy-6,11-dioxo- biperidinyloxyl Retramethyl-1- piperidinyloxyl Retramethyl-1- piperidinyloxyl hexahydro-2,5,12- methoxy-7- methoxy-11-dioxo- 4-[[2,3,4-fi,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; of anti			anno-2,3,0-maeoxy-	anthracycline; DNA	
hexopyranosyl)oxy]1, 2,3,4,6,11-hexahydro- 2,5,12-trihydroxy-7- methoxy-6,11-dioxo- 2- naphthacenyl]ethylide ne]hydrazono-2,2,6,6- tetramethyl-1- piperidinyloxyl Retramethyl-1- piperidinyloxyl hexahydro-2,5,12- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended marketed mathracycline; DNA intercalator mathracycline; DNA intercalator antibiotic; c antibio			alpnaL-lyxo-	intercalator	
2,3,4,6,11-hexahydro- 2,5,12-trihydroxy-7- methoxy-6,11-dioxo- 2- naphthacenyl]ethylide ne]hydrazono-2,2,6,6- tetramethyl-1- piperidinyloxyl R hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- Suspended antibiotic; Suspended antibiotic; Marketed antibiotic; c antibio			hexopyranosyl)oxy]1,		
2,5,12-trihydroxy-7- methoxy-6,11-dioxo- 2- naphthacenyl]ethylide ne]hydrazono-2,2,6,6- tetramethyl-1- piperidinyloxyl Rentanoic acid, (2S- nithracycline; DNA hexahydro-2,5,12- methoxy-7- methoxy-7- methoxy-7- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended matribiotic; antibiotic; canthracycline; DNA intercalator intercalator; estrogen			2,3,4,6,11-hexahydro-		
methoxy-6,11-dioxo- 2- naphthacenyl]ethylide ne]hydrazono-2,2,6,6- tetramethyl-1- piperidinyloxyl Restand Pentanoic acid, (2S- antibiotic; cis)-2-[1,2,3,4,6,11- anthracycline; DNA hexahydro-2,5,12- intercalator trihydroxy-7- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; conthracycline; DNA intercalator Marketed antibiotic; conthracycline; DNA intercalator intercalator marketed antibiotic; conthracycline; DNA intercalator intercalator setrogen intercalator; estrogen intercalator; estrogen			2,5,12-trihydroxy-7-		
naphthacenyl]ethylide ne]hydrazono-2,2,6,6- tetramethyl-1- piperidinyloxyl sc		_	methoxy-6,11-dioxo-		
naphthacenyl]ethylide ne]hydrazono-2,2,6,6- tetramethyl-1- piperidinyloxyl sc Pentanoic acid, (2S- cis)-2-[1,2,3,4,6,11- nethoxy-7- methoxy-7- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; antibiotic; c anthracycline; DNA intercalator methoxycline; DNA intercalator antibiotic;			2-		
he]hydrazono-2,2,6,6- tetramethyl-1- piperidinyloxyl Rentanoic acid, (2S- cis)-2-[1,2,3,4,6,11- hexahydro-2,5,12- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; c anthracycline; DNA intercalator Amarketed antibiotic; c anthracycline; DNA intercalator antibiotic; c anthracycline; DNA intercalator c antibiotic; c anthracycline; DNA intercalator strogen intercalator; estrogen			naphthacenyl]ethylide		
tetramethyl-1- piperidinyloxyl SC Cis)-2-[1,2,3,4,6,11- anthracycline; DNA hexahydro-2,5,12- trihydroxy-7- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- Suspended antibiotic; contexpended antibiotic; contexpendentered antibiotic; contexpendentered antibiotic; contexpendentered antibiotic; contexpendentered antibio			ne]hydrazono-2,2,6,6-		
biperidinyloxyl Rentanoic acid, (2S- antibiotic; cis)-2-[1,2,3,4,6,11- anthracycline; DNA hexahydro-2,5,12- intercalator trihydroxy-7- methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo-hexopyranosyl]oxy]- Suspended antibiotic; canthracycline; DNA intercalator antibiotic; canthracycline; DNA intercalator; estrogen intercalator; estrogen			tetramethyl-1-		
tic Marketed Pentanoic acid, (2S- antibiotic; cis)-2-[1,2,3,4,6,11- anthracycline; DNA hexahydro-2,5,12- intercalator trihydroxy-7- methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]-2-naphthacenyl]-2- oxoethyl ester antibiotic; continercalator antibiotic; conti			piperidinyloxyl	•	
Nexabydro-2,5,12- hexabydro-2,5,12- hexabydro-2,5,12- methoxy-7- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended Suspended antibiotic; anthracycline; DNA intercalator methoxy-6,11-dioxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester antibiotic; anthracycline; DNA intercalator matthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator intercalator; strogen	valrubicin; antibiotic	Marketed	Pentanoic acid, (2S-	antibiotic;	cancer
hexahydro-2,5,12- intercalator trihydroxy-7- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; anthracycline; DNA intercalator Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator intercalator antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator; estrogen	AD 32; AD 32; NSC		cis)-2-[1,2,3,4,6,11-	anthracycline; DNA	
trihydroxy-7- methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; anthracycline; DNA intercalator Suspended Aarketed antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator intercalator antibiotic; anthracycline; DNA intercalator intercalator antibiotic; anthracycline; DNA intercalator; estrogen	246131; VALSTAR		hexahydro-2,5,12-	intercalator	
methoxy-6,11-dioxo- 4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; anthracycline; DNA intercalator Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator intercalator antibiotic; anthracycline; DNA intercalator intercalator antibiotic; anthracycline; DNA intercalator; strogen intercalator; estrogen			trihydroxy-7-		
4-[[2,3,6-trideoxy-3- [(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator; strogen intercalator; estrogen			methoxy-6,11-dioxo-	1	
[(trifluoroacetyl)amin o]-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester antibiotic; anthracycline; DNA intercalator Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator intercalator; strogen			4-[[2,3,6-trideoxy-3-		
oj-alfa-L-lyxo- hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator; estrogen			[(trifluoroacetyl)amin		
hexopyranosyl]oxy]- 2-naphthacenyl]-2- oxoethyl ester Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator antibiotic; a			oj-alfa-L-lyxo-		
Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator; anthracycline; DNA intercalator; strogen intercalator; estrogen			hexopyranosyl]oxy]-		
Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator intercalator antibiotic; antibiotic; antibiotic; antibiotic; antibiotic; antibiotic; antibiotic; anthracycline; DNA intercalator; estrogen	٠		z-iiapiiiiiacenyij-z- oxoethyl ester		
Suspended antibiotic; Marketed antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator; strogen intercalator; estrogen		Suspended		antibiotic;	cancer
Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator; extrogen intercalator; estrogen				anthracycline; DNA	
Suspended antibiotic; anthracycline; DNA intercalator antibiotic; anthracycline; DNA intercalator; extrogen				intercalator	
Marketed antibiotic; antibracycline; DNA antibiotic; anthracycline; DNA intercalator; estrogen	H.	Suspended		antibiotic;	cancer
Marketed antibiotic; anthracycline; DNA intercalator; estrogen	conjugated			anthracycline; DNA	
Marketed antibiotic; anthracycline; DNA intercalator; estrogen	doxorubicin			intercalator	
	doxorubicin +	Marketed	_	antibiotic;	cancer
	estrone; estrone +			anthracycline; DNA	
C10	doxorubicin; DDS- DEA			intercalator; estrogen	

amrubicin; SM 5887 Phase II	Phase II	(7S-cis)-9-acetyl-9-	antibiotic:	Cancer
			anthracycline: DNA	Toolino.
		beta-D-	topoisomerase	
		erythropentopyranosy inhibitor	inhibitor	
<u>-</u>		1)oxy]-7,8,9,10-		
		tetrahydro-6,11-		
		dihydroxy-5,12-		
		naphthacenedione		
		hydrochloride		
MEN 10755; BMS	Phase I	(7S-cis)-7-[[4-O-(3-	antibiotic;	cancer
C19561		amino-2,3,6-trideoxy-anthracycline; DNA	anthracycline; DNA	
		alpha-L-lyxo-	topoisomerase	
		6	inhibitor	
	-	dideoxy-alpha-L-		
		lyxo-		
		hexopyranosyl]oxy]-		
		7,8,9,10-tetrahydro-		
		6,9,11-trihydroxy-9-		
		(hydroxyacetyl)-5,12-		
		naphthacenedione		
	·	hydrochloride		
BU 4704	Discontinued	1-(4-methoxyphenyl)-antibiotic; antifungal 4-(4-		mycosis; cancer
		hydroxysulfonyloxyp		-
		neny1)-2,3-		
		diisocyano-1,3-		
		butadiene		
NK 860279I	Discontinued	44-homooligomycin a B	antibiotic; antifungal	mycosis; cancer
NK 860279II	Discontinued	44-homooligomycin a	antibiotic; antifungal	mycosis; cancer
		¥		

D-144110

reveromycin A	Preclinical	10-[9-buty]-8-[4-	antibiotic: antifingal	hactorial infaction:
		carboxy-3-methyl-	ng	cancer: mycosis
		1(E),3(E)-		caroot, in y costs
		butadienyl]-9-(hydrox		
•		ysuccinyloxy)-3-	· ·	
		methyl-1,7-	•	
		dioxaspiro-		
-,		[5.5]undec-2-yl]-5-		
		hydroxy-4,8-		
		dimethyl-		
		2(E),6(E),8(E)-		
		decatrienoic acid		
sultriecin	Discontinued		antibiotic; antifungal	cancer: mycosis
				2000 ((
		hydroxy-5-methyl-4-		-
	:	hydroxysulfonyloxyh		
		eptadec-1,7,9,11-		
		tetraenyl)-2H-pyron-		
100 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		2-one		
USIM ASBUUT	Preclinical		antibiotic; antioxidant; cancer; bacterial	cancer; bacterial
		<u> </u>	cicatrizant	infection;
				gastrointestinal
TOM DOVE OUT				disorder; skin ulcer
	Freclinical	,u	antibiotic; antioxidant; cancer; bacterial	cancer; bacterial
		<u>, v</u>	cicatrizant	infection;
				gastrointestinal
TONE DIA COO!				disorder; skin ulcer
100cAld Mich	Frecinical	<i>c</i> o	antioxidant;	cancer; bacterial
			cicatrizant	infection;
				gastrointestinal
10040 10040		-		disorder; skin ulcer
ocia iaciam	Preclinical	<u></u>	antibiotic; beta lactam	cancer
derivatives, Pliva			-	

clavalanine; SYN	Preclinical	[3S-	antibiotic; beta lactam cancer	cancer
1931; Ro 22-5417		[3alpha(R*),5alpha]]-	,	
-		alpha-amino-7-oxo-4-		
		oxa-1-		
		azabicyclo[3.2.0]hept	-	
		ane-3-propanoic acid	-	
SYN 1127	Preclinical	3-(hydroxymethyl)-4-	3-(hydroxymethyl)-4- antibiotic; beta lactam	cancer
		oxa-1-		
		azabicyclo[3.2.0]hept		
		an-7-one	-	
SYN 1932	Preclinical	[3R-	antibiotic; beta lactam	cancer
		[3alpha(alphaS*,beta	-	
		R*),5alpha]]-alpha-		
		amino-7-oxo-beta-		
		(phenylmethoxy-4-		
		oxa-1-	-	
		azabicyclo[3.2.0]hept		
		ane-3-propanoic acid		
MAb, doxorubicin	Preclinical		antibiotic;	cancer
conjugate			biotechnology;	
			monoclonal antibody;	
			anthracycline; DNA	
			intercalator	
MAb, drug delivery	Preclinical		antibiotic;	cancer
system, liposome			biotechnology;	
doxorubicin			monoclonal antibody;	
conjugate; MAb,			anthracycline; DNA	
STEALTH	· · - ·		intercalator	
doxorubicin				
conjugate; SPI 49			-	
drug delivery system,	Preclinical	- ~	antibiotic; DNA	cancer
micellar doxorubicin;			intercalator;	
doxorubicin micelle			anthracycline	

IST 622; A 132; NSC Phase II	Phase II	3-ethoxypropanoic	antihiotic: DNA	Cancer
639830		acid (S)-10-[[6-	topoisomerase	
		deoxy-2-O-(6-deoxy-	inhibitor	
		3-0-methyl-alfa-D-		
		galactopyranosyl)-		
		3,4-0-		
		(phenylmethylene)-		
		beta-D-		
		galactopyranosyl]oxy		
]-5,12-dihydro-1-		
		methyl-5,12-	·	
		dioxobenzo[h][1]benz		
		opyrano[5,4,3-		
		cde][1]benzopyran-6-		
	•	yl ester	•	
NSC 655649; BMY	Phase I	1,11-dichloro-6-[2-	antibiotic; DNA	cancer
27557			topoisomerase	
		4	inhibitor; DNA	
		O-met hyl-beta-D-	intercalator	
-		glucopyranosyl)-5H-		
		indolo[2,3-		
	-	a]pyrrolo[3,4.	·· <u>.</u>	
		c]carbazol e-5,7(6H)-		
		dione		
WIN 58161	Preclinical	(S)-10-(2,6-dimethyl- antibiotic; DNA	antibiotic; DNA	cancer
		fluoro-	opoisomerase	
			inhibitor; quinolone	
		pyrido[1,2,3-de]-1,4-		
		benzothiazine-6-		
- 1		carboxylic acid		
MI 4337F11; MI 43	Preclinical		antibiotic;	cancer
			Immunostimulant	

gludancin: FK 565	Discontinued		11-3-4	
FK 41565			antiolotic;	cancer; HIV
		glutamyl-(L)-meso- diaminopimelyl-(D)-	Immunostimulant; peptide	infection
		alanine	L	
feldamycin; BMY	Discontinued	(S)-N-methyl-L-	antibiotic; melanin	cancer
28565		histidyl-N3-[1-	synthesis inhibitor	
	:	carboxy-2-(1H-		
		imidazol-4-yl)ethyl]-		
		L-threo-2,3-		
		diaminobutanoic acid		
cordycepin; NSC 63984	Phase I		antibiotic; nucleoside; cancer	cancer
1001			antimetabolite	
C 102/	Preclinical	Antibiotic C	antibiotic; peptide	cancer; bacterial
J. 10000	-			infection
cecropin B	Discontinued		antibiotic; peptide	bacterial infection;
1.4:0 -0:4:4				cancer
Tylic peptides, Proteus Discontinued International	Discontinued		antibiotic; peptide	bacterial infection;
110		1 2 2		cancer
verucopeptini; BU 3983T; BMY 28782	Discontinued		antibiotic; peptide	cancer
placetin A	Preclinical		antibiotic, platelet	hrombogie, bootonial
				infection: cancer
placetin B	Preclinical		telet	thrombosis; bacterial
				infection; cancer
MS 073	Preclinical	1:1-	noline	cancer
		dihydro-5H-	•	
		dibenzo(a,d)cyclohept		-
		ene-5-yl)piperazin -1-		
		-2(1)	•	-
		hydroxypropoxy)quin		

A 74932	Discontinued	Discontinued 6-[2-[(2-aming-1-	ontibiotic control	
		oxopentyl)amino]-1-	antiolone, quinolone	cancer
		pyrrolidinyl]-5-		
	-	fluoro-3-oxo-3H-	-	
		pyrido[3,2,1-		
		k]phenoxazine-2-		
		carboxylic acid	-	
		monohydrochloride		
E 7010	Discontinued	N-[2-[(4-	antibiotic; sulfonamidecancer	cancer
		hydroxyphenyl)amino		
•		[]-3-pyridinyl]-4-		
		methoxybenzenesulfo		
0000		namide		
0/0/ F	Phase I		antibiotic; sulfonamidecancer	cancer
ER 34410	Preclinical	ihydro-2-	antibiotic; sulfonamidecancer	cancer
		dibenzo[b,e][1,4]diaz		
		epin-6-yl)-4-		
		methoxybenzenesulfo	-	
		namide		
ER 35744	Preclinical	N-(3-chloro-1H-	antibiotic; sulfonamidecancer	cancer
		1)-1,4-	-	
		penzene-		
		disulfonamide		
HMN 214	Preclinical	(E)-N-[(4-	antibiotic; sulfonamidecancer	cancer
		sulfo		
		nyl]-N-[2-[2-(1-		
		oxido-4-	-	
		pyridinyl)ethenyl]phe		
		nyl]acetamide		
	al		antibiotic; terpene	cancer
PN 271; PN 27,1; AndroCar	Phase II			cancer; restenosis

020				
PN 2/2	Preclinical		antibiotic; terpene	cancer
PN 273	Preclinical		antibiotic: temene	Cancer
PN 274	Preclinical		antihiotic: ternene	Cancer
PN 275	Preclinical		antibiotic: temene	Cancer
giracodazole;	Discontinued	[S-(R*,R*)]-2-amino-antihiotic: tRNA	antibiotic: fRNA	Cancar
girodazole; girolline;		alfa-(2-amino-1-	synthetase inhihitor	7001001
(+)-girolline; RP		chloroethyl)-1H-		
49532; RP 49532A;		imidazole-4-methanol		-
NSC 627434		-		
glycopine;	Marketed	N2-[N-[N-acetyl-4-0-antibiotic; vaccine	antibiotic; vaccine	psoriasis: cancer.
glucosaminylmuramy		[2-(acetylamino)-2-	adjuvant;	leukopenia; septic
alpeptiae; GMDP;		deoxy-beta-D-	immunostimulant;	shock; infectious
LICOPID; LIKOPID		glucopyranosyl]mura glycopeptide	glycopeptide	disease; eye disease
		moyi]-L-alanyi]-D- aluha-olutamine		
antiestrogens, AVAX Preclinical	Preclinical		antiestrogen	100000
Technologies			11090 1100 1100 I	Calicol
antiestrogens, BioNumerik	Preclinical		antiestrogen	cancer
antiestrogens, Ligand Preclinical	Preclinical		antiestrogen	cancer;
clomifene analogues	Cugnonded			endometriosis
aiognes	panuadsne		antiestrogen	cancer
droloxitene;	Pre-		antiestrogen	cancer; osteoporosis
hydroxydamoxifan V	registration	(dimethylamino)ethox		
21060E citrate		y]phenyl]-alpha- ethvl-3-stilbenol	5, 5, 1	
drug delivery system, GEOMATRIX	Discontinued		antiestrogen	cancer
controlled release				
tamoxifen; tamoxifen				
GEOMATRIX				
	٠			

SD-144 10

EN 120				
CIVI 1 39	Preclinical	(7alfa, 16alfa, 17beta)- antiestrogen	antiestrogen	cancer
-		N-butyl-16-chloro-	- !	
		3,17-dihydroxy-N-	-	
		methylestra-		
		1,3,5(10)-triene-7-	-	
		undecanamide	•	
EM 170	Preclinical	(7alfa, 16alfa, 17alfa)-	antiestrogen	cancer
		N-butyl-16-chloro-	•	
		3,17-dihydroxy-N-		
		methylestra-		
		1,3,5(10)-triene-7-	• .	
		undecanamide	-	
EM 800	Phase III	2,2-	antiestrogen	cancer
		dimethylpropanoic	0	
		acid (S)-4-[7-(2,2-		
		dimethyl-1-		
		oxopropoxy)-4-		
		methyl-2-[4-[2-(1-		
		piperidinyl)ethoxy]ph		
		enyl]-2H-1-		
		benzopyran-3-		
estrogen antagonists	Discontinued	אין אונפוואו פאנפו		
Telik	naniminaet e		antiestrogen	cancer
	Phase III	(7alpha 17beta)-7-[9, antiactioner	Intiactrogen	
2780;		[(4,4,5,5,5-	minesii Ogeii	cancer;
Zeneca 182780; ICI		pentafluoropenty])sul		gyirecological
182780; FASLODEX		phinyl]nonyl]-estra-		
		1,3,5(10)-triene-3,17-		
		beta-diol		-
		T		

iproxifene. TAT 50	Dhaca III	(12) 4 (1) (4 (2)		
fromienc, 171 55	r mase III	(E)-4-[1-[4-[2-	antiestrogen	cancer
		(dimethylamino)ethox		
		[v]phenyl]-2-[4-(1-		
		methylethyl)phenyl]-		
		1-butenyl]phenol		
		dihydrogen phosphate		
		(ester)		
MDL 103323	Suspended	(E)-4-[4-(2-chloro-	antiestrogen	cancer
-		1,2-		
		diphenylethenyl)phen		
		oxy]-N,N-		
		diethylbutanamine		
panomifene; EGIS	Discontinued	(E)-2-[[2-[p-(3.3.3-	antiestrogen	10000
5650; GYKI 13504		trifluoro-1,2-		Carloci
		diphenylpropenyl)phe		
		noxy]ethyllamino]eth		
		anol		
R 1128B	Discontinued	ہے	antiestrogen	cancer
		butylanthraquinone		
RU 53637	Discontinued		antiestrogen	cancer
			•	
		N-(methylethyl)-19-		
- ~		norpregna-1,3,5(10)-		
•		trien-20-yne-11-		
		undecanamide		
RU 58668; RU 59428 Discontinued	Discontinued		antiestrogen	cancer
SH 646	Phase I		antiestrogen	cancer
toremifene;	Marketed	2-(p-((Z)-4-chloro-	antiestrogen	cancer
tolemifene; FC				
1157a; NK 622;		butenyl)phenoxy)-		
FAKESTON; TREMIEEN		N,N-dimethyl		
1		emylamine		

zindoxifene; D 16726 Discontinued 2-[4-	Discontinued		antiestrogen	cancer
		(acetyloxy)phenyl]-1- ethyl-3-methyl-1H- indol-5-ol acetate (ester)		
arzoxifene; LY 353381	Phase II	2-(4-methoxyphenyl)-antiestrogen; estrogen 3-[4-[2-(1-piperidinyl)ethoxy]ph enoxy]benzo[b]thioph ene-6-ol	antiestrogen; estrogen agonist	cancer
ERA 923	Preclinical	SUI DAA Tuuri Tuuri	antiestrogen; estrogen agonist	cancer
estrogen receptor modulator, Genaissance; estrogen receptor modulator, Telik	Preclinical		gen; estrogen	cancer; osteoporosis
estrogen receptor modulators, Nanodesign	Preclinical		antiestrogen; estrogen cancer; osteoporosis agonist	cancer; osteoporosis
idoxifene; SB 223030; CB 7432	Phase II	(E)-1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethy		cancer
LY 326315	Preclinical	phenyl)- thoxy]ph -2-		cancer

raloxifone. Leovifone: Mantental	. A foulton	İ		
LY 139481; LY	, ivial neted	lo-nyaroxy-4-(4- hydroxymhenyl)henzo	ogen; estrogen	osteoporosis;
156758; EVISTA		[b]thien-3-yl][4-[2-(1-	480111St	hyperlipidemia; mvocardial
		piperidinyl)		infarction: cancer
	-	ethoxy]phenyl]metha		
		none		
aminopterin;	Phase II	N-[4-[[(2,4-diamino- antifolate	antifolate	cancer
amnopterine;		-9		
pteramina; NSC 739;		pteridinyl)methyl]ami		
APGA		no]benzoyl]-L-		
		glutamic acid		
anticancer agent,	Discontinued	N-[4-[3-(2,4-diamino-antifolate		cancer
Eisai		6,7-dihydro-5H-		
		cyclopenta[d]pyrimidi		
-		n-5-		
		yl)propyl]benzoyl]-L-		
	- 1	giulamic acid		
edatrexate;	Discontinued	N-[p-[1-[(2,4-	antifolate	cancer
aminopterin, O-ethyl-		diamino-6-		
10-deaza; 10 EDAM;		pteridinyl)methyl]pro		
EDAM 10; CGP		pyl]benzoyl]-L-	-	
4 9		giutamic acid		
	Phase I	(R)-N-[4-[2-(2-	antifolate	cancer
249543; LY 264618		amino-1,4,5,6,7,8-		
-		hexahydro-4-		
		oxopyrido[2,3-		
		d]pyrimidin-6-		
		yl)ethyl]benzoyl]-L-		
		glutamic acid		
	•			

						1								т-						T					r					_
cancer							cancer							cancer	****					cancer					cancer;	pneumocystis;	toxoplasmosis			
antifolate			-				antitolate							antifolate						intifolate;	antimetabolite				antifolate;	dihydrofolate	eductase inhibitor			
-amino-	1,4,5,6,7,8- hexahydro-4-	oxopyrido[2,3-	d]pyrimidin-6-	yl)ethyl-2-	thienyl]carbonyl]-L-		IN-((2,4-diamino-	5,4,5,6,7,8-	hexahydropyrido[2,3-	d]pyrimidine-6-	yl)ethyl)-2-	thienylcarbonyl-L-	glutamic acid	(S)-2-[[[4-carboxy-4-	[[4-[[(2,4-diamino-6-	pteridinyl)methyl]ami	no]benzoyl]amino]but	yl]amino]carbonyl]be	nzoic acid	N-[4-[3-(2,4-diamino-antifolate;	1H-pyrrolo[2,3-	d]pyrimidin-5-	yl)propyl]benzoyl]-L-	glutamic acid	F . %	;	nethyl-		d]pyrimidine-2,4-	ulannine
Phase I							Frecinical							Preclinical						Discontinued	-							- -		
LY 254155						I V 335580	777700	-						PT 523						TNP 351					piritrexim; BW 301U;Phase II	NSC 351521				

0-144110

Trega Biosciences/RiboGen e liarozole; liarozole hydrochloride; liarozole fumarate; R 75251; R 85246; LIAZAL	Pre- egistration		6	mycosis; cancer
s/RiboGen arozole I de; r marate; R 5246;	e- jistration			Land carron
arozole la de; na marate; R 5246;	s- ;istration			
arozole l de; r marate; R 5246;	e- jistration			
marate; R 5246;		5-[(3-chlorophenyl)- H-imidazol-1-	antifungal; androgen	cancer; psoriasis
5246;			synthesis minonor, imidazole	
		benzimidazole		
	Preclinical		antifungal;	cancer
		-	anthrapyrazole	
BBR 3439 Disc	Discontinued		antifungal;	cancer
DI ID 942	Discontinued		anthrapyrazote	
			antitungal;	cancer
losoxantrone.	111	Т	antin apyrazone	
	riiase III	/-nydroxy-2-[2-[(2-	antitungal;	cancer
iosovalinolle		hydroxyethyl)amino]eanthrapyrazole	anthrapyrazole	
nyarochloride;		thyl]-5-[[2-[(2-		
biantrazole; CI 941;		hydroxyethyl)amino]e		
DuP 941; NSC		thyllamino		
357885; PD 113785;		anthra[1.9-		
BIANDA		cd]pyrazol-6(2H)-		
	7	one,		
	Discontinued	7-10-dihydroxy-2-[2- antifungal;		cancer
teloxantrone		[(2-	anthrapyrazole	
hydrochloride;		hydroxyethyl)aminole	-	
moxantrazole; DUP	- 	thyl]-5-[[2-		
937; CI 937; PD	<u> </u>	(methylamino)ethylla		
113309; NSC 355644		mino]anthra[1,9-	-	
		cd]pyrazol-6(2H)-		
	٠,	one, dihydrochlonde,	-	
	I	monohydrate		

cancer therapy, Lorus Preclinical Therapeutics/Ion	Preclinical		antifungal; imidazole	cancer
clotrimazole; BAY	Marketed		antifungal; imidazole	mycosis; sickle cell
CUTAMYCON;				anemia; cancer;
ENSCHENT;		-		
FUNGIZID;				
HAKUSERIN;				
LOTRIMIN AF;		-		
MYCO-HERMAL;				
MYKO CORDES;				
IRIGENTAX;		1		
CANESTEN; COTRIMIN				
asplakinolide;	Preclinical	[2S-	antifungal: nentide	mycosis: cancer
aspamide	-	(2R*,4E,6S*,8R*)]-		in Jeans, carred
		N-[2-bromo-N-(8-		-
		hydroxy-2,4,6-		
		trimethyl-1-0xo-4-		
		nonenyl)-L-alanyl]-		
		N-methyl-D-		
		tryptophyl]-L-3-(4-		
		hydroxyphenyl)-beta-		
minoimidazole	Digognetimend	alanine rno-lactone		-
arboxamide	Disconvillaca		~	cancer; inflammation
ibonicleotide			i i i i i i i i i i i i i i i i i i i	
ioonacieonae	-		tormyltransferase	
ormyltransierase			inhibitor; NSAID;	
Inibitors, Agouron;			imidazole	
Agouron				

pentyl 1-(3-deoxy-betaD- nibofuranosyl)-5- fluoro-1,2-dihydro-; oxo-4- pyrimidinecarbamat 5-deoxy-5- fluorouridine	ribofuranosyl)-5- fluoro-1,2-dihydro-2- oxo-4- pyrimidinecarbamate doxifluridine; DFUR; Marketed FURTOLON; FURTULON drug delivery system, Preclinical ATRIGEL sustained release fluorouracii:

1011771

drug delivery system, Marketed	, Marketed		lantimetabolite	Cancer neoriaeie.
fluorouracil;				wirel infection
fluorouracil		**************************************	·	אווימן ווווסכתוסוו
Therapeutic Implant;				١
MPI 5003; AccuSite				
drug delivery system, Discontinued	Discontinued.		antimetabolite	Concor
fluorouracil;	•			Calicol
fluorouracil		•	-	
Therapeutic Implant;				
MPI 5011;				
INTRADOSE-FU				
drug delivery system,	Preclinical		antimetabolite	Cancer
fluorouracil;				Certo
fluorouracil			-	
Therapeutic Adhesive				
drug delivery system,	Discontinued		antimetabolite	100000
methotrexate;				Califor
methotrexate delivery		-		
system; HYAL				
CV1281				
drug delivery system,	Discontinued		antimetabolite	.0000
sustained release				Calicol
methotrexate;				
methotrexate				
DepoFoam			-	
fazarabine;	Phase II	4-amino-1-beta-D-	antimetabolite	Sancer
arabinosyl-5-		arabinofuranosyl-		
azacytosine; ara-AC;		1.3.5-triazin-2(1H)-	-	
NSC 281272		one		
fludarabine +	Discontinued		antimetabolite	Cancer
chlorambucil;				
chlorambucil + fludarabine				

Glaxo Wellcome levamisole + Regis fluorouracil; fluorouracil + levamisole T 506 Disco	Registered	5,6,7,8- tetrahydropteroyl)-L-	antimetabolite	cancer
+ :: +		tetrahydropteroyl)-L-		
+ +	stered			·
±; ±			antimetabolite	Toomon.
+				Califori
	Discontinued	mono[2-	antimetabolite	cancer
		hyl ester of 2'-deoxy-		
		5-fluoro-5'-uridylic		
		acid 3'-(9-		
		octadecenoate)		
		nydroxide inner salt		
IAS 102 Phase 1	31		antimetabolite	cancer
tegafur; BMS Marketed			antimetabolite	cancer
20060401; MJF		(tetrahydro-2-		
12264; NSC 148958;		furany])-		
DAIYALOSE;		2,4(1H,3H)pyrimidin		
FENTAL;	<u>. U</u>	edione		
FTORAFUR;				
FTORALON;		16.41		-
FURAFLOR;	<u></u>			
FUTRAFUL;		 		
LAMAR; NEBERK;		-		
\neg		-		
ZYN-LINKER Suspended	papua	8	antimetabolite	cancer
conjugated				
fluorouracil		-	·.	

brequinar; brequinar	Suspended	6-fluoro-2-(2'-	antimetabolite:	cancer: autoimmine
sodium; DUP 785; NSC 368390		fluoro[1,1'-biphenyl]- immunosuppressant 4-yl)-3-methyl-4-		disease; transplant rejection
		quinolinecarboxylic acid		•
ZYN-LINKER	Suspended		antimetabolite; NSAIDcancer: rheumatoid	cancer: rheumatoid
conjugated methotrexate				arthritis; psoriasis
cytarabine ocfosfate;	Marketed	4-amino-1-[5-0-	antimetabolite:	cancer
phosteabine sodium;		sylox		
YNK 01; C18PCA;		y)phosphinyl]-beta-		
STARASID		D-arabinofuranosyl]		
drug delivery system, Marketed	Marketed		antimetabolite;	cancer
DepoFoam			nucleoside analogue	
cytarabine; cytarabine	•			
DepoFoam; DTC				1
101; DepoCyt;			-	
SAVEDAR		-		
	Preclinical		antimetabolite;	cancer
analogues, Oklahoma University			nucleoside analogue	
6	Preclinical	2,2'-difluoro-2'-	antimetabolite:	cancer
		1		
		2,6-diaminopurine (dFdAP)	reductase inhibitor	
antineoplaston A10	Phase II		antineoplaston; peptidecancer	ancer
antineoplaston AS2-1 Phase II	Phase II		antineoplaston; peptideHIV infection;	HV infection;
				cancer

nitroxide antioxidant, Preclinical	, Preclinical		antioxidant; free	respiratory distress
LIN			radical scavenger;	syndrome;
			NSAID	inflammation;
				cancer; reperfusion
4 1. 3. 4 - 1.4				injury
antioxidants,	Preclinical	√2 . -	antioxidant; NSAID	skin disease;
Oniversity of California	•••			inflammation; cancer
naphterpin; CL	Preclinical	(4aS-cis)-3,4a,5,12b-	antioxidant; NSAID	diabetes:
90Y2			<u>-</u> -	cardiovascular
		dihydroxy-2,5,5,9-	···	disease; cancer;
		tetramethyl-4H-		inflammation
	٠	benzo[d]naphtho[2,3- b]pyran-7,12-dione		
OS 535	Preclinical		antiplasmin	cancer
.G 1127	Preclinical		antiprogestogen	cancer;
				endometriosis
LG 1147	Preclinical	-	antiprogestogen	cancer;
				endometriosis
LG 1447	Preclinical		antiprogestogen	cancer;
	-	6-phenyl-		endometriosis
		quinoline		
mifepristone; RU	Marketed	(11beta,17beta)-11-	antiprogestogen	abortion; cancer;
60, AU 4600, AU		-+-		contraception
36460; R 36460; MIFEGYNE		(dimethylamino)phen		
		71]-11-410 di OAy-11-(1-		
		piopyliyi Jestra-4,9-		
		aicil-2-0ile		

onapristone; ZK 98299; SH 549; ZK	Discontinued	Discontinued (11beta,13alfa,17alfa) antiprogestogen -11-14-	antiprogestogen	cancer; contraception
599	·	(dimethylamino)phen		
		yl]-17-hydroxy-17-(3-		
3 *		hydroxypropyl)estra-		
0.5.0		4,9-dien-3-one		
ORG 31/10	Discontinued	(6beta, 11beta, 17beta) antiprogestogen	antiprogestogen	cancer
		(dimethylamino)phen		
		yl]-4',5'-dihydro- 6-		
		methyl-spiro[estra-		
		4,9-diene-17,2'(3'H)-		
		furan]-3-one		
ORG 31806	Discontinued	(7beta, 11beta, 17beta) antiprogestogen	antiprogestogen	cancer
		-11-[4-	-	
		(dimethylamino)phen		
		yl]-4',5'-dihydro-7-		
		methyl-spiro[estra-		
		4,9-diene-17,2'(3'H)-		
		furan]-3-one.		
ORG 33245	Discontinued		antiprogestogen	cancer: abortion
ORG 33628	Discontinued	(11beta,17alpha)-11-	antiprogestogen	cancer
)	
		17,23-epoxy-19,24-		
		dinorchola-4,9,20-		
0,000,000		trien-3-one		
UKG 33832	Discontinued		antiprogestogen	cancer; abortion
KU 46556	Discontinued	(11beta,17beta)-11-	antiprogestogen	cancer;
	-	[4-		endometriosis; labor
		(methylthio)phenyl]sp		induction
		ro estra-4,9-diene-		
		17,2'(5'H)-furan]-3-		
		эпо		

D11.4000£				
0.0 49293	Discontinued	Discontinued (11beta,17beta)-11-	antiprogestogen	cancer;
,		-+)		endometriosis
		acetylphenyl)spiro[est	-	
		ra-4,9-diene-	. -	
		17,2'(5'H)-furan]-3-		
		one	~ .	
SH 207	Phase I		antiprogestogen	cancer
ZK 112993	Discontinued	(11beta,17beta)-11-	antiprogestogen	cancer
·		(4-acetylphenyl)-17-))	
		hydroxy-17-(1-		
		propynyl)estra-4,9-		
		dien-3-one		
ZK 136798	Discontinued	Ι	antiprogestogen	Cancer
		Z)		
	_)]-9,11-dihydro-17-		
		hydroxy-17-(3-	-	
		hydroxy-1 -		
		propenyl)-3-oxo-		
		4'Hnaphth[3',2',1':10,		
		9,11]estra-4,9(11)-	• •,•	
-		dien-6' -		
		yl benzonitrile		
21-substituted	Preclinical		antiprogestogen:	endometriosis: Jahor
progesterone			ment	induction: hormone
derivatives, NIH				deficiency: cancer
topsentin; topsentine; Preclinical		(6-hydroxy-1H-indol-	(6-hydroxy-1H-indol-antiproliferative agent	cancer
opsentin B1;		3-yl)[4-(1H-indol-3-		
opsentine B1		yl)-1H-imidazol-2-		
		yl]methanone	٠	-

carboxvamidotriazole	Phase I	5.2mino 1 [[2 6	1:5	
; CAJ; NSC 609974;			dinipionieranye agent; cancer imidazole	cancer
L 651582		chlorobenzyl)phenyl]		
		methyl]-1H-1,2,3-		
		triazole-4-		
onticonco		carboxamide		
annsense oligemale et de	Preclinical		antisense;	cancer
ougonacieonae,			oligonucleotide;	
BCL-X			biotechnology	
antisense	Preclinical	-	antisense;	cancer
oligonucleotide, c-fos		··	oligonucleotide;	
			biotechnology	
antisense	Preclinical		antisense;	cancer
oligonucleotide, c-jun			oligonucleotide;	•
			biotechnology	
antisense	Preclinical			cancer
oligonucleotide,			otide:	
calcium binding	-		biotechnology	
protein in placenta;		79 25	6	
antisense	•			
oligonucleotide,				
Se	Phase I			
eotide, DNA		<u>a c</u>	alitisciise,	cancer
methyltransferase;			biotechnology	-
MG 98			(9)	-
	Preclinical		antisense:	cancer
oligonucleotide,			sotide:	
Epstein Barr virus;		<u>.</u>	biotechnology	
antisense			ì	
oligonucleotide, EBV		-		

antisense	Preclinical		antisense;	cancer
oligonucleotide, jun			oligonucleotide;	
kınase-1			biotechnology	
antisense	Preclinical		antisense;	cancer
oligonucleotide,			oligonucleotide;	
transforming growth		٠	biotechnology	
factor beta; antisense			; -	
oligonucleotide, TGF-				
beta; antisense				
oligonucleotide,			••	
cancer				
antisense	Preclinical	-	antisense;	cancer
oligonucleotides,		Turan	oligonucleotide;	
basic fibroblast		-	biotechnology	
growth factor			3	
oligonucleotides,	Preclinical		antisense;	cancer
cancer, Children's	-		oligonucleotide;	
Hospital of Orange			biotechnology	
County			.	
antisense	Preclinical		antisense;	cancer
oligonucleotide,	-	<u>.</u>	oligonucleotide;	-
multiple drug			biotechnology; mRNA	•
resistance			translation inhibitor	
anticancer agents, OSI/Pfizer	Preclinical		apoptosis inducer	cancer
apoptosis inhibitors,	Preclinical	-	apoptosis inducer	cancer; cardiac
Oxford				therapy; transplant
Asymmetry/LXR			-	rejection;
Biotechnology	,			gastrointestinal
				disorder

			.21	
breast cancer therapy, Preclinical Temple University; breast cancer therapy	Preclinical		apoptosis inducer	cancer
Alliance		-	•	
C 857	Preclinical	2-[(1-nitro-9- acridinyl)amino]ethan	apoptosis inducer	cancer
cancer therapy,	Preclinical		apontosis inducer	Cancer
Axiom				Calicol
Biotechnologies/Zaiy a	-			
cancer therapy,	Preclinical		apoptosis inducer	cancer
Pharma/ImmunoGen			- · · · · · · · ·	
1	Phase I		apoptosis inducer	Cancer
				1001100
therapy, Nippon				
py,	Preclinical	·	apoptosis inducer	cancer
Idun/Abbott				
erapy, Rigel	Preclinical		apoptosis inducer	cancer
	Preclinical		apoptosis inducer	cancer
Fas modulators,	Preclinical		apoptosis inducer	cancer
V22 175	Desclinical			
T	riccinical		apoptosis inducer	cancer
	Preclinical		apoptosis inducer	cancer
-1-	Preclinical		apoptosis inducer	cancer
Cadus			2.44	
E2F inhibitors,	Preclinical		apoptosis inducer:	Cancer, neoriaeie.
Prolifix			gent	viral infection;
				restenosis

D-144110

apoptosis inducer, IDUN	Preclinical		apoptosis inducer;	cancer
CP 461	Phase I		apoptosis inducer; phosphodiesterase	cancer
			inhibitor	
exisulind; FGN 1; PREVATAC	Phase III	(1Z)-5-fluoro-2- methyl-1-[[4-	apoptosis inducer;	cancer
		(methylsulfonyl)phen inhibitor yl]methylene]-1H - indene-3-acetic acid	inhibitor	
apoptosis inhibitor, Biota	Discontinued		apoptosis inhibitor	cancer
apoptosis modulators, Preclinical	Preclinical		apoptosis inhibitor;	cancer; autoimmune
University of Colorado			apoptosis inducer	disease; nenrodegeneration
anastrozole; ZD 1033; Marketed	:Marketed	alpha, alpha, alpha', alp aromatase inhibitor	aromatase inhibitor	cancer
ICI D1033;		ha'-tetramethyl-5-		
A CHARLOCK		(1H-1,2,4-triazoi-1- vimethyl)-1 3.		
		benzenediacetonitrile		
aromatase inhibitor, Menarini	Preclinical		aromatase inhibitor	cancer
aromatase inhibitor,	Discontinued	19-acetylenic-	aromatase inhibitor	cancer
Merrell Dow		ne	-	
aromatase inhibitors,	Preclinical		aromatase inhibitor	cancer
Washington Research	•			
- 1	-		· -	
e; SH 489;	Discontinued	1-methylandrosta-1,4-aromatase inhibitor	aromatase inhibitor	cancer; benign
		diene-3,17-dione		prostate hypertrophy
CGP 47645	Discontinued		aromatase inhibitor	cancer
		-		

מטט מטניסו טטט		-		
CGS 18320B; CGS	Discontinued	1	aromatase inhibitor	cancer
18320		ylmethylene)bis[be	• ••••	
		nzonitrile compound		
		with butanedioic acid	٠.	
		(2:1)		
dexaminoglutethimid	Phase III	3-(4-aminophenyl)-3- aromatase inhibitor	aromatase inhibitor	cancer
e; D 3967		ethyl-2,6-		
		piperidinedione		
exemestane; FCE	Pre-	6-methyleneandrosta- aromatase inhibitor	aromatase inhibitor	cancer
24304; PNU 971;	registration	1,4-diene-3,17-dione		
ONC 0028;				
AROMASIN			-	
fadrozole; CGS	Marketed	4-(5,6,7,8-	aromatase inhibitor	cancer
16949A; AFEMA		midazo[1,5]		
		-a]pyridin-5-	-	
		yl)benzonitrile		
formestane; CGP	Marketed	4-hydroxyandrostene- aromatase inhibitor	aromatase inhibitor	cancer
32349; AT 0931;		3,17-dione		
LENTARON;				
LENTARE				
letrozole; CGS	Marketed	4,4'-(1H-1,2,4-triazol-aromatase inhibitor	aromatase inhibitor	cancer
20267; FEMARA			د پید د د	
٠		ylmethylene)bisbenzo		
		nitrile		
minamestane; FCE	Discontinued	4-aminoandrosta-	aromatase inhibitor	cancer
24928		1,4,6-triene-3,17-		
		dione	٠.	
213; MPV	Phase I	4-[3-(4-	aromatase inhibitor	cancer; benign
2213ad		fluorophenyl)-2-		prostate hypertrophy
		hydroxy-1-(1H-1,2,4-		•
		triazol-1-		
		yl)propyl]benzonitrile		

NIVO 01				
IO CALL	Discontinued	Uiscontinued 14alpha-hydroxy-4-	aromatase inhibitor	cancer
		androstene-3,6,17-		
000000000000000000000000000000000000000	-	d lolle		
OKG 30938	Discontinued	19-	aromatase inhibitor	cancer
		(ethyldithio)androst-	-	
		4-ene-3,17-dione		
ORG 33201	Discontinued	(3alphaR)-trans-1-[(3	aromatase inhibitor	cancer:
		alpha-ethyl-9-		endometriosis
		(ethythio)-	<u>-</u>	
		2,3,3alpha,4,5,6-	,	
		hexahydro-1H-		
		phenalen-2-yl)-		
		methyl]-1H-imidazole		
		HCI		
pentrozole; SH 582;	Preclinical	1.2-[(1-	aromatase inhibitor	cancer
ZK 154065		oxohexyl)oxy]-19-		
		norpregn-4-ene-3,20-		
		dione		
rogletimide;	Discontinued	(+,-)-3-ethyl-3-(4-	aromatase inhibitor	cancer
pyridoglutethimide				
		piperidinedione	-	
RU 54115	Discontinued		aromatase inhibitor	cancer;
		(methylthio)ethyl]estr		endometriosis
		a-4,9(11)-diene-3,17-		
	- 1	dione		
SAE 9	Discontinued		aromatase inhibitor	cancer
TAN 931	Preclinical	4-(2,6-	aromatase inhibitor	cancer
		dihydroxybenzoyl)-3-		
		formyl-5-		
		hydroxybenzoic acid		

		ſ		
vorozole; R 76713; R	Phase III	_	aromatase inhibitor	cancer
83842; JK 201;				
RIVIZOR		ylmethyl]-1-methyl-		
		1H-benz otriazole		
YM 511	Phase II	4-[[(4-	aromatase inhibitor	cancer;
		bromophenyl)methyl]		endometriosis
		-4H-1,2,4-triazol-4-		
	-	ylamino]benzonitrile	-	
YM 553	Preclinical	4-[[(3,5-	aromatase inhibitor	cancer
		difluorophenyl)methy		
		1]-5-		
		pyrimidinylamino]be		
		nzonitrile		
sparfosic acid;	Phase III	N-(phosphonoacetyl)- aspartate	aspartate	cancer; viral
sparfosate sodium;		L-aspartic acid,	transcarbamylase	infection
PALA; platinum		disodium salt	inhibitor	
complex; CI 882;				
NSC 224131; Pt 268;				
NSC 328005	,			
AV 04	Discontinued		azaanthraquinone	cancer
AV 17	Discontinued		azaanthraquinone	cancer
AV 38	Discontinued		azaanthraquinone	cancer
AV 43	Discontinued		azaanthraquinone	cancer
AV 57	Discontinued	6,9-dihydro-4-	azaanthraquinone	cancer
		methyl-6-(2-		
		nitrophenyl)-		
		pyrido[3,2-		
		gjquinoline- 2.5.10(1H)-trione		
AV 61	Discontinued		azaanthraquinone	cancer
AV 66	Discontinued		azaanthraquinone	cancer
AV 80	Discontinued		azaanthraquinone	cancer

-144110

1				
imu v eri	Discontinued		biological response	cancer
ONO 4005	Discontinued		biological response	Cancer
			modifier	Callon
ONO 4007	Phase II	(S)-2-deoxy-2-[[1-	biological response	cancer
		oxo-3-[1-0xo-9-	modifier	
•		phenylnonyl)oxy]tetra		
		decyl]amino-D-		
		glucose, 3-		
		benzenenonanoate 4-		
_		(hydrogensulfate),		
		monosodium salt.	•	
VIRULIZIN	Registered		biological response	cancer
			modifier	
RS 83277	Discontinued		biological response	cancer
			modifier; peptide	
adiposin; lipotropin	Preclinical		biotechnology	obesity; cancer
alpha mutein; mutein, Preclinical alpha; HT 003	Preclinical		biotechnology	cancer
anticancer	Preclinical		hiotechnology	***************************************
oligonucleotides,			oroccomion 63	Calicol
MicroProbe				
	Preclinical		biotechnology	cancer
Ą.	Phase II		biotechnology	retinopathy:
2036; TROVERT			}	acromegaly; cancer;
		-		diabetes; kidney
				disease
cancer	Discontinued		biotechnology	cancer
immunotherapy, MedImmune				

cancer		cancer	cancer	cancer	cancer	cancer	cancer		cancer		cancer	cancer		cancer	cancer	cancer
biotechnology	5 July -	biotechnology	biotechnology	biotechnology	biotechnology	biotechnology	biotechnology		biotechnology		biotechnology		··	biotechnology	biotechnology	biotechnology
	,- ·					-										
Preclinical		Preclinical	Preclinical	Preclinical	Preclinical	Preclinical	Preclinical		Preclinical		Phase I	Preclinical		Preclinical	Preclinical	Preclinical
cancer therapy,	Technologies International	cell lysis factor, Texas University	colon cancer therapy, Preclinical Axis Genetics	cytolytic factor; CF	DCC tumor suppressor gene	drug delivery system, HIT breast cancer	drug delivery system, ONYX 015; ONYX	015, viraMASC coating; ONYX 015	drug delivery system, ONYX 838; ONYX	838, viraMÁSC coating	G 207	gene discovery,	hereditary glioma, Myriad	gene discovery, leukemia, Myriad	guı	gene therapy, anti- erbB-2 single chain

gene therapy, antisense insulin-like	Phase I		biotechnology	cancer
growth factor-1; gene	•			
therapy, antisense IGF-1				
gene therapy, breast	Preclinical		biotechnology	cancer
cancer; gene therapy, breal. MB 200			3	
gene therapy,	Preclinical		biotechnology	Cancer
interleukin-2			3	
HER-2/neu oncogene	Discontinued		biotechnology	cancer
protein) ** **	
HGF/NK1	Preclinical		biotechnology	cancer
hPRL G129R	Preclinical		biotechnology	cancer
HSV 1716	Phase I		biotechnology	Cancer
human chorionic	Phase III		biotechnology	infertility: cancer
gonadotropin; hCG;		: :	6	ייווכוניול), כמוזכנו
OVIDREL		. at		
IL-2 analogue; INGN Preclinical	Preclinical		biotechnology	Cancer
301; F42K			6	Calleon
iroplact; platelet	Phase II		biotechnology	henarin
factor 4; PF4;			6	neutralization
endostatin B;				msoriasis: HIV
REPLISTATIN				infections,
			.50.	mection; cancer;
mismatched double	Pre-		biotechnology	allergy; viral
stranded KNA;	registration		-	infection; blood
poly(1)poly(C(sub12)				clotting disorder;
OJ; AMPLIGEN		-		cancer; chronic
				fatigue syndrome
neu differentiation factor; NDF	Discontinued		biotechnology	cancer
NV 1020	Preclinical		biotechnology	cancer

ONYX 015	Phase II	-	otechnolomi	
Osteonrotegerin: OPG Phase	Dhoca I		Concentration of the contract	Cancer
Saccopiolegeiiii, Or C	r nase 1	Q	biotechnology	osteoporosis; cancer
p53 gene	Preclinical	iq.	biotechnology	cancer
prostate cancer	Preclinical	<u>q</u>	biotechnology	cancer
therapy, Axis			3 · ·	
Genetics				
protein replacement	Preclinical	10	biotechnology	cancer
therapy,			6	
retinoblastoma	<u></u>	*		
protein; protein				
replacement therapy,		-		
Rb protein				
Salmonella	Preclinical	jq	biotechnology	cancer
typhimurium,	-		3	
mutagenized;				
mutagenized S				
typhimurium				
single chain antigen	Preclinical	bi	biotechnology	diagnosis; cancer
binding protein; SCA			•	
transcription factor, GM-CSF	Preclinical	iq	biotechnology	cancer
urogenital sinus-	Preclinical	iq	biotechnology	cancer. henion
derived growth			(Q)	prostate hymertronhy
inhibitory factor;	·- <u>-</u>			License at peraphry
UGIF; ps20	-			
vaccine, beta-human	Preclinical	iā	biotechnology	cancer
chorionic			3	
gonadotrophin,				
Vaxcel; vaccine,	- -			
cancer				
vaccine, cancer,	Preclinical	bic	biotechnology	cancer
Ludwig	• • •)	
Institute/SIGA		-		

01100110

•		***************************************		
vaccine, non-	Preclinical		biotechnology	cancer
Hodgkin's B cell			} -	
lymphoma				
verotoxin	Preclinical		biotechnology	Cancer
angiogenesis	Draclinical		1, 1, 1	caricon
inhibitor, Genzyme	Licennical		ototechnology; angiogenesis inhihitor	cancer
angiopoietin 2	Preclinical		biotechnology;	cancer
			angiogenesis inhibitor	
ANGIOSTATIN	Preclinical		biotechnology;	retinopathy; cancer
BST 2001;	Preclinical		hiotechnology:	Concer
ANGIOCOL			angiogenesis inhibitor	Toolino.
gene therapy,	Preclinical		biotechnology;	cancer
endostatin		8	angiogenesis inhibitor	
Del-1 angiogenic	Preclinical		biotechnology;	cancer; ischemia;
protein based		8	angiogenesis inhibitor; restenosis	restenosis
illerapies		ca	angiogenesis inducer	
drug delivery system, Preclinical	Preclinical	م	biotechnology;	cancer
ICS, antisense		ea	angiogenesis inhibitor;	
oligonucleotide,		- RG	antisense;	
VEGFR; antisense		0.	oligonucleotide	
oiigonucleotide, VEGFR, TCS)	
BST 2002	Preclinical	Q	biotechnology;	cancer
		<u>а</u> <u>С</u>	angiogenesis inhibitor; peptide	
	Phase I	q	ology;	cancer
oligonucleotide, -		<u></u>	•	1
myb; LR 3001; INX 3001			oligonucleotide	
antisense	Preclinical		biotechnology;	cancer
oligonucleotide, c-kit		·		
		O	oligonucleotide	i

antisense	Preclinical	hiotechnology.	100000
oligonucleotide, c-		antisense:	i carrot
myb		oligonucleotide	
antisense	Preclinical	biotechnology;	cancer
oligonucleotide,		 antisense;	
cancer, Enzo		oligonucleotide	
antisense	Preclinical	biotechnology;	cancer
oligonucleotide,		antisense;	
cancer, INSERM		oligonucleotide	
antisense	Preclinical	biotechnology;	cancer
oligonucleotide,		antisense;	
chimeric 2-5A,		oligonucleotide	
chronic myelogenous		•	
leukemia			
antisense	Discontinued	biotechnology;	cancer
oligonucleotide,		antisense:	
chronic myelogenous		oligonucleotide	
leukemia; RGA 1512		2	
antisense	Preclinical	biotechnology:	Cancer
oligonucleotide,		 antisense:	700170
epidermal growth		oligonucleotide	
factor receptor;)	
antisense		<u>.</u>	
oligonucleotide,			
EGFR	-		
antisense	Phase I	biotechnology;	cancer
oligonucleotide,		 antisense:	
insulin-like growth		oligonucleotide	
factor-1 receptor;		· · ·	
antisense	-	- 	
oligonucleotide, IGF-		.:	
154 VATT (17)			

antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			antisense;	
mdm2			oligonucleotide	
antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			antisense;	
multi-drug resistance			oligonucleotide	
protein-1; antisense				
oligonucleotide, MDR-1				
antisense	Discontinued	,	biotechnology;	cancer
oligonucleotide,			antisense;	
myelogenous		-	oligonucleotide	
leukemia; GT 1102				
antisense	Discontinued		biotechnology;	cancer
oligonucleotide,			antisense;	
myelogenous			oligonucleotide	
leukemia; GT 1106		1		
antisense	Preclinical	-	biotechnology;	cancer
oligonucleotide,			antisense;	
p120; ISIS 3466			oligonucleotide	
antisense	Preclinical.		biotechnology;	cancer
oligonucleotide,			antisense;	
phospholipase A2;		-	oligonucleotide	
antisense				
oligonucleotide,				
PLA2				
antisense	Phase II		biotechnology;	cancer
oligonucleotide,		-	antisense;	
protein kinase A;			oligonucleotide	
707 7170				

antisense	Phase II		hiotechnology.	100000
oligonucleotide,			antisense;	Carico
protein kinase C- alpha; antisense			oligonucleotide	
oligonucleotide,				
cancer; ISIS 3521;				
CGP 64128A; ISI				
antioneo	D-001:-::-01			
oligonucleotide,	Frecinical		biotechnology;	cancer
protein kinase type I;		ē.	oligonucleotide	
antisense		-))	
oligonucleotide;				
Luxur				
antisense	Discontinued		biotechnology;	cancer
oligonucleotide,	. , .		antisense;	
fumor necrosis factor;	٠.		oligonucleotide	
antisonse	Descritter			
olioonucleotide	1 recilineal		piotecnnology;	cancer
vascular endothelial	•		annsense, olioonucleotide	
growth factor; AR	-	٠	oniBonnesion	
639				
antisense	Preclinical		biotechnology:	retinonathy. cancer.
oligonucleotide,			antisense;	skin disease
vascular endothelial			oligonucleotide	
growth factor;				•
antisense				
oligonucleotide,				
VEGF; GEM 220			-	
antisense	Discontinued		biotechnology;	cancer
oligonucleotides,			antisense;	
cancer, Matritech			oligonucleotide	

antisense	Preclinical		hiotechnology.	Cancer wirel
oligonucleotides,			antisense:	infection
human			olizonucleotide	TO TO TO
papillomavirus 16/18;				
antisense			. :	
oligonucleotides, HPV 16/18			-	
antisense	Preclinical		Diotechnology:	100000
oligonucleotides,			antisense:	Caricel
multi-drug resistance			oligonucleotide	
protein; antisense))	
oligonucleotides, MRP				
drug delivery system, Preclinical	Preclinical		biotechnology:	cancer
antisense			antisense:	
oligonucleotide,			oligonucleotide	
erbB-2) 	
drug delivery system, Preclinical	Preclinical		biotechnology;	cancer
antisense			antisense;	
oligonucleotide, p27			oligonucleotide	
drug delivery system, Preclinical	Preclinical	-	biotechnology:	cancer
TCS antisense			antisense;	
oligonucleotide, c-			oligonucleotide	
myb; antisense) _	
oligonucleotide, TCS				
c-myb; INX 3000,				
201				
arug delivery system,	Preclinical		biotechnology;	cancer
3280 TCS; INXC			antisense; oligonucleotide	
6295				

1	-		
arug delivery system, Preclinical TCS, antisense oligonucleotide, IGF-1R; antisense oligonucleotide, IGF-1R, TCS; INX 4437, TCS	, Preclinical	biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, bcl- 2; G 3139	Phase II	biotechnology; antisense; oligonucleotide; chemosensitizer	cancer
antisense oligonucleotide, raf-1, Neopharm; drug delivery system, antisense oligonucleotide, raf-1, Neopharm	Preclinical	biotechnology; antisense; oligonucleotide; radiosensitizer	cancer
antisense oligonucleotide, p65 NF-kappaB	Preclinical	biotechnology; antisense; oligonucleotide; transcription factor regulator	cancer
tumor necrosis factor Preclinical apoptosis inducing ligand; TRAIL	Preclinical	er.	cancer
secreted apoptosis related proteins; SARPS	Preclinical	er; itor	cancer, myocardial infarction; stroke
keratinocyte growth factor antagonist, NeXstar; KGF antagonist	Preclinical.		cancer

NeXstar			(1907)	
			antamer:	
			oligonucleotide	
a antagonist,	Preclinical		biotechnology;	cancer
NeXstar			aptamer;	
			oligonucleotide	
NX 1838	Phase I		biotechnology;	cancer; diabetes;
			aptamer;	retinopathy
		-	oligonucleotide;	
			angiogenesis inhibitor	
MIG	Preclinical		biotechnology;	cancer
			chemokine;	
			angiogenesis inhibitor	
somatomedin binding Suspended	Suspended		biotechnology;	skin ulcer; cancer
protein; insulin-like			cicatrizant	
growth factor binding				
protein; IGF BP-1				
interleukin-1 beta; IL-Discontinued	Discontinued		biotechnology;	cancer; infectious
l beta			ine;	disease
			vaccine adjuvant	
	Phase II	transforming growth	biotechnology;	cancer; skin ulcer;
transforming growth		beta3 (human),	cicatrizant; growth	mucositis
factor beta-3; TGF		dimer	factor	
beta-3; CGP 46614				
or-	Discontinued		biotechnology;	eye disease; cancer;
alpha; TGF-alpha			zant; growth	skin ulcer
			factor	
	Suspended		mology;	arthritis; cancer; skin
anticollagenase; FIBAC;			cicatrizant; NSAID	ulcer; arthritis
anticollagenase				-
fibroblast			-	

7 1 1 1				
ussue innibitor of	Discontinued		biotechnology;	cancer
metalloproteinase 2;			collagenase inhibitor;	
1 IMIF-2			matrix	
			metalloproteinase	
-			inhibitor; proteinase	
			inhibitor; gene	
BC 1; AS 122;	Phase I		biotechnology;	cancer; diagnosis
AngioMab			contrast medium;	
			monoclonal antibody;	
			radiotherapeutic;	
			radiodiagnostic;	
			angiogenesis inhibitor	
senescence derived	Discontinued		biotechnology: cyclin	cancer: psoriasis: eve
inhibitor 1; Sdi 1			dependent kinase	disease: cancer
			irhibitor	Tooms (amount
multiple tumor	Preclinical		biotechnology; cyclin	cancer
suppressor 1-based			dependent kinase	
therapy	-		inhibitor; gene	•
AR 324	Discontinued		biotechnology;	cancer
			cytokine	
	Phase II	-	biotechnology;	cancer
ALVAC-hIL-2			cytokine	
•	Preclinical		biotechnology;	cancer
interleukin secreting			cytokine	
implant; interleukin				
secreting implant				
	Preclinical		biotechnology;	cancer
Ajmomoto; Gal3			cytokine	
modified IL-2				

interleukin-	Suspended		biotechnology:	cancer:
3/interleukin-6			cytokine	thrombocytonenia
mutein chimeric				umornoocy roperina
molecule; IL-3/IL-6			<u>.</u> .	
m chimeric molecule		•		
interleukin-6; IL-6	Suspended		biotechnology;	cancer
			cytokine	
Interleukin-6; IL-6;	Discontinued		biotechnology;	cancer;
969			cytokine	thrombocytopenia;
interlenkin-6. II -6.	Dhace II			тепкорепіа
SIGOSIX	11930 11		niotechnology;	cancer;
interlement of			cytokine	thrombocytopenia
meneral cukin-o mulem;	rnase I	-	biotechnology;	cancer;
27809			cytokine	thrombocytopenia
nagrestinen.	Discontinued	(h):mom of one		
nagrectin. DD 10010.	Danilling		biotechnology;	cancer; HIV
magnestip, do 10010;		ophage.	cytokine	infection
Mik-Taipha		inflammatory		
		reduced), 26-L-		
		alanine-lymphokine MIP 1alpha		
SC 68420; MPO 1	Discontinued		biotechnology;	cancer
			cytokine	
sonermin; tumor	Discontinued	3-157-tumor necrosis biotechnology;	biotechnology;	cancer
necrosis factor; TNF;		factor (human)	cytokine	
FI USU; LIENEF; TINEF				
sonermin; tumor	Pre-	3-157-tumor necrosis hiotechnology.	biotechnology.	Cancer: neoriagis
necrosis factor; TNF; registration PAC 4D	registration	factor (human)	cytokine	cancer, poemasis

tasonermin; tumor	Registered		biotechnology;	cancer
necrosis factor alpha;			cytokine	
TNF-alpha; FK 516;		:		
BEROMUN		•	: '	
tumor necrosis factor; Discontinued	Discontinued		biotechnology:	cancer
TNF			cytokine	
tumor necrosis factor; Discontinued	Discontinued		biotechnology:	cancer
TNF			cytokine	
tumor necrosis factor Preclinical	Preclinical		biotechnology:	cancer
alpha; TNF-alpha			cytokine	
tumor necrosis factor	Discontinued		biotechnology:	cancer
alpha tip mutants;			cytokine	
TNF-alpha tip				
mutants			•	
gene therapy, IL-12;	Preclinical		biotechnology:	Cancer
gene therapy, cancer			cytokine; gene	
		. 	therapy;	
		<u></u>	biotechnology;	
		I	immunostimulant	
	Phase II	<u> </u>	biotechnology;	cancer
interteron-alpha; gene			cytokine; gene	
therapy, cancer		•	therapy;	
			immunostimulant;	
			interferon	

daniplestim;	Discontinued	Discontinued [14-ala-18-ile-25-his- biotechnology:	biotechnology;	cancer
interleukin-3		29-arg-32-asn-37-pro-cytokine: prowth	cytokine: prowth	
synthokine; IL-3		42-ser-45-met-51-arg-factor	factor	
synthokine; SC 55494	4	55-thr-59-leu-62-val-		
		67-his-69-glu-73-gly-	A 40.00 m	
		76-ala-79-arg-82-gln-	-	
		87-ser-93-ser-98-ile-		
		101-ala-105-gln-109-	-	
	-	glu-116-val-120-gln-	-	
		123-glu-14-125-	-	
		interleukin 3 (human	<u>.</u> .	
IL-6/IL-2 fusion	Preclinical	VIOLUS DATA	hiotochnology	***************************************
nrotein	-		oreicemones,	Califor
			cytokine; growth	
			factor; hematopoietic	
			factor	
interleukin-6; IL-6;	Suspended			cancer;
BETATROPIN				thrombocytopenia
			, hematopoietic	
		- 1	factor	
aldesleukin;	Marketed		biotechnology;	cancer; HIV
interleukin-2; IL-2;		interleukin 2 (human	cytokine;	infection
			immunostimulant	
	Phase II		biotechnology;	cancer
monkey vero cell line	<u>.</u>		cytokine;	
secreting IL-2; vero-			immunostimulant	
777				

celmoleukin;	Marketed	A-P-T-S-S-S-T-K-K- biotechnology:	biotechnology:	viral infection:
interleukin-2; IL-2;		T-Q-L-Q-L-E-H-L-L-cytokine;	cytokine;	cancer
TAKELEUKIN;		L-D-L-Q-M-I-L-N-G-immunostimulant	immunostimulant	
CELEUK		I-N-N-Y-K-N-P-K-L-		
		T-R-M-L-T-F-K-F-Y-		
		M-P-K-K-A-T-E-L-		
		K-H-L-Q-C-L-E-E-E-		
		L-K-P-L-E-E-V-L-N-		
		L-A-Q-S-K-N-F-H-L-		
		R-P-R-D-L-I-S-N-I-		
		N-V-I-V-L-E-L-K-G-		
		S-E-T-T-F-M-C-E-Y-	*	
		A-D-E-T-A-T-I-V-E-	÷ , .	
		F-L-N-R-W-I-T-F-C-		
		Q-S-I-I-S-I-L-I		
drug delivery system,	Discontinued		biotechnology;	cancer; HIV
aldesleukin; drug		-	cytokine;	infection
delivery system,			immunostimulant	
interjeukin-2;		•		
aldesleukin				
DepoFoam				
drug delivery system, Discontinued	Discontinued		biotechnology;	viral infection;
interleukin-2;	•		cytokine;	cancer
interleukin-2 delivery			immunostimulant	
system; drug delivery				
system, IL-2				
drug delivery system,	Phase II		biotechnology;	cancer
liposome interleukin-			cytokine;	
2; interleukin-2			immunostimulant	
liposome; OTx 287;				
OncoLipin-2;	•			
OncoLipin				

interferon alfa-N1.	Morton			
IFN alfa-N1;	Maineted		biotechnology;	cancer; viral
WELLFERON;			Egrokine, imminostimulant	Infection
SUMIFERON; HUMOFFRON				
interleukin-1 · II -1	Discontinued		1. 2. 4 1 1	
	Ciscontinued	-	biotechnology;	cancer
			cytokine; imminostimiilant	
interleukin-1 alpha;	Discontinued		biotechnology:	Cancer
IL-la			cytokine;	Tooling
			immunostimulant	-
interleukin-1 alpha	Suspended		biotechnology;	cancer
denivative; OCT 7000			cytokine;	
			ımmunostımulant	
interieukin-1 beta; IL-Pre-	Pre-		biotechnology;	cancer
1 beta; OCT 43;	registration		cytokine;	
- 1			immunostimulant	
interleukin-2; IL-2	Suspended		biotechnology;	cancer
		<u> </u>	cytokine;	
		,	immunostimulant	
Interleukin-2; IL-2;	Phase III		biotechnology;	cancer
INSC 600664;		0	cytokine;	
			immunostimulant	
interleukin-2; IL-2	Discontinued		biotechnology;	cancer
		9 .,	cytokine;	
T			mmunostimulant	
interieukin-5; IL-5	Discontinued	_	biotechnology;	cancer
		0	cytokine;	
			immunostimulant	
interleukin-6; IL-6	Suspended		biotechnology;	cancer
		<u>o</u>	cytokine;	
			immunostimulant	
		-		

interleukin-7; IL-7	Preclinical	biotec	biotechnology;	cancer
		cytokine; immunosi	cytokine; immunostimulant	
mitoflaxone +	Discontinued	biotec	biotechnology;	cancer
interleukin-1;	-	cytokine;	ne;	
Interleukin-1 + mitoflaxone		nmuj	immunostimulant	
oprelvekin;	Marketed	biotec	biotechnology;	cancer: HIV
interleukin-11; IL-11;		cytokine;	ne;	infection; mucositis;
YM 294; NEUMEGA		ummi	immunostimulant	Crohn disease
polyethylene glycol	Phase II	biotec	logy;	HIV infection;
interleukin 2; PEG		cytokine;		cancer
IL-2; interleukin 2		nmmi	immunostimulant	
SC 71858; PMP	Phase I	biotec	biotechnology;	cancer
		cytokine;	ne;	
		immui	immunostimulant	
interleukin-1 beta; IL-Preclinical	Preclinical	biotec		cancer; skin ulcer
l beta		cytokine;	ne;	
		mmmi	immunostimulant;	
		cicatrizant	zant	
IL-3;	Suspended	biotec	logy;	cancer
ALLEVORIN		cytokine;	ne;	
		immui	immunostimulant;	
		growth	growth factor;	
		hemat	hematopoietic factor	
interleukin-3; IL-3	Discontinued	biotec	logy;	cancer
		cytokine;	ne;	
		muni	immunostimulant;	
		growt	growth factor;	•
		hemat	opoietic factor	

. TT C	,			
interieukin-3; IL-3	Phase I		biotechnology;	cancer; leukopenia
•			cytokine;	•
			immunostimulant;	
			growth factor;	
			hematopoietic factor	
lendistim; SC 70935; Phase III	Phase III		biotechnology;	cancer
IMIFO			cytokine;	
			immunostimulant;	
			growth factor;	
			hematopoietic factor	
mupiestim;	Phase III	human interleukin 3	biotechnology;	cancer;
interieukin-3; IL-3;			cytokine;	thrombocytopenia;
3D2 1LE904; 1LE			immunostimulant;	leukopenia
904; HEMOKINE			growth factor;	•
			hematopoietic factor	
drug delivery system,	Discontinued		biotechnology;	viral infection;
Procease interferon	-		cytokine;	cancer
alia; interieron alta			immunostimulant;	
- 1			interferon	
-1L-2	Preclinical		biotechnology;	cancer
rusion protein			cytokine;	
			immunostimulant;	
interlentin 1. II 1.	DL. 2.2. 11		monoclonal antibody	
	ruase II		biotechnology;	cancer; viral
OITADDAVINE	-	-	cytokine;	infection;
ZNINANJACA ZNINANJACA			stimulant;	rheumatoid arthritis
Interleukin-12; IL-12; Phase II	Phase II		ology;	viral infection;
timulature cell		:		cancer
NIVEE: VACOLO			immunostimulant;	-
ANDE, TIM OIC			vaccine adjuvant	

mutants		מסומ	orotectinology;	cancer; infectious
		cyto	ne	disease
		adju	adjuvant;	_
		radic	radioprotectant;	
	Jeoglini ool		immunosumulant	
	Frecinical	biote	biotechnology; DNA	cancer
ongonucieonde,		trans	transcription inhibitor;	
calicer, DIVA binding	•	antis	antisense;	
oligonucleotide		າສີແດ 	ongonacieonae	
antisense	Discontinued	biote	biotechnology; DNA	cancer
oligonucleotide,		trans	::	
epidermal growth		antis	antisense;	
factor receptor; triple		oligo	oligonucleotide	
helix oligonucleotide,		<u>· </u>		
EGFR; T 03101				
antisense	Discontinued	biote	biotechnology; DNA	cancer
oligonucleotide, her-		trans	ranscription inhibitor;	
2; triple helix		antis	antisense;	
oligonucleotide, her-2		oligo	oligonucleotide	
sense oligonucleotide, Discontinued	Discontinued	piote	ONA	cancer; viral
NF-kappaB decoy		trans	scription inhibitor;	infection
		oligo	oligonucleotide;	
	•	trans	ranscription factor	-
		regu	regulator	
o V	Preclinical	biote	biotechnology;	cancer
9301; ONCase		enzyme	yme	

acidic fibroblast	Discontinued	biotechnology: filsion cancer	cancer
growth factor-		toxin	
Pseudomonas			
exotoxin fusion		:	
protein; aFGF-			
Pseudomonas			
exotoxin fusion			
protein		. · ·	
DWP 408	Preclinical	biotechnology; fusion toxin	cancer
epidermal growth	Phase II	biotechnology: firsion	Cancer, restenosis.
factor diphtheria toxin		toxin	nsoriasis
chimeric protein;			
EGF diphtheria toxin		\$ 	
chimeric protein;	•		
EGF fusion protein;			-
DAB 389-EGF; DAB			
389-EGF			
fusion toxin,	Preclinical	biotechnology; fusion	cancer
interleukin-13 fusion		toxin	
protein; hIL13.E13K- PE4E		T	
GM-CSF diphtheria	Discontinued	biotechnology: fusion	cancer
toxin chimeric		toxin	
protein; DT388 GM- CSF		 	
heregulin-	Preclinical	biotechnology: fision	Cancer
Pseudomonas			
exotoxin fusion			
protein		٠	
-			

II -4 filsion toxin: II - Dhasa II	Dhasa II			
4(38-37)-PE38KDEL	11 20011	010technol	olotechnology; fusion cancer	cancer
interleukin-4 fusion				
toxin; NBI 3001				
IL13-PE38QQR;	Preclinical	biotechnol	biotechnology: fusion	cancer
interleukin-		toxin		Tooling.
13/pseudomonas				
exotoxin derivative				
interleukin-4-	Preclinical	biotechnol	biotechnology, fission	Cancer
pseudomonas		tot		called
exotoxin A; IL-4-PE				
interleukin-6	Preclinical	Diotechnolo	biotechnology, fileion	HIV infection:
diphtheria toxin		toxin		rar mirecuoli,
chimeric protein; IL-6				calicel
diphtheria toxin				
chimeric protein; IL-6				
fusion protein				
interleukin-6-	Preclinical	biotechnolo	biotechnology: fision	Cancer
Pseudomonas		toxin		
exotoxin 40 chimeric				
protein; IL-6-PE40				
interleukin-6-	Preclinical	biotechnolo	biotechnology: fision	Cancer
Pseudomonas		toxin		
exotoxin 66(4Glu)				
chimeric protein; IL-				
6-PE66(4Glu)				
melanocyte	Preclinical	biotechnology: firsion		cancer
stimulating hormone		toxin		
diphtheria toxin	. •			
chimeric protein;				
MSH diphtheria toxin	 :	<u> </u>		
chimeric protein;				-
MSH fusion protein		*. . .		

.84. 34.

mitotoxin fibroblast	Discontinued		biotechnology; fusion cancer restenosis:	cancer: restenosis.
growth factor-			toxin	eve disease
saporin; mitotoxin,				
FGF-saporin;				
PANTARIN				
TGFalpha-PE38;	Preclinical		biotechnology; fusion	cancer
TGFalpha PE38				
fusion toxin			:	
transferrin-CRM107;	Phase II		biotechnology: fision cancer	cancer
transferrin-toxin; HN		-	toxin	
00099				
transforming growth	Preclinical		biotechnology: fusion	cancer
factor alpha-				
Pseudomonas				
exotoxin 40 chimeric		-		
protein; TGF alpha-	•			
PE40; TGFa-PE40				
	Preclinical		biotechnology: fusion autoimmine disease:	autoimmine disease.
			toxin:	transplant rejection:
chimeric protein; IL-4			nosuppressant	cancer: HIV
diphtheria toxin				infection
chimeric protein; IL-4				
fusion protein				
flitox;	Marketed	1-388-toxin		diabetes: HIV
interleukin-2		(Corneybacterium	toxin; NSAID	infection:
diphtheria toxin		diphtheriae strain		rheumatoid arthritis.
chimeric protein;		C7), N-L-methionyl-		psoriasis: cancer
interleukin-2 fusion	. •	387-L-histidine-388-		
protein; DAB 389-IL-		L-alanine-,		
2; LY 335348;	2	(388.fwdarw.2')-		
DAB389IL2;		protein with 2-133-		
ONTAK		interleukin 2 (human		
		clone pTIL2-21a)		

diphtheria toxin	Discontinued		biotechnology; fusion	diabetes; HIV
chimeric protein;			MAZIII, INSAID	intection;
interleukin-2 fusion				cancer
toxin; IL-2 fusion				
toxin; DAB 486-IL-2; D-IL-2				
cancer therapy, int6	Preclinical		biotechnology: gene	cancer
cancer therapy, tumor Preclinical	Preclinical		biotechnology: gene	cancer diagnosis
suppressor,			8 (76	derical, did
University			•	
Technologies				
International				
melastatin	Preclinical		biotechnology; gene	cancer
BRUSH-1 gene based Preclinical	Preclinical		biotechnology; gene	cancer
therapy; cancer			therapy	
therapy				
cancer therapy,	Preclinical		biotechnology; gene	cancer
modified adenovirus,			therapy	
Onyx; ONYX 838			2.0	
gene therapy,	Preclinical		biotechnology; gene	cancer
adenoviral herpes		- ;-	therapy	
simplex virus				
thymidine kinase;			e de la companya de l	
gene therapy, cancer				
gene therapy, anti-	Clinicals		biotechnology; gene	cancer
metastasis technology				
gene therapy,	Preclinical		ology; gene	cancer
anticancer stem cell;				
gene therapy, cancer				

gene therapy, anticancer T cell; gene therapy, CC49; CC 49	Phase II	<u>1</u>	biotechnology; gene therapy	cancer
gene therapy, antisense c-myc; gene therapy, prostate cancer	Preclinical	<u> </u>	biotechnology; gene therapy	cancer
gene therapy, Bcl-xS, Preclinical cancer, IDUN	Preclinical	, T	biotechnology; gene therapy	cancer
gene therapy, BCR-ABL transcription inhibitor protein	Preclinical	, , , , , , , , , , , , , , , , , , ,	biotechnology; gene therapy	сапсет
gene therapy, brca1, Vanderbilt University	Phase II	ti Ti	biotechnology; gene therapy	cancer
gene therapy, breast cancer, gene therapy, brca1, MB 300	Preclinical		biotechnology; gene therapy	cancer
gene therapy, breast cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Preclinical	-Q	biotechnology; gene therapy	cancer
1	Phase I	b ti	biotechnology; gene therapy	cancer
gene therapy, cancer; GENECEUTICALS	Preclinical	D T	biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, T-body	Discontinued	ti Ti	biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical	4 0	biotechnology; gene therapy	cancer
gene therapy, cancer Preclinical	Preclinical	<u>o</u> 1	nology; gene	cancer

bene therany cancer	Draclinical			
range of data in a second			biotechnology; gene therapy	cancer
gene therapy, cancer;	Preclinical		hiotechnology, gene	100000
gene therapy, cationic			therapy	Califor
lipid vectors		-		
gene therapy, cancer;	Phase II		biotechnology; gene	cancer
gene therapy,			therapy	
immunostimulatory		**	•	
genes				
gene therapy, cancer,	Preclinical		biotechnology; gene	cancer
Copernicus Gene			therapy	
Systems				
gene therapy, cancer,	Preclinical		biotechnology; gene	cancer
, ion v			therapy	
gene therapy, chronic Phase I	Phase I		biotechnology; gene	cancer
myelogenous			therapy	
leukemia	-			
gene therapy, CIITA;	Preclinical	-	biotechnology; gene	cancer
gene therapy, MHC		_	therapy	
class II deficiency				
gene therapy,	Phase I		biotechnology: gene	cancer
cytosine deaminase			therapy	
gene therapy,	Suspended		biotechnology; gene	cancer
cytotoxic T cells;		-	therapy	
gene therapy, cancer			•	
gene therapy, del-1;	Preclinical		biotechnology; gene	coronary artery
gene therapy, vascular		+		disease; peripheral
disease; del-1				vascular disease;
				cancer
gene therapy, delta-	Preclinical		biotechnology; gene	cancer
2000 41			петару	
gene merapy, ang	Preclinical	· .	biotechnology; gene	cancer
acti vation		2	therapy	

gene therapy. E1A	Phase II			
repressor; gene			biotechnology; gene	cancer
therapy, cancer; RGG				
0853; RGA 0853; tgDCC-E1A				
gene therapy, Egr-1 + Preclinical	Preclinical		hiotechnology, gene	20000
TNF-alpha; gene			therapy	כפווכפו
therapy, Ad5.Egr-		-		
I'NF; gene therapy,			-	
technology		-		
gene therapy, ErbB2- Preclinical	Preclinical		biotechnology, gene	Cancer
R; gene therapy,			therapy some	
gene therapy, fas	Preclinical			
ligand: gene therany	T T COTTITION T		biotechnology; gene	cancer
cancer			tnerapy	
gene therapy,	Preclinical	1.2	iotechnology, gan	
fasdeltaTM; gene			therany	cancer
therapy, cancer		<u> </u>	(dn is:	
G156A	Preclinical	-C	biotechnology: gene	Cancer
MGMT; gene		===	therapy	Carlo
therapy, cancer		-		
gene therapy,	Preclinical	9	biotechnology; gene	cancer
giloolastoma; G20/		#	therapy	
gene therapy, glioma	Discontinued	9	biotechnology; gene	cancer
		T.	therapy	
gene merapy, GM-	Preclinical	ĮQ.	biotechnology; gene	cancer
		th.	therapy	
gene therapy, H-Nuc	Preclinical		biotechnology; gene	cancer
7710		tt	therapy	
gene therapy, H19;	Preclinical	<u>.</u>	biotechnology; gene	cancer
Bone undapy, cancel		L th	therapy	

S	Phase I	biotechnology; gene	ene cancer	
simplex thymidine kinase		therapy		
gene therapy, herpes	Preclinical	biotechnology; gene	ene cancer	
simplex tyrosine		therapy		
kinase; gene therapy HS-tk			· · · · · · · · · · · · · · · · · · ·	
gene therapy, HLA-	Preclinical	hiotechnology: gene	one cancer	T
B7; gene therapy,		therapy		
melanoma				
gene therapy, human	Preclinical	hiotechnology; gene	ine cancer	T
papillomavirus; gene		therapy		
merapy, HPV				
gene therapy, IL-12	Preclinical	biotechnology; gene	ne cancer; viral	
		therapy		
	Phase I	biotechnology; gene	ľ	
interleukin-2;		therapy	-	
gene therapy, interleukin-7	Discontinued	biotechnology; gene	ne cancer	
gene therapy. LeIF	Discontinued	hiotophall	T	T
		therapy	ne cancer	
gene therapy,	Phase I	biotechnology: gene	ne cancer	Τ
leukemia, Novartis; GVH 313		therapy		
	Preclinical	biotechnology: gene	ne cancer	Τ
- <u>}</u>		therapy		
stimulating factor	-			
gene therapy, mda-7; Preclinical	Preclinical	biotechnology; gene	ne cancer	T
gene therapy,	-	therapy		

gene therany MDR-	Phace I		hiotochan learn	
1. gene therany	•		ototeomiology, gene	cancer
cancer			therapy	
gene therapy, men1;	Preclinical		biotechnology: gene	cancer
gene therapy, cancer			therapy	
gene therapy, multi-	Preclinical		biotechnology; gene	cancer
drug resistance		t	therapy	
gene therapy,	Discontinued		biotechnology; gene	cancer
multiple drug		-	therapy	
resistance-1; gene			• .	
merapy, MDN-1				
gene therapy, p16,	Preclinical	<u> </u>	biotechnology; gene	cancer
Introgen; gene			therapy	
therapy, cancer,			- •	
Introgen; INGN 221				
gene therapy, p53;	Phase II		biotechnology; gene	cancer
gene therapy, cancer;			therapy	
SCH 58500		-		
gene therapy, p53;	Phase II		biotechnology; gene	cancer
gene therapy,		'	therapy	
retroviral p53; INGN			•	
101		:		
gene therapy, p53;	Phase II		biotechnology; gene	cancer
gene therapy,		\	therapy	
adenovirus p53; INGN 201		-		
gene therapy, p53;	Preclinical		biotechnology: gene	cancer
gene therapy, cancer;		<u> </u>	therany	
p53 TCS				
gene therapy, p53;	Preclinical	<u>a</u>	biotechnology; gene	cancer
gene therapy, cancer		t]	therapy	
gene therapy,	Preclinical	<u>: م.</u>	biotechnology; gene	cancer
DOS/INITIAIVE		1	therapy	

gene therapy, p53/WAF1	Discontinued		biotechnology; gene	cancer
gene therapy,	Phase I		biotechnology; gene	cancer
pancreatic cancer,			therapy	
Bavarian Nordic			•	
Research Institute;				
Procon CYP2B1				
gene therapy,	Preclinical		hiotechnology, gene	Concor
pRb2/p130; gene	<u>.</u>	-	therapy	Calloci
therapy, cancer				
gene therapy, pro-	Preclinical		biotechnology, gene	Cancer
drug activation		- ·	therapy	Calicol
gene therapy, prostate Phase I	Phase I		biotechnology: gene	Cancer
cancer, Calydon; CN		agente. T	therapy	TO THE
706		-		
	Preclinical		biotechnology: gene	cancer
gene therapy, cancer			therapy	
gene therapy, RB 94; Preclinical	Preclinical		hiotechnology, gene	
SG 94; RB 94		-	therapy	cancel
	Preclinical		biotechnology; gene	cancer
recombinant		-	therapy	
oncolytic HSV				
expressing CYP2B1;			~	
rRp450				
	Preclinical		biotechnology: gene	cancer
retinoblastoma gene;	_	_	therapy	
gene therapy, Rb				
Baile, ACIVID				

gene therapy,	Preclinical		hiotechnology, gene	10000
ribozyme, cancer,			therany	- Valloci
City of Hope Medical				
Center; ribozyme,				
cancer, City of Hope		• •	٠.	
Medical Center			**************************************	
gene therapy, scFv-	Preclinical		biotechnology; gene	cancer
gene therany colid	Droclinical		Therapy	
Build are apply, sollid	rrecimical		biotechnology; gene	cancer
BioMedica; MetXia			tnerapy	
gene therapy, T cell	Discontinued		biotechnology: gene	cancer
chimeric receptor;			therapy	
gene therapy, cancer		-		
gene therapy,	Phase III		biotechnology; gene	cancer
thymidine kinase;			therapy	
gene therapy, cancer;			•	
gene therapy, HS-tk;				
SDZ GLI328; GLI				
328				
gene therapy,	Discontinued		biotechnology: gene	Cancer
thymidine kinase;			therapy	
gene therapy,				
leptomeningeal				
carcinomatosis; gene				
therapy, HS-tk gene				
	Phase I		biotechnology: gene	cancer
			therapy	
gene therapy, HS-tk;		-		
gene therapy,				
mesothelioma				
		I		

gene therapy,	Phase I		biotechnology, gene	10000
thymidine kinase;		 -	therapy	Calical
gene therapy, HS-tk;			Change	
gene therapy brain				
cancer				
gene therapy,	Discontinued		hiofechnology, gene	***************************************
thymidine kinase;			therapy	calicel
gene therapy, HS-tk			urotapy .	
gene therapy,	Suspended		hiotechnology, gene	100000
thymidine kinase;			therapy	רשווכבו
gene therapy, HS-tk			dayan	
gene therapy,	Phase I		hiotechnology, gene	100
thymidine kinase;			therange	cancer
gene therapy, HS-tk			uici apy	
gene therapy,	Preclinical		hiotechnology, gene	
thymidine kinase;			theran;	Calicel
gene therapy, HS-tk			utciapy	
gene therapy,	Preclinical		biotechnology, gene	roote
thymidine kinase;			therany	Califor
gene therapy, HS-tk;			(day)	
gene therapy, cancer				
gene therapy,	Preclinical		biotechnology, gene	10000
thymidine kinase;			therapy	
gene therapy, cancer; INXC-gTK				
ķ,	Phase I		hiotechnology, gene	
lase,	-		therany	cancer
National Institute of			(day)	
Neurological	•			
Disorders and Stroke;			-	
gene therapy, HS-tk, NINDS		-		

gene therapy, TNF	Preclinical	biotechnology: gene	cancer
alpha		therapy	
gene therapy, tumor necrosis factor alpha.	Phase II	biotechnology; gene	cancer
gene therapy, solid		inerapy	
tumor			
toxigenes	Preclinical	biotechnology; gene	cancer
gene therapy,	Preclinical	biotechnology: gene	cancer
epithelial cell cancer,		therapy; alkylating	
CTL 302		agent	
gene therapy, liver	Preclinical	biotechnology: gene	cancer
cancer, Cobra		therapy; alkylating	
Therapeutics; CTL	-	agent	
gene therany prostate	Dreelinieel		
cancer. Cobra	riccillical	biotechnology; gene	cancer
Therapeutics: CTI		rnerapy; aikylating	-
401		agent	
	Preclinical	biotechnology; gene	cancer
angiogenesis	-	therapy: angiogenesis	
		inhibitor	
	Preclinical	biotechnology; gene	cancer
antiangiogenesis		 therapy: angiogenesis	
genes, cancer		inhibitor	
cancer;	Preclinical	biotechnology; gene	cancer
gene therapy,		therapy; angiogenesis	
angiogenesis		inhibitor	
Innibition			

como de caron				
gene merapy,	Frecinical	<u>.</u>	biotechnology; gene	cancer
antisense K-ras;		=	therapy; antisense;	
antisense		<u>o</u>	oligonucleotide	
oligonucleotide, K-				
ras; INGN 111				
gene therapy,	Preclinical	9	biotechnology; gene	cancer
chemotherapy-			therapy;	
resistance genes; gene		Ö	chemoprotectant;	
therapy, MDR		Ę	hematoprotectant	
	Phase I	q	biotechnology; gene	cancer
gene therapy, cancer;		7	therapy:	
gene therapy, MDR-		<u>'</u>	chemoprotectant:	
1; MDRx1		Ē	nematoprotectant	
gene therapy, MDR-	Phase I		biotechnology; gene	cancer
1; gene therapy,	-	-	therapy;	
cancer			chemoprotectant;	
		, Č	hematoprotectant	
	Preclinical	Q	biotechnology; gene	cancer
gp91phox; gene		<u> </u>	therapy; coagulation	
therapy chronic	•		factor	-
granulomatous				
disease			₹	
gene therapy, Sdi 1;	Discontinued	iq	biotechnology; gene	cancer
gene therapy, cancer		th	therapy; cyclin	
		<u>ਚੌ</u>	dependent kinase	
		ii	nhibitor	
er;	Phase I	iq.	biotechnology; gene	cancer
gene therapy, VV-		4	therapy; cytokine;	
СМ		i	immunostimulant	

gene therapy, cancer; Preclinical	Preclinical	biotechnology; gene	gy; gene	cancer
gene therapy,		therapy; cytokine;	okine;	
cytokine; gene		immunostimulant	nulant	
therapy,				
immunostimulatory				
cell surface molecules				
gene therapy,	Preclinical	biotechnology; gene	gy; gene	cancer
consensus interferon;		therapy; cytokine;	okine;	
gene therapy, IFN-		immunostimulant	nulant	
con1; gene therapy,				
cancer			* • •	
gene therapy, IL-2;	Phase II	biotechnology; gene	gy; gene	cancer
gene therapy, cancer;		therapy; cytokine;	okine;	
BIWB 2		immunostimulant	nulant	
gene therapy, IL-3,	Preclinical	biotechnology; gene	gy; gene	cancer
IntroGene; gene		therapy; cytokine;	okine;	
therapy, cancer,		immunostimulant	nulant	
IntroGene				
gene therapy,	Preclinical	biotechnology; gene	gy; gene	cancer
interferon beta; gene		therapy; cytokine;	okine;	
therapy, cancer		immunostimulant	nulant	
gene therapy,	Phase II	biotechnology; gene	gy; gene	cancer
interleukin-12; gene		therapy; cytokine;	okine;	
therapy, cancer		immunostimulant	nulant	
gene therapy,	Preclinical	biotechnology; gene	gy; gene	cancer
interleukin-12/B7-1;		therapy; cytokine;	okine;	
gene therapy,		immunostimulant	nulant	
AdIL12.B7-1; gene				
therapy, cancer;	·		•	
AdIL12.B7-1				
	Phase I	biotechnology; gene	gy; gene	cancer
interleukin-2; gene		therapy; cytokine;	okine;	
therapy, cancer		immunostimulant	nulant	٠

gene thereas:	101			
interlenting,	rnase i		biotechnology; gene	cancer
therapy, cancer			therapy; cytokine;	
gene therapy,	Preclinical		biotechnology; gene	cancer
interleukin-2; gene			therapy; cytokine;	
therapy, melanoma			immunostimulant	
gene therapy,	Phase II		biotechnology; gene	cancer
interleukin-2; gene			therapy; cytokine;	
therapy, cancer			immunostimulant	
gene therapy,	Phase I		biotechnology: gene	Cancer
interleukin-2; gene			therapy: cytokine:	
therapy, cancer; AC			immunostimulant	
9401; MetaGene				
gene therapy,	Phase II		biotechnology, gene	Cancer
interleukin-2; gene			therany cytokine.	
therapy, cancer; VCL			imminostimiilant	
1102; LEUVECTIN				
gene therapy,	Discontinued		biotechnology, gene	rongo
interleukin-2; gene			therapy: cytokine.	
therapy, breast			imminostimilant	
cancer; AVECTIN		•		
gene therapy,	Discontinued		biotechnology: gene	Cancer
interleukin-2; gene		<u> </u>	therapy: cytokine:	
therapy, cancer;		·#	immunostimulant	
	Preclinical	,D	biotechnology; gene	cancer
interleukin-2; gene			therapy; cytokine;	
er			immunostimulant	
	Phase I	. <u></u>	biotechnology; gene	cancer
interleukin-2; gene			therapy; cytokine;	
therapy, cancer			immunostimulant	

gene therapy,	Phase I		hiotochao logan	
interleukin-2; gene			therapy: Cytokine:	cancer
therapy,			imminostimilant	
neuroblastoma				
gene therapy,	Phase I		biotechnology: gene	Cancer
interleukin-2; gene			therapy: cytokine:	700
therapy, colon cancer			immunostimulant	
gene therapy,	Phase I		hiotechnology, gene	100000
interleukin-2; gene			therapy cytokine.	Canoca
therapy, IL-2; gene			imminostimilant	
therapy, melanoma				
gene therapy,	Preclinical		hiotechnology, gene	***************************************
interleukin-2 +			therapy cytokine.	כמוזכנו
interferon gamma;			imminostimulant	
gene therapy, cancer				
gene therapy.	Phase I		hintohan lamin	
interleukin-2 +			olotechilology; gene	cancer
thymidine binese:			therapy; cytokine;	
my minding Killase,			immunostimulant	•
gene therapy, cancer			€	
gene therapy,	Preclinical		biotechnology: gene	cancer
interleukin-2,			therapy: cytokine:	
interferon gamma,		-	imminostimilant	
thymidine kinase;		· ·		
gene therapy, cancer			-	
gene therapy,	Preclinical		biotechnology; gene	cancer
interleukin-4; gene			therapy: cytokine:	
therapy, melanoma			immunostimulant	
	Suspended		100	Cancer
interleukin-7; gene				
therapy, IL-7; gene			immunostimulant	
therapy, malignant			- da	
melanoma				
			T	

	Phase I	4	biotechnology, gene	Cancer
interleukin-7; gene	-	1	therapy: cytokine:	
therapy, IL-7		i	immunostimulant	
gene therapy, tumor	Preclinical	q	biotechnology; gene	cancer
necrosis factor; gene		th the	therapy: cytokine:	
therapy, TNF; gene			mmunostimulant	
therapy, cancer				
!	Phase I		biotechnology: gene	cancer
		丑	therapy; cytokine;	
therapy, cancer		ui.	immunostimulant	
NV 1030	Preclinical	iq	biotechnology; gene	cancer
		##	herapy; cytokine;	
		<u>.u.,</u>	immunostimulant;	
		ar	angiogenesis inhibitor	
,	Phase I	iq	biotechnology; gene	cancer
granulocyte		1	therapy; cytokine;	
macrophage-colony			mmunostimulant:	
stimulating factor,			Vaccine	
Geniva; gene therapy,	 ,	<u> </u>		-
cancer, Geniva		<u> </u>		
MDR,	Phase II	id	biotechnology: gene	cancer
GenPak; gene		ţ.		
therapy, cancer	-	he	hematoprotectant;	
		ch	chemoprotectant	
	Preclinical	bid	ene	cancer
gene therapy, cancer		th.	therapy;	
		he	hematoprotectant;	-
		ch	chemoprotectant	

gene therapy, HLA-	Phase III		biotechnology, gene	cancer
B7; gene therapy,			therapy:	
cancer; gene therapy,			immunostimulant	
Action 1				
complex;			- ^	
ALLOVECTIN-7			- · ·	
gene therapy, IL-2;	Phase I		biotechnology; gene	cancer
gene therapy, small			therapy;	
cell lung cancer; gene			immunostimulant	
therapy, BPV vector		-		
erapy, suicide	Preclinical		biotechnology; gene	cancer
gene +		٠	therany	
immunotherapeutic;			immunostimulant	
gene therapy, cancer				
gene therapy, gamma	Phase I		biotechnology: gene	cancer
interferon; gene			therapy:	
therapy, cancer			immunostimulant:	
			cytokine	
gene therapy, GM-	Phase II		biotechnology; gene	cancer
CSF; gene therapy,			therapy;	
cancer; vaccine,			immunostimulant:	
cancer; GVAX			cytokine	
gene therapy,	Preclinical		biotechnology; gene	cancer
interleukin-10; gene		•	therapy;	
therapy, cancer	•		immunostimulant;	
			cytokine	
	Phase I		biotechnology; gene	cancer
interleukin-2; gene			therapy;	
therapy, melanoma;			immunostimulant;	
gene therapy,			cytokine	
tyrosinase promoter				
		7		

gene therany	Dt. 7			
Some merapy,	r liase I		biotechnology; gene	cancer
merieukin-z; gene		_	therapy;	
therapy, melanoma			immunostimulant;	-
			cytokine	
gene therapy,	Phase I		biotechnology; gene	cancer
interleukin-2; gene			therapy;	
therapy, melanoma			immunostimulant;	
			cytokine	
gene therapy,	Phase I		biotechnology; gene	cancer
interleukin-2; gene		- 	therapy;	
therapy, melanoma		<u></u>	mmunostimulant;	
		0	cytokine	
gene therapy,	Phase I		biotechnology; gene	cancer
interleukin-2; gene			therapy;	
therapy, AdCAIL-2;			immunostimulant;	
gene therapy, cancer;		7: . .a.	cytokine	
		-		
	Phase I	<u>a</u>	biotechnology: gene	cancer
ene			therapy:	
therapy, cancer		ii.	immunostimulant;	
		3	cytokine	
gene therapy,	Preclinical	<u>q</u>	biotechnology; gene	cancer
interleukin-4; gene			therapy;	
therapy, melanoma		<u>: II</u>	mmunostimulant;	
		C	cytokine	
gene therapy,	Preclinical	Q_	biotechnology; gene	cancer
leukemia; gene		=	therapy;	
therapy,		<u>.:11</u>	immunostimulant;	
hmmunostimulatory molecules		<u>ö.</u>	cytokine	
in course				

gene therapy,	Preclinical	hiotechnology: gene	
interferon alfa		therapy;	carico
		immunostimulant;	
•		cytokine; interferon	
gene therapy,	Preclinical	biotechnology; gene	cancer
interteron gamma;		therapy;	
gene therapy, cancer		immunostimulant;	
		 cytokine; interferon	
gene therapy, MRP;	Preclinical	 biotechnology; gene	cancer
gene therapy, cancer	•	 therapy; MDR	
		inhibitor	
gene therapy,	Discontinued	biotechnology: gene	Cancer
multidrug resistance;		therapy: MDR	
gene therapy, MDR		inhibitor	
gene therapy, herpes	Phase I	biotechnology: gene	rhenmatoid arthritic.
simplex thymidine	•	therapy: NSAID	restenosis: cancer
kinase gene; gene			coronosis, cancon
therapy, cancer		-	
	Phase I	biotechnology: gene	cancer
growth		therapy:	
factor beta;		oligonucleotide	
oligonucleotide, TGF		-	
beta	• •		
	Preclinical	biotechnology; gene	cancer
hammerhead	~	therapy:	
ribozyme, cancer,		 oligonic leotide:	
Berlex Biosciences;	-	 rihozyme	
ribozyme, c-erb-B2,			
Berlex Biosciences			

2000 th 0000	14			
Adamerapy,	Fnase II		biotechnology; gene	cancer
thomas: Ordering		-	therapy;	
ulerapy, cytosine	110		radiosensitizer	
deaminase; gene				
therapy, colon cancer				
gene therapy, p53;	Preclinical		biotechnology; gene	cancer
vaccine, p53; gene			therapy: vaccine	
therapy, cancer				
vaccine, gene-based,	Phase I		biotechnology: gene	cancer
B cell lymphoma			therapy; vaccine	
vaccine, gene-based,	Preclinical		biotechnology: gene	cancer
carcinoembryonic	٠.	٠	therapy: vaccine	
antigen; vaccine,				
gene-based, pGT37;	-			
vaccine, gene-based,				
cancer				
vaccine, gene-based,	Preclinical		biotechnology: gene	cancer
E7; vaccine, gene-			therapy: vaccine	
based cancer			omoon, (dame	
	Phase I		biotechnology; gene	cancer
gp100; vaccine, gene-	٠.		therapy: vaccine	
based, melanoma				
vaccine, gene-based,	Phase II		biotechnology: gene	cancer
gp100 + MART-1;			therapy; vaccine	
vaccine, gene-based,				
melanoma			-	
TÎ	Phase I		biotechnology: gene	cancer
MART-1; vaccine,			therapy: vaccine	V
gene-based, cancer				

vaccine, gene-based.	Preclinical		biotechnology, gene	cancer
melanoma, Bavarian		<u> </u>	therapy; vaccine	
Nordic Research				
Institute; gene				
therapy, melanoma,			~	
Bavarian Nordic			-	
Research Institute;				
MVA TYR			•	
vaccine, gene-based,	Preclinical		biotechnology; gene	cancer
NY-ESO-1; vaccine,		1.	therapy; vaccine	
gene-based, cancer			- •	
vaccine, gene-based,	Preclinical	, L	biotechnology; gene	cancer
T cell cancer		<u> </u>	therapy; vaccine	
vaccine, human	Discontinued	T.	biotechnology; gene	cancer
papillomavirus		'42'	therapy; vaccine	
antigens; vaccine				
HPV antigens;				
vaccine, cervical			•	
cancer				
anti-dorsalizing	Preclinical		biotechnology; growth cancer	cancer
morphogenetic		<u> </u>	factor	
protein-1				
heregulin; Neu	Discontinued	. :	biotechnology; growth cancer	cancer
differentiation factor;			factor	
TONI TONI				
megakai yocyte	Discontinued	<u> </u>	biotechnology; growth cancer	cancer
Statitulatilig lactor		4	ractor	
Red blood cell growthPreclinical	Preclinical	<u>م</u>	biotechnology; growth cancer	cancer
factor		¥1	factor	
transforming growth	Preclinical	<u>.a.</u>	biotechnology; growth cancer; mucositis	cancer; mucositis
factor beta; TGF beta;		44	factor	
2101 1701EJ				

keratinocyte growth Phase II factor 2; KGF 2; HG granulocyte growth Phase II factor 2; KGF 2; HG granulocyte process and the macrophage colony stimulating factor muteins, GM-CSF muteins GM-CSF muteins, GM-CSF muteins polyethylene glycol phase I factor process and development factor; percelinical process and development factor; percelinical process and development factor; percelinical process and development factor glycol; PeG-GM-CSF; PolyMASC-GM-CSF; PolyMASC-GM-CSF; PolyMASC-GM-CSF; PolyMASC-GM-CSF; PolyMASC-GM-CSF; PolyMASC-GM-CSF thrombopoietin; TPO; Phase III factor growth and development factor; percentage and development factor development factor development factor development factor development facto	Preclinical biotechnology; growth mucositis; cancer;	is; cancer;
ocyte growth Phase II 2; KGF 2; HG boyte Preclinical brage colony tting factor s; GM-CSF s sylene glycol Phase I lobin; PEG- lobin lylene glycol Discontinued and and oment factor; IGDF lylene Preclinical brage colony ting factor PEG-GM- olyMASC- SF s sylene and oryte hage colony ting factor PEG-GM- olyMASC- SF sylene hage colony ting factor PEG-GM- olyMASC- SF sylene brage colony ting factor PEG-GM- olyMASC- SF sylene opoietin; TPO; Phase III	factor musculo	musculoskeletal
ocyte growth Phase II 2; KGF 2; HG bodyte Preclinical hage colony tting factor s; GM-CSF s stylene glycol Phase I lobin; PEG- lobin lylene glycol Discontinued and and ment factor; IGDF ylene bylene preclinical ting factor PEG-GM- olyMASC- SF stylene bylene by	disorder	•
2; KGF 2; HG beyte hage colony ting factor s; GM-CSF s sylene glycol Phase I lobin; PEG- lobin sylene glycol Discontinued and sylene glycol Discontinued and sylene glycol Discontinued and tryocyte and tryocyte hage colony ting factor PEG-GM- olyMASC- SF sylene FRG-GM- olyMASC- SF sylene sylene by and tryocyte and sylene by Freclinical coyte hage colony tryocyte and	II biotechnology; growth cancer; mucositis;	mucositis;
byte hage colony tting factor s; GM-CSF s sylene glycol lobin; PEG- lobin; PEG- lobin nylene glycol Discontinued and mycyte and myerye figDF ylene hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO; Phase III ryocyte and myerye hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO; Phase III ryocyte and mment factor; figner fign	factor; cicatrizant; skin ulce	skin ulcer; alopecia;
bhage colony tting factor s; GM-CSF s sylene glycol Phase I lobin lylene glycol Discontinued aryocyte and oment factor; IGDF lobin lylene phase I lobin sylene glycol Discontinued and oment factor; IGDF lylene Preclinical cyte hage colony ting factor PEG-GM- olyMASC- lyF opoietin; TPO; Phase III ryocyte and and myocyte hage colony ting factor perclinical cyte hage colony ting factor preclinical cyte hage colony ting factor		disease
beyte Preclinical hage colony thing factor s; GM-CSF s si GM-CSF s; GM-CSF si GM-CSF si GM-CSF si GM-CSF si GM-CSF si GM-CSF subject glycol Discontinued and and sund factor bylene glycol Discontinued bylene glycol Discontinued and sund sund strong factor bylene Preclinical bylene b	cytoprotectant	
tting factor s; GM-CSF s; GM-CSF sylene glycol Phase I lobin; PEG- lobin lylene glycol Discontinued and sment factor; IGDF sylene hage colony ting factor PEG-GM- olyMASC- lylene hage colony ting factor PEG-GM- and sylene hage colony ting factor had factor	nical biotechnology; growth cancer	
tting factor s; GM-CSF s GM-CSF s GM-CSF sylene glycol Phase I lobin; PEG- lobin sylene glycol Discontinued and sment factor; GDF sylene cyte hage colony ting factor PEG-GM- olyMASC- sylene olyMASC- sylene and nyocyte and nyocyte and nyocyte and nyocyte and	factor; hematopoietic	
s; GM-CSF s lobin; PEG- lobin lobini, PEG- lobin lylene glycol Discontinued aryocyte and sment factor; IGDF lylene loyte hage colony ting factor PEG-GM- olyMASC- lyF opoietin; TPO; Phase III ryocyte and mment factor; logmand logma	factor	
sylene glycol Phase I lobin; PEG- lobin sylene glycol Discontinued aryocyte and sment factor; IGDF sylene Preclinical coyte hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO; Phase III ryocyte and mment factor;		
ylene glycol Phase I lobin; PEG- lobin lylene glycol Discontinued aryocyte and oment factor; IGDF ylene Preclinical cyte hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO; Phase III ryocyte and and ment factor;		
lobin; PEG- lobin sylene glycol Discontinued and sment factor; IGDF sylene Preclinical cyte hage colony ting factor PEG-GM- olyMASC- SyF opoietin; TPO; Phase III tryocyte and and ment factor;	I biotechnology; growth cancer: anemia	anemia
lobin sylene glycol Discontinued and and ment factor; IGDF ylene Preclinical cyte hage colony ting factor PEG-GM- olyMASC- syF opoietin; TPO; Phase III uyocyte and ment factor;	factor; hematopoietic	
aryocyte and oment factor; (GDF ylene cyte hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO; Phase III uryocyte and oment factor;	factor	
aryocyte and ment factor; IGDF ylene cyte hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO;Phase III ryocyte and ment factor;		
and ment factor; IGDF ylene Preclinical cyte hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO;Phase III ryocyte and ment factor;	factor; hematopoietic thrombo	thrombocytopenia
oment factor; IGDF ylene Preclinical cyte hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO;Phase III uryocyte and ment factor;		•
IGDF ylene Preclinical cyte hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO; Phase III ryocyte and ment factor;		
ylene Preclinical hoyte hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO; Phase III uyocyte and and	7.	
hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO;Phase III uyocyte and ment factor;	nical biotechnology; growth cancer	
hage colony ting factor PEG-GM- olyMASC- SF opoietin; TPO;Phase III tryocyte and oment factor;	factor; hematopoietic	
ting factor PEG-GM- olyMASC- SF opoletin; TPO;Phase III rryocyte and oment factor;	factor	
PEG-GM- olyMASC- SF opoietin; TPO;Phase III uryocyte and ment factor;		
olyMASC- SF opoietin; TPO; Phase III uyocyte and and ment factor;		
opoietin; TPO; Phase III uyocyte and ment factor;		
opoietin; TPO;Phase III ryocyte and oment factor;		
uryocyte and oment factor;	III biotechnology; growth cancer;	
and oment factor;	factor; hematopoietic thromboo	thrombocytopenia
development factor;		•
#C5W		

mountain, 11 O	thrombopotetin; TPO Discontinued		biotechnology: growth cancer.	cancer.
			factor; hematopoietic	thrombocytopenia
hrombopoietin; TPO Preclinical	Preclinical		biotechnology; growth cancer:	cancer;
			factor; hematopoietic	thrombocytopenia
milodistim;	Discontinued	APARSPSPST	biotechnology: growth cancer	Cancer
granulocyte		OPWEHVNAIO	factor: hematonoietic	California
macrophage colony		EALRLLDLSR	factor; cytokine;	
stimulating		DTAAEMNEEV	immunostimulant	
factor/interleukin-3		EVISEMFDLQ		
chimeric; GM-		EPTCLQTRLE		
CSF/IL-3 chimeric		LYKQGLRGSL		
protein; PIXY 321;		TKLKGPLTMM		
BMS 185032;		ASHYKQHCPP	-	
PIXYKINE		TPETSCATQI		
		ITFESFKENL		
		KDFLLVIPFD		
		CWEPVQEGGG		
		GSGGGGSAD		
		MTQTTPLKTS		
	•	WVDCSNMIDE		
		ITHLKQPPL		
		PLLDFNNLNG		
•		EDQDILMENN		
		CRRPNLEAFN		
		RAVKSLQDAS		
	3	AIESILKNLL		
	-	PCLPLATAAP		
-		RHPIHIKDG		
		OWNEFRRKLT		
	<u> </u>	FYLKTLENAQ		
	7	AQQTTLSLAI F		

SD-144110.1

cilmostim;	Discontinued		biotechnology; growth hyperlipidemia.	hyperlipidemia:
macrophage colony			factor; hematopoietic	bacterial infection;
stimulating factor; M-			factor;	cancer
CSF; MACSTIM			immunostimulant	
filgrastim;	Marketed	N-L-methionyl-	biotechnology; growth cancer; HIV	cancer; HIV
granulocyte colony		colony-stimulating	factor; hematopoietic	infection;
stimulating factor; G-		factor (human clone		pneumonia;
CSF; neutropoietin;		1034)	immunostimulant;	leukopenia; skin
KRN 8601;			cicatrizant	ulcer
NEUPOGEN;				
GRANULOKINE;		-		
GRAN; GRIMATIN				
filgrastim SD01;	Phase II		biotechnology; growth cancer; HIV	cancer; HIV
PEG-granulocyte-		-	factor; hematopoietic	infection;
colony stimulating				pneumonia;
factor; PEG-GCSF;			immunostimulant	leukopenia
SD-NEUPOGEN		•		
granulocyte	Phase III		biotechnology; growth cancer; leukopenia	cancer; leukopenia
macrophage colony			factor; hematopoietic	•
stimulating factor;			factor;	
GM-CSF;			immunostimulant	
LEUCOTROPIN				
macrophage	Preclinical		biotechnology; growth cancer	cancer
inflammatory protein-			factor; hematopoietic	
lalpha; MIP-1alpha			factor;	
			immunostimulant	

molgramostim;	Marketed	colony stimulating	biotechnology; growth cancer; leukopenia	cancer; leukopenia
granulocyte		factor 2 (human clone factor; hematopoietic	factor; hematopoietic	4
macrophage colony		pHG25 protein	factor;	
stimulating factor;		moiety reduced)	immunostimulant	
GM-CSF; GMC				
89107; SCH 39300;				
CSF 39300;				
LEUCOMAX				
nartograstim;	Marketed	1-(N-L-methionyl-L-	biotechnology; growth cancer: leukonenia	cancer: leukonenia
marograstim;		alanine)-3-L-	factor; hematopojetic	
granulocyte colony		threonine-4-L-	factor;	
stimulating factor		စ္ခဲ	immunostimulant	
mutein; G-CSF		17-L-serine-colony-		
mutein; KW 2228;		stimulating factor		
NEU-UP		(human clone 1034)		
	PapuadsnS	Г	biotechnology; growth cancer	cancer
pegylated G-CSF			factor; hematopoietic	
mutein; PEG-G; Ro			factor;	
258315; Ro 25-8315;			immunostimulant	
Ro 25-8315/000				
polyethylene glycol	Discontinued		biotechnology; growth cancer	cancer
granulocyte colony			factor; hematopoietic	
stimulating factor;	•		factor:	
PEG-G-CSF;			mmunostimulant	
granulocyte colony			-	
stimulating factor				
macrogol				
	Preclinical		biotechnology; growth cancer	cancer
progenipoietin G; SD			factor; hematopoietic	
1001			factor;	- 11
			immunostimulant	

11				
footpotent stem cell	Prechnical		biotechnology; growth cancer	cancer
racioi, 1-5CF			factor; hematopoietic	
			factor;	
			immunostimulant	
FLT3 ligand, DNAX Preclinical	Preclinical		biotechnology; growth cancer	cancer
Research Institute;			factor;	
FLT 3			immunostimulant;	
			hematopoietic factor	
Fit3 ligand,	Phase II		biotechnology; growth cancer	cancer
Immunex; FLT 3;			factor;	
FLI 003; MOBIST			immunostimulant;	
			hematopoietic factor;	
			vaccine adjuvant	
stem cell proliferation Preclinical	Preclinical		biotechnology; growth cancer	cancer
ractor; SCPF			factor;	
	•		immunostimulant;	
			hematopoietic factor	
DWP 404	Preclinical		biotechnology;	cancer;
			hematopoietic factor:	thrombocytonenia
			growth factor	1
TPO-Rp	Preclinical	- -	biotechnology;	thrombocytopenia:
			hematopoietic factor;	cancer
			growth factor; peptide	
thyroid stimulating	Marketed	thyrotropin (human	biotechnology;	cancer; diagnosis;
normone; ISH;		.betasubunit)	hormone	hypothyroidism
MANAGERA		complex with		
		gonadotropin (human		
lycol	Discontinued		biotechnology;	cancer
arginase; PEG-			hydrolase; arginase;	
at ginase, at ginase macrogol			enzyme	

pegaspargase; polyethylene glycol L-asparaginase: PEG-	Marketed	pegaspargase	biotechnology; hydrolase;	cancer
L-asparaginase;	····		مالالإعام، مسكري	
asparaginase				
macrogol; ONCASPAR			•	
cervical cancer	Preclinical		biotechnology;	cancer
therapy, Transgene			immunostimulant	
immunotherapeutic,	Phase II		biotechnology;	cancer
cancer, Transgene			immunostimulant	
mistletoe lectin;	Preclinical		biotechnology;	cancer
mistellektin			immunostimulant	
is.	Discontinued		biotechnology;	cancer
receptor; FLK 2			immunostimulant	
gene therapy,	Phase II		biotechnology;	cancer
macrophage activated			immunostimulant;	
killer cells plus			gene therapy	
bispecific antibody;				
MAK therapy; MAK			- · -	
em cell	Pre-	N-L-methionyl-1-	biotechnology;	cancer
••	registration	165-hematopoietic	immunostimulant;	
STEMGEN		cell growth factor KL growth factor;	growth factor;	
			hematopoietic factor	
	-	V 19.8:nSCF 162) dimer		
í	Suspended		biotechnology;	cancer
stimulating factor;			immunostimulant;	
BM 800001			growth factor;	
			hematopoietic factor	

interleukin-9; IL-9	Discontinued		biotechnology;	cancer
-			immunostimulant;	
			growth factor; hematonoietic factor	
lenograstim;	Marketed	133-[O-[O-(N-acetyl-biotechnology;	biotechnology;	anemia; HIV
granulocyte colony		alpha-neuraminosyl)- immunostimulant;	immunostimulant;	infection; cancer;
stimulating factor; G-		(2-3)-O-beta-D-	growth factor;	leukopenia
CSF; pluripoietin;		galactopyranosyl-(1-	hematopoietic factor	•
NEUTROGIN;		3)-2-(acetylamino)-2-		
GRANOCYTE;		deoxy-beta-D-		
EUPROTIN;		galactopyranosyl]-L-		
MYELOSTIM		threonine]-colony		
		stimulating factor		
		(human clone 1034)		
sargramostim;	Marketed	Ŀ	biotechnology;	cancer: infections
granulocyte			immunostimulant;	disease; HIV
macrophage colony		(human clone pHG25	growth factor;	infection; leukopenia
stimulating factor;		protein moiety)	hematopoietic factor;	
GM-CSF; BI 61012;			vaccine adjuvant	
rhu GM-CSF;				
LEUKINE;				
PROKINE;			-	-
INTERBERIN				
stem cell factor; SCF	Discontinued	٠	biotechnology;	cancer
		• ===	immunostimulant;	
		<u>uu</u>)	growth factor;	
			hematopoietic factor	
ImmTher	Phase II	<u></u>	biotechnology;	cancer
		<u>.</u>	immunostimulant;	
			peptide	

D-144110

			* : ·	
vaccine, prostate	Phase II		biotechnology;	cancer
cancer; JT 1001;		-	immunostimulant:	
Onco Vax-P;			vaccine	
Onco Vax-Pr				
cytokine cocktail;	Phase II		biotechnology:	cancer, infections
BC-IL; leukocyte		-45	imminostimilant	disease. HIV
interleukin injection:			Washing administration	infootion
MULTIKINË			vaccine aujuvani, cvtokine	Intection
ZYN-LINKER	Suspended		biotechnolopy:	rhenmatoid arthritie.
conjugated	,		immunosuppressant:	cancer
superantigens		.:e	immunostimulant:	
			NSAID	
MAb, human	Phase I		biotechnology	autoimmune disease.
interleukin-6		•	imminosimpressant.	Canonia discaso,
receptor; MAb,	-		monoclonal antihody	Cario
human IL-6 receptor;		•		
hPM-1; MRA				
E 21R	Preclinical		biotechnology;	cancer;
		<u>.a</u>	immunosuppressant;	inflammation;
		4		allergy
G28-5 sFV-PE40	Preclinical	q	ology;	cancer
		.E	immunotoxin	
in,	Discontinued	<u>.a.</u>	biotechnology;	cancer
oma		· E	immunotoxin	
	Phase I	<u>.a</u>	biotechnology;	cancer
giloma/neuroblastoma		<u>. II</u>	mmunotoxin	
-gelonin; GLIOMAB- H	``			
immunotoxin, cancer,	Preclinical	Q	biotechnology:	cancer
Immunomedics/NCI			1.00	
		TT	יייייייייייייייייייייייייייייייייייייי	

A C A L				
pyrao, epidermai	Preclinical	biotechnology.	loov.	Concor
growth factor		mminotoxin	viet,	1001180
receptor-DM1; MAb,		nologia	monoclonel entitled	
EGFR-DM1		TOPOTOTI	iat aiitibouy	
MAb, interleukin-13- Preclinical	Preclinical	hiotochuologu	10001	
PE38QQR;		imminotoxini	Jogy,	cancer
immunotoxin. IL-13-			, ;; · ;	
PE38QQR			monocional antibody	
MAb, ricin A	Discontinued	hiotechnology	1001	
immunotoxin. MAh			, 65,	Calicel
colonatel and The		immunotoxin;	xin;	
colorectal cancer; LD		monoclon	monoclonal antibody	
0490; ICI D0490			ar arresoldy	
MAh SS(AsEv) DE38 Draglining	Drootinioot			
טכט גיין אפש)טט יטי יזיי	riccillical	biotechnology;		cancer
		immunotoxin;	xin;	
		monoclona	monoclonal antibody	
ф	Preclinical	biotechnology;	T	cancer; diagnosis
ciusiei conjugate		immunotoxin;)
		monoclona	monoclonal antibody	

nacolomab tafenatox; Phase I	Phase I	20-244-	biotechnology:	cancer
MAb, C242-		immunoglobulin G1,		
staphylococcal		anti-(human	monoclonal antibody	
enterotoxin A; FAb,		colorectal tumor	•	
C242-staphylococcal		antigen C242) Fab		
enterotoxin A; PNU		fragment (mouse		
214565; LS 4565;		monoclonal r-	-	
TTMA LS 4585		C242Fab-SEA clone		
		pKP941 gamma1-		
		chain) fusion protein		
		with enterotoxin A	. %	
		(Staphylococcus		
		aureus), disulfide		
		with mouse	•	
		monoclonal r-	<u></u>	-
		C242Fab-SEA clone		
		pKP941 kappa-chain	·.	
MAb, doxorubicin	Phase II		biotechnology:	cancer
conjugate; MAb, BR			immunotoxin:	
96-doxorubicin;			monoclonal antihody.	
MAb, BR 96-DOX;			anthracycline.	_
BMS 182248; BMS			antibiotic: DNA	
18224801			intercalator	
MAb, B43-genistein; Phase I	Phase I		.00	- Concor
B43-Gen		•••		
immunoconjugate	٠		monoclonal antibody;	
			tyrosine kinase	
			inhibitor	

drug delivery system, Pre- interferon alfa; regi	Pre- registration		biotechnology; interferon	viral infection;
interferon alfa drug delivery system;)			
SUMIFERON MINIPELLET				
drug delivery system,	Discontinued		biotechnology;	cancer; viral
interferon beta;		• • • •	interferon	infection; cancer;
interieron beta		. 1.	<u>.</u>	viral infection
delivery system; drug		***	· .	
delivery system, IFIN beta				
drug delivery system, Suspended	Suspended		biotechnology:	cancer: viral
oral interferon alfa-		-	interferon	infection
2a; İFN alfa-2a, oral				
interferon alfa,	Marketed		biotechnology;	cancer: viral
natural; IFN-alfa,	-		interferon	infection
natural; EGIFERON				
interferon alpha,	Preclinical		biotechnology;	viral infection;
hybrid; hybrid			interferon	cancer
interferon alpha				
interferon alpha,	Pre-		biotechnology;	viral infection:
natural; FPI 31	registration		interferon	cancer
interferon beta; IFN-	Marketed		biotechnology;	viral infection;
beta; DL 8234; FERON			interferon	cancer; retinopathy
interferon beta; IFN-	Discontinued		biotechnology;	cancer: viral
			interferon	infection
	Marketed	interferon beta-1a	biotechnology;	viral infection;
IFN beta; AVONEX			interferon	multiple sclerosis;
				cancer

interteron beta-1a;	Marketed		biotechnology;	cancer; viral
heta: REBIE			interteron	infection; multiple
octa, ALLLIII				sclerosis;
				inflammatory bowel
interference Late 11.				disease
illerieron beta-10;	Marketed	2-166-interferon beta	biotechnology;	multiple sclerosis;
interteron beta-serine;		1 (human fibroblast	interferon	cancer; viral
SH 579; ZK 157046;		reduced)		infection
BETASERON;				
BENESERON;				
BETAFERON				
mega;	Phase II		biotechnology:	viral infection.
			interferon	Cancer
polyethylene glycol	Phase III		hiotechnology.	viral infaction.
interferon alfa-2b;			interferon: cytokine	rital milection,
PEG-interferon alfa-			merica cui, cy torum	Carioci
2b; interferon alfa-2b				
macrogol; PEG-			•	
INTRON A				
interferon alfa-2b;	Marketed		biotechnology:	cancer viral
IFN alfa-2b; SCH			interferon: cytokine:	infection
30500; YM 1490;			immunostimulant	
INTRON A;				
CIBIAN;				
VIRAFERON				
tumor necrosis factor	Discontinued		biotechnology:	cancer
+ interferon alfa-2a;			vth	
interferon alfa-2a +		<u> </u>	factor	
tumor necrosis factor;	٠			
TNF + IFN alfa-2a				

interferon alfa-2a:	Marketed	Chiman leukocyte	hiotochaolom	.:1
IFN alfa-2a; Ro		protein moiety)	interferon:	vital intection;
228181; ROFERON A; CANFERON A;		interferon alpha A	immunostimulant	Cancol
ROFERON		-		
interferon gamma-1a; Marketed	Marketed		biotechnology;	cancer
BIOGAMMA	-		interteron; immunostimulant	
interferon gamma-1b; Marketed	Marketed		biotechnology;	cancer: hacterial
interferon gamma;			interferon;	infection: chronic
IFN gamma;			immunostimulant	granulomatous
ACTIMMUNE;				disease; tuberculosis
GAMMA				
interferon, consensus; Marketed	Marketed	interferon alpha 1	biotechnology.	wiral infaction.
consensus interferon;	•	last	interferon:	cancer
interferon alfacon-1;			immunostimulant	
YM 643; INFERGEN		methionyl-22-L-arg-		
		76-L-ala-78-L-asp-		
		79-L-glu-86-L-tyr-90-		
		L-tyr-156-L-thr-157-		
3622Wod. BW	Dhosa II	L-asn-138-L-leu-		
-	TT DODIT			cancer
Sdi 1	Discontinued		inomocional anmoody	
	Pantitutioner		ototechnology;	cancer
detrimomoh. MAk	7:55		monoclonal antibody	
			biotechnology;	cancer
Ivmphoma: MAb. B		:	monocional antibody	
cell lymphoma; B cell		. ~-		
lymphoma MAb;				
SFECIFID			_	

drije delivery system Draclinical	Draclinical			
liposome MAb, 273-	, - 1001111041		biotecnnology; monoclonal antibody	cancer
34A; MAb, 273-34A				
lipsome; liposome,				
MAb 273-34A				
edrecolomab; MAb,	Marketed	immunoglobulin G 2abiotechnology;	biotechnology;	cancer
17-1A; MAb,		(mouse monoclonal	monoclonal antibody	
colorectal cancer;		17-1A gamma-chain		
MAb, CO17-1A; 17		anti-human colon		
IA; C-1; PANOREX		cancer tumour-		
		associated antigen),		
		disulfide withmouse		
		monoclonal 17-1A		
		light chain dimer		
lintuzumab; MAb,	Phase III	immunoglobulin G1	biotechnology;	cancer
humanized M195;	-	(human-mouse	monoclonal antibody	
MAb, humanized		monoclonal		
CD33; SMART		HuM195.gamma.1-	- - -	
M195; HuM195		chain anti-human		
		antigen CD 33),		
•.		disulfide with human	-	
		monoclonal		
,		HuM195.kappa		
lintuzumab-bismuth-	Phase I	סוומחו, טווווכו	hiotochaologa	
213; MAb,	4		monoclonal antibod:	cancer
humanized M195-	-		monocional annionay	
213Bi				
LYM 2	Preclinical		1	cancer
			monoclonal antibody	
MA6, 12G5	Preclinical	,	biotechnology;	ancer
			ilonocional antiloguy	

NAAL OATT BEAT	:			
MAD, ZAII; MAD,	Phase II		biotechnology;	cancer
gastilli releasing peptide			monoclonal antibody	
MAb, 323A3; 323A3 Discontinued	Discontinued		biotechnology.	Cancer
			monoclonal antibody	
MAb, 3F8; IgG3 anti-Phase I	-Phase I		biotechnology:	Cancer
ganglioside GD 2;			monoclonal antihody	
MAb, neuroblastoma		•	de la constant annocada	
MAb, 42/6; MAb,	Phase I		biotechnology;	cancer
transferrin receptor			monoclonal antibody	
MAb, 88BV59-	Discontinued	- 12 - 2	biotechnology;	cancer
rhenium 186			monoclonal antibody	
MAb, 977; MAb,	Preclinical	2.2	biotechnology;	cancer; diagnosis
bladder cancer			monoclonal antibody)
MAb, 9D9	Preclinical		biotechnology;	cancer
			monoclonal antibody	
MAb, adrenomedullin Preclinical	Preclinical		biotechnology;	cancer; diabetes;
			monoclonal antibody	Alzheimer disease;
				diagnosis
MAb, antiganglioside Preclinical	Preclinical		biotechnology;	cancer
GM2; KM 966			monoclonal antibody	
MAb, antinuclear	Preclinical		biotechnology;	cancer
auto-antibodies;			monoclonal antibody	
_	Preclinical		biotechnology;	cancer
- 1			monoclonal antibody	
	Phase I		biotechnology;	cancer
interleukin-6; MAb,		- 8	monoclonal antibody	
			•	
MAb, B4-DC1	Discontinued		biotechnology;	cancer
			monoclonal antibody	

0.00				
MA6, B6.2/212	Discontinued		biotechnology;	cancer
single chain antibody;			monoclonal antibody	
MAb, B6.2/212 SCA			-:	
MAP, BCD F9-	Phase I		biotechnology;	cancer: diagnosis
radionuclide; MAb,			monoclonal antibody	
breast cancer; BCD		-	•	
F9				
MAb, bispecific	Discontinued		biotechnology;	cancer
F(ab')2 OC/TR;			monoclonal antibody	
OCTR				
MAb, bispecific hu-	Discontinued		biotechnology;	cancer
bsF(ab')2		H	monoclonal antibody	
MAb, bladder	Discontinued		biotechnology:	cancer
carcinoma; RG 355		. Haj	monoclonal antibody	
MAb, BR 96; BR 96	Discontinued		biotechnology;	cancer
		<u> </u>	monoclonal antibody	
MAb, breast cancer	Discontinued		biotechnology;	cancer
antigen; Pro 1.5.3		H	monoclonal antibody	
MAb, BW 494	Discontinued	.0	biotechnology;	cancer
		Li .	monoclonal antibody	
MAb, c-Nd2; c-Nd2	Preclinical		biotechnology;	cancer
		5	monoclonal antibody	
	Phase II		biotechnology;	cancer
staphylococcal		_ F	monoclonal antibody	
enterotoxin; FAb,		-		
C215-SEA			-	
MAb, C242; MAb,	Discontinued	<u>Q</u>	biotechnology;	cancer; diagnosis
colonic	-	<u>E</u>	monoclonal antibody)
adenocarcinoma			•	
MAb, C242-DM 1	Preclinical	<u>.</u>	biotechnology;	cancer
conjugate; huC242-		E	tibody	
DMI				
	•			

SD-144110.1

MAb, C242-	Preclinical		biotechnology;	cancer
may tansine conjugate	_		monoclonal antibody	
MAb, cancer	Phase III		biotechnology; monoclonal antibody	cancer
MAb, cancer; MAb, EpCAM	Preclinical		biotechnology;	cancer
MAb, cancer; BW	Preclinical		biotechnology;	cancer
MAN COLOR L. L. L.	-		monoclonal antibody	
wash, cancer; nybrid	Preclinical		biotechnology;	cancer
anti-CD3			monoclonal antibody	
	Preclinical		biotechnology:	cancer
			monoclonal antibody	
melanoma, glioma,				
neuroblastoma; MDX				
260	·			
Mab, cancer, BioInvent	Preclinical		biotechnology;	cancer
Tur			monocional annocio	
IMAD, cancer, FFL	Freclinical	<u>.</u>	biotechnology; monoclonal antibody	cancer
MAb, cancer, XTL	Preclinical		biotechnology:	Cancer
Biopharmaceuticals;			monoclonal antibody	
MAb,		<u>.</u>		
cancer, Neoprobe				
	Preclinical		biotechnology:	cancer
			monoclonal antibody	
antigen; MAb, CEA		<u>-</u>		
MAb,	Preclinical	.0	biotechnology:	cancer
carcinoembryonic		: = :	monoclonal antibody	
antigen; MAb, CEA				

244	•			
MAb, SK-1; MAb,	Fnase I	biotec	biotechnology; monoclonal antibody	cancer
cancer;) 200	
MONOPHARM C				
MAb, CC49; MAb,	Phase II	biotec	biotechnology;	cancer
TAG B723; MAb,		ouom	monoclonal antibody	
B723 second				
generation				
MAb, CC49-	Discontinued	biotec	biotechnology;	cancer
interleukin-2; fusion		oouou	monoclonal antibody	
protein, CC49-1L-2				
MAb, CC49-lutetium	Discontinued	biotec	biotechnology;	cancer
177; MAb, anti-TAG-	-	ouom	monoclonal antibody	
//-Intenum 1//				
MAb, CC83; MAb,	Discontinued	biotecl	biotechnology;	cancer
TAG B723; MAB,		ouou	monoclonal antibody	
B723 second			•	
generation				
MAb, CD19/CD3;	Preclinical	biotech	biotechnology;	cancer
bispecific antibody,		ponom	monoclonal antibody	-
cancer				
MAb, CD28/CD30;	Preclinical	biotech	biotechnology;	cancer
Bi-MoAb		monoc	monoclonal antibody	
MAb, CD3/CD30;	Preclinical	biotech	biotechnology;	cancer
Bi-MoAb; bispecific		conom	nonoclonal antibody	
antibody, CD3, CD30				
MAb, CD34; anti-	Phase I	biotech	biotechnology;	cancer
CD34		monoc	monoclonal antibody	
MAb,	Preclinical	biotech	biotechnology;	cancer
cancer, Wilex Biotechnology		топос	monoclonal antibody	
	Dhone II			
	rnase II	Diotech	biotechnology; monoclonal antibody	cancer

MAb.	Discontinued		1	
chemotherapeutic			professional grafther de	cancer
conjugates, IDEC	•		monocional antibody	
MAb, chimeric	Phase I		biotechnology.	cancer
CC49; MAb,			monoclonal antihody	1001100
chimeric TAG B723		;		
MAb, chimeric	Phase I		biotechnology:	Cancer
CC83; MAb, TAG			monoclonal antibody	
B/23				
MAb, chimeric IgG1	Preclinical		biotechnology;	cancer
anti CD20			monoclonal antibody	
MAb, colon-DMI	Preclinical		biotechnology;	cancer
MAb, colorectal	Phase I		hiotochologii	
cancer			monoclonal antihody	cancer, diagnosis
MAb, CYT 372	Preclinical		biotechnology.	cancer
humanized; MAb,	-	•	monoclonal antihody	
C46 humanized;				
MAb, humanized			• • •	
panadenocarcinoma		٠	-	
MAb, directed	Preclinical		biotechnology:	cancer
enzyme prodrug	· · · · · ·		monoclonal antibody	,
therapy; ADEPT,				
				-
	Phase II		biotechnology;	cancer
enzyme prodrug			monoclonal antibody	
therapy + CMDA;				
ADEPT + CMDA;				
ZD 2767				
MAb, EGF-R and Fc; Phase II	Phase II		biotechnology;	cancer
bispecific antibody,			monoclonal antibody	
447; EMD 82633				
		7		

SD-144110.1

Ab, EGF Ab, EGF Ab, EGF Ab, EGF Ab, 528; mal r Nb, 62 62 mal r, Nb, 63 mal li, MAb, lized; ized;	MAb enidemal	Discontinued	4	1 - 4 1 1	
The EGF To the continued antibody and the preclinical to the continued antibody anticed; The EGF To the continued to the control of the continued to the conti	Prowth factor		<u></u> .	notectinology;	cancer
mal Preclinical biotechnology; and BGF; monoclonal antibody antibody and before the biotechnology; and before the biotechnology; and before the biotechnology; and before the biotechnology; and before the biotechnology; and before the biotechnology; and before the biotechnology; and before the biotechnology; and before the biotechnology; and before the biotechnology; and before the biotechnology; and biotechno	receptor; MAb, EGF	:		nonocional annocay	
mal Preclinical biotechnology; Ab, 528; mal Phase III biotechnology; Trans Phase I biotechnology; Trans Preclinical biotechnology;	receptor; EMD 55900	[(
Ab, EGF Ab, 528; mal Phase III biotechnology; ral Phase I biotechnology; r, r, r, r, r, r, r, r, r, r	MAb, epidermal	Preclinical		viotechnology;	cancer
Phase III biotechnology; Phase I biotechnology; Phase I biotechnology; Phase I biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology; Preclinical biotechnology;	growth factor		E	nonoclonal antibody	
The phase III biotechnology; The phase III biotechnology; The phase I biotechnology;	receptor; MAb, EGF				
mal Phase III biotechnology; That Phase I biotechnology; That Preclinical biotec	receptor; MAb, 528;			- 	
mal Phase III biotechnology; honoclonal antibody robote EGFr; mal Phase I biotechnology; honoclonal antibody robote ized; mal Phase I biotechnology; honoclonal antibody robote ized; mal Preclinical biotechnology; honoclonal antibody biotechnology; honoclonal antibody robote ized; biotechnology; honoclonal antibody preclinical biotechnology; honoclonal antibody biotechnology; honoclonal antibody robote ized; honoclonal antibody biotechnology; honoclonal antibody robote in monoclonal antibody robote in monoclonal antibody	MoAb528				
The hase I biotechnology; Mal Phase I biotechnology; Mab, EGF, MAb, Preclinical biotechnology; Mab, Preclinical biotechnology; Monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; mium biotechnology; mium biotechnology; mium biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	MAb, epidermal	Phase III	-8	iotechnology;	cancer
mal Phase I biotechnology; Ab, 62 mal Phase I biotechnology; MAb, Mab, Preclinical biotechnology; MAb, Preclinical biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	growth factor		<u>. </u>	nonoclonal antibody	
mal Phase I biotechnology; Ab, 62 mal Phase I biotechnology; MAb, ized; MAb, Preclinical biotechnology; Monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	receptor; MAb, EGFr;				
mal Phase I biotechnology; Ab, Mal Phase I biotechnology; MAb, ized; MAb, Preclinical biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody mitCEA biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	C 225				
MAb, Preclinical monoclonal antibody piotechnology; monoclonal antibody preclinical min monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody preclinical minonoclonal antibody mitCEA preclinical minonoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	nal	Phase I	0	iotechnology:	cancer
hb, for mal Phase I biotechnology; fr, fr, fred; fred; fred; fredinical biotechnology; freclinical bio			ш	nonoclonal antibody	
mal Phase I biotechnology; MAb, ized; MAb, Preclinical biotechnology; Preclinical biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody miCEA biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	receptor; MAb,				
mal Phase I biotechnology; MAb, ized; MAb, Preclinical biotechnology; Preclinical biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody mitCEA biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	EGFR; ICR 62				
r, MAb, ized; MAb, Preclinical Preclinical nium Discontinued Discontin	lal	Phase I	9	iotechnology;	cancer
MAb, Preclinical biotechnology; Preclinical biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; mium biotechnology; micEA biotechnology; monoclonal antibody biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody	growth factor,		E	10noclonal antibody	
ized; MAb, Preclinical biotechnology; Preclinical biotechnology; monoclonal antibody biotechnology; mium biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	humanized; MAb,				
; MAb, Preclinical biotechnology; monoclonal antibody Preclinical biotechnology; monoclonal antibody Discontinued biotechnology; monoclonal antibody atiCEA preclinical biotechnology; monoclonal antibody monoclonal antibody	EGF, humanized;				
Hab, Preclinical biotechnology; Preclinical biotechnology; Discontinued biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody	EMD 72000				
Preclinical monoclonal antibody Discontinued biotechnology; mium monoclonal antibody ntiCEA preclinical biotechnology; monoclonal antibody monoclonal antibody monoclonal antibody	erbB-2; MAb,	Preclinical	q	iotechnology;	cancer
Preclinical biotechnology; Discontinued biotechnology; nium monoclonal antibody artiCEA Preclinical biotechnology; monoclonal antibody monoclonal antibody	cancer		T.	nonoclonal antibody	
monoclonal antibody nium hitCEA Preclinical monoclonal antibody monoclonal antibody monoclonal antibody monoclonal antibody	MAb, erbB2	Preclinical	<u>.</u>	iotechnology;	cancer
Discontinued biotechnology; nium ntiCEA Preclinical biotechnology; monoclonal antibody			III	nonoclonal antibody	
Preclinical biotechnology; monoclonal antibody monoclonal antibody	MAb, F(ab)2	Discontinued	.		cancer
Preclinical biotechnology; monoclonal antibody	NRC002-rhenium			ibody	
Preclinical biotechnology; monoclonal antibody	186; MAb, antiCEA		-		
monoclonal antibody		Preclinical	ŢĢ		cancer
			E		

MAb. FAb NRL1110- Phase I	- Phase I		toologie	
radionuclide; MAb,			ototectatorogy; monoclonal antibody	cancer, diagnosis
lung cancer; MAb,			mocronal antibody	
prostate cancer				
MAb, fas; MAb,	Preclinical	piot	biotechnology;	cancer
bladder cancer		mor	monoclonal antibody	
MAb, FC-2.15	Phase II	biot	biotechnology;	cancer
MAb. fibroblast	Discontinued	10111	iocionalianinouay	
growth factor	Danillillingo	1010	biotechnology; monoclonal antihodi:	cancer
receptor; MAb, FGFR	~		iocional annibody	
MAb, germ cell	Discontinued	biot	biotechnology:	cancer
cancer; ImmuRAID- HCG		mom	monoclonal antibody	
MAb, gp75;	Preclinical	hiot	hiotechnology.	recorder
MELVAX II		nom	monoclonal antihody	carioci
Mab, heparanase	Preclinical	biot	biotechnology;	cancer; diagnosis
		moin	monoclonal antibody	
MAb, HER-2	Discontinued	biot	biotechnology;	cancer
ımmunoliposome		mom	monoclonal antibody	
MAb, HER2/neu20	Preclinical	biote	biotechnology;	cancer
immunoliposomes,		пош	monoclonal antibody	
MAh Hodekin's	Desclinical			
lymnhoma	riecimical	biote	biotechnology;	cancer
A A A T		mom	monoclonal antibody	
MAD, numan	Phase II	biote		cancer
anngangnoside		nom	monoclonal antibody	
MAb, human	Preclinical	biote		cancer
Constitution of the second		uom	monoclonal antibody	
Bonadouropin; MAb, hCG; CTP 103		12 248	÷ .	

MAb, human	Preclinical	biotec	biotechnology:	cancer
chorionic		ouom	monoclonal antibody	
gonadotropin, human;	• • •		-	
MAb, hCG, human				
MAb, human	Preclinical	biotec	biotechnology:	cancer
EpCAM; UBS 54		nonom	monoclonal antibody	
MAb, humanized	Phase II	biotec	biotechnology:	cancer
LL2; MAb, B cell		bouom	monoclonal antibody	
lymphoma;				
LymphoCide				
MAb, humanized	Preclinical	biotec	biotechnology;	cancer
N901-DCI		monoc	lonal antibody	
MAb, humanized,	Discontinued	biotec	biotechnology;	cancer
cancer; MAb, cancer humanized		monoc	monoclonal antibody	
MAh IoG1 frament	Droolinion			
MANAGEMENT LIBORINGE	riecimicai	biotec	biotechnology;	cancer
		ponom	monoclonal antibody	
MAb, IGX	Preclinical	biotech	biotechnology;	cancer
		nonoc	monoclonal antibody	
-1; MAb,	Discontinued	biotech	biotechnology;	cancer
- 1		monoc	monoclonal antibody	
MAb, interleukin-6;	Phase I	biotech	biotechnology;	ancer
- 1		monoc	monoclonal antibody	
KAII; MAb,	Preclinical	biotech	biotechnology;	cancer
П		monoc	monoclonal antibody	
vb, KM641; KM	Discontinued	biotech	biotechnology; c	cancer
		monoc	monoclonal antibody	
MAb, L 6; L 6	Discontinued	biotech	_	cancer
		monoc	monoclonal antibody	

MAb, L6 alkaline	Discontinued		biotechnology:	cancer
phosphatase			monoclonal antibody	
conjugate; L6 alkaline	a			
phosphatase MAb				
conjugate; MAb,				
carcinoma				
MAb, Lewis Y; ABL	Phase I		biotechnology;	cancer
364; SDZ ABL 364	-		monoclonal antibody	
MAb, Lewis Y,	Preclinical		biotechnology;	cancer
humanized; HuABL			monoclonal antibody	
364; SMART ABL				
364; BR 55-2				
MAb, LL2-rhenium	Preclinical		biotechnology;	cancer
188; Re-188-LL2			monoclonal antibody	
MAb, MAb fragment, Discontinued	Discontinued		biotechnology;	cancer
REC A33-nuclide	•		monoclonal antibody	
MAb, mB43-	Phase II		biotechnology;	cancer: diagnosis
technetium 99m; Tru-			monoclonal antibody	
Scint OV				
MAb, MDX 11;	Phase II		biotechnology;	cancer
MAb, myeloid	-		monoclonal antibody	
leukemia; MAb,				
CD15; MDX 11; PM		- '		
81				
MAb, melanoma;	Preclinical		biotechnology;	cancer
MAb, cancer;		_=	monoclonal antibody	
MONOPHARM M				
MAb, melanoma,	Phase I		biotechnology;	cancer
Novartis; CGP 62360		H	monoclonal antibody	
	Phase II		biotechnology;	diagnosis; cancer
carcinoembryonic		_ 	monoclonal antibody	
antigen; MAb, MN-		-	•	
anio arra tracara				

MAAL MEDIT OF				
MAD, MIKK 20;	Preclinical		biotechnology;	cancer
MKK 20			monoclonal antibody	
MAb, multiple	Preclinical		biotechnology;	cancer
myeloma, U-BiSys			monoclonal antibody	
MAb, oncology,	Preclinical		biotechnology:	cancer
Glaxo Wellcome			monoclonal antibody	1
MAb, ONS M21;	Preclinical		biotechnology;	cancer
ONS M21			monoclonal antibody	
MAb, P-67; MAb,	Preclinical		biotechnology;	cancer
acute myelogenous		÷.	monoclonal antibody	
leukemia	-			
MAb, PAM4	Phase I		biotechnology;	cancer
			monoclonal antibody	
MAb, polymorphic	Discontinued		biotechnology;	cancer
epithelial mucin;			monoclonal antibody	
MAb, PEM; AS 125				
MAb, prostate cancer Preclinical	Preclinical	:	biotechnology;	cancer
			monoclonal antibody	
MAb, prostate cancer Discontinued	Discontinued		biotechnology;	cancer
			monoclonal antibody	
MAb, prostate cancer Preclinical	Preclinical		biotechnology;	cancer
			monoclonal antibody	
MAb, SM3	Discontinued		biotechnology;	cancer
phosphorus 32			monoclonal antibody	
MAb, TAG-72	Preclinical		biotechnology;	cancer
			monoclonal antibody	
MAb, TAG-72 and	Phase II		biotechnology;	cancer
rc; bispecific			monoclonal antibody	
antibody, cancer; MDX 220			;	

MAH TROA himan	Droclinical			
MAP TR94 19A11		<u> </u>	ororecunology;	cancer
MAb, small cell lung			monocional antibody	
cancer				
MAb, TH69	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, transcobalamin Preclinical	Preclinical	.0	biotechnology;	cancer
II; MAb, vitamin B12		. E.	monoclonal antibody	
carrier protein,			•	
Keceptagen				
MAb, transferrin	Preclinical	Q	biotechnology:	cancer
receptor targeted		<u> </u>	monoclonal antibody	
immunotoxin; MAb,				
tfnR targeted	•			
immunotoxin; tfnR-				
CRM107				
MAb, tumor necrosis	Preclinical	Đ.	biotechnology;	Crohn disease:
factor; MAb, TNF;		1	monoclonal antibody	cancer: sentic shock
SMA TNF				Wood of the training
MAb, tumor necrosis	Discontinued	9	biotechnology;	cancer
factor alpha; MAb,		<u>.</u> E	monoclonal antibody	
TNF-alpha; MAb32				
MAb, U36/E48	Discontinued	iq.	biotechnology;	cancer
		THE STATE OF THE S	monoclonal antibody	
MAbs, cancer,	Preclinical	0	biotechnology;	cancer
human, Medarex		L	monoclonal antibody	
MAbs, chimeric,	Preclinical	iq.	biotechnology;	cancer
cancer		E .	monoclonal antibody	
MAbs, pancarcinoma, Preclinical	Preclinical	Į Q	biotechnology;	cancer
B-cell tumor;		<u>E</u>	monoclonal antibody	
bispecific antibody,		<u> </u>		
cancer				
•			T	

D-144110

Marketed immunoglobulin G1 (human-mouse monoclonal IDEC- C2B8 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC- C2B8 kappa-chain, dimer Marketed immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer b, Preclinical chain dimer chain dimer	prostate carcinoma Discontinued		biotechnology;	cancer; diagnosis
Marketed immunoglobulin G1 (human-mouse Monoclonal IDEC- C2B8 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC- C2B8 kappa-chain, dimer Marketed immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer MAb, Preclinical thelial MAb, Preclinical whelial fibit	iens		monoclonal antibody	·
ko C 102; C 102; C 208 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC- C2B8 kappa-chain, dimer Marketed immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer chain dimer MAb, Preclinical MAb, Preclinical thelial MAb, Preclinical	Marketed	globulin G1	biotechnology;	cancer
c 102; C2B8 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8 kappa-chain, dimer dimer anti-(human-mouse monoclonal receptor) (human-mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 ight chain dimer chain dimer chain dimer disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer disulfide with human-mouse monoclonal rhuMab, Preclinical disulfide with human-mouse monoclonal rhuMab, Preclinical displayed.	· · ·	-mouse	monoclonal antibody	
C 102; C 102; C 102; C 208 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8 kappa-chain, dimer Marketed immunoglobulin G1, anti-(human-p185neu receptor) (human-mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer chain dimer chain dimer MAb, Preclinical MAb, Preclinical MAb, Preclinical MAb, Preclinical MAb, Preclinical MAb, Preclinical		onal IDEC-		
anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC- C2B8 kappa-chain, dimer Marketed immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer thelial 101 MAb, Preclinical whelial thelial MAb, Preclinical whelial thelial		amma 1-chain		
With human-mouse monoclonal IDEC-C2B8 kappa-chain, dimer dimer Marketed immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer chain dimer chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer		nan antigen	~	
With numan-mouse monoclonal IDEC-C2B8 kappa-chain, dimer dimer Marketed immunoglobulin G1, anti-(human-nouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer chain dimer chain dimer MAb, Preclinical dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer	CD 20),	disultide		
monoclonal IDEC- C2B8 kappa-chain, dimer Marketed immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer chain dimer MAb, Preclinical MAb, Preclinical thelial MAb, Preclinical thelial	with nur	man-mouse		· ·
C2B8 kappa-chain, dimer dimer 183; Phase I dimer Marketed immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer chain dimer chain dimer 101 MAb, Preclinical dimer chain dimer	monoclo	onal IDEC-	-	
Marketed immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer chain dimer chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer MAb, Preclinical chain dimer	C2B8 ka	appa-chain,	··· ,	
Marketed immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer chain dimer MAb, Preclinical MAb, Preclinical whelial MAb, Preclinical	Phase I		biotechnology;	cancer
Marketed immunoglobulin G1, anti-(human p185neu receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer chain dimer MAb, Preclinical MAb, Preclinical indimer			monoclonal antibody	
anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer chain dimer chain dimer (human dimer chain) 101 MAb, Preclinical chain dimer chain	Marketed		biotechnology;	cancer
receptor) (human- mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer chain dimer thelial MAb, Preclinical MAb, Preclinical fittelial MAb, Preclinical			monoclonal antibody	
mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer chain dimer chain dimer chain dimer withelial MAb, Preclinical differential management of the field	receptor	(human-		
rhuMab HER2 gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer chain dimer 101 MAb, Preclinical MAb, Preclinical fithelial fithelial	monse m	nonoclonal		
gamma 1-chain), disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer chain dimer 101 MAb, Preclinical thelial fullial	rhuMab	HER2		
disulfide with human- mouse monoclonal rhuMab HER2 light chain dimer chain dim	gamma 1	1-chain),		
mouse monoclonal rhuMab HER2 light chain dimer chain dimer thelial 101 MAb, Preclinical MAb, Preclinical thelial	disulfide	with human-		
rhuMab HER2 light chain dimer chain dimer thelial 101 MAb, Preclinical thelial	mouse m	nonoclonal		
MAb, Preclinical chain dimer the lial MAb, Preclinical MAb, Preclinical the lial	rhuMab	HER2 light		
MAb, Preclinical thelial 101 MAb, Preclinical thelial		mer		
rthelial 101 MAb, Preclinical thelial			biotechnology;	cancer
MAb, Preclinical	lothelial		monoclonal antibody;	
MAb, Preclinical			angiogenesis inhibitor	-
MAb, Preclinical	2 101			
thelial			biotechnology;	cancer
	lothelial		monoclonal antibody;	
			angiogenesis inhibitor	
receptor; CPICII	1011	-	•	

. 4.41 1474				
MAD, VNK integrin;	Phase II	biotechnology;	ology;	cancer
LM 609; VIIAXIN		monoclo	monoclonal antibody;	
		angioger	angiogenesis inhibitor	
MAb, CEA and	Preclinical	biotechnology;	ology;	cancer
doxorubicin; MAb,		monoclo	monoclonal antibody;	
26-61-10; bispecific	-	anthracy	anthracycline; DNA	
antibody, CEA and		intercala	intercalator; antibiotic	
doxorubicin			•	
MAb, antilaminin	Preclinical	biotechnology;	ology;	cancer; diagnosis
gamma2 chain; BST		monoclo	monoclonal antibody;)
1004		contrast medium	medium	
MAb, cancer; MAb,	Preclinical	biotechnology;	ology;	cancer
tumor necrosis	-	monoclo	monoclonal antibody;	
technology; MAb,		contrast medium;	medium;	
TNT		radiodiagnostic;	gnostic;	
	-	radiotherapeutic	apeutic	
MAb, cancer,	Phase I	biotechnology;	ology;	cancer; diagnosis
radiolabeled;		monoclo	monoclonal antibody;)
NOVOMAb-G2		contrast medium;	medium;	
		radiodiagnostic;	mostic;	
İ		radiotherapeutic	apeutic	
าลไ	Phase I	biotechnology;		cancer; diagnosis
growth factor		monoclo	ibody;	
receptor; MAb, EGFr;		contrast medium;	nedium;	
DiaCIM; TheraCIM;		radiotherapeutic;	apeutic;	
RadioTheraCIM		radiodiagnostic	mostic	-
MAb, TC5-Au198	Preclinical	biotechnology;		cancer; diagnosis
		monoclo	monoclonal antibody;	
		contrast medium;	nedium;	-
		radiotherapeutic;	apeutic;	-
		radiodiagnostic	nostic	

MAb, B cell-cytokine Preclinical	Preclinical		biotechnology:	cancer
fusion protein			monoclonal antibody;	
			cytokine	
interleukin-2,	Preclinical		biotechnology;	cancer
antiganglioside			monoclonal antibody;	
chimeric protein; G2-			cytokine: growth	
IL2 fusion protein;			factor	
MAb-G2 IL-2 fusion			-	
protein; ch14.18-IL2				
MAb, L49-sFv-beta-	Preclinical	-	biotechnology;	cancer
lactamase			monoclonal antibody;	
		_	enzyme	
MAb, 2C11.F(ab')2 + Discontinued	Discontinued		biotechnology:	bacterial infection:
microbeads; MAb,		•	monoclonal antibody:	cancer
anti-CD3 +	-		immunostimulant	
microbeads;				
PLATAR construct			. T.	
덜	Phase I		biotechnology:	cancer
CD16; bispecific			monoclonal antibody:	
antibody, c-erbB-2	•	··=	immunostimulant	
and CD16; 2B1				
MAb, c-Mpl; MAb,	Preclinical		biotechnology;	thrombocytopenia;
thrombocytopenia;	•	_ =-	ibody;	cancer
BAH 1		• •		
MAb, CD3 F(ab')2 +	Discontinued		biotechnology;	bacterial infection:
microbeads; MAb,			ibody;	cancer
CD3 + microbeads;		. 	immunostimulant	
PLATAR construct				

MAb, HER-2 and Fc: Phase II	Phase II		hiotechnology.	10000
bispecific antibody,			monoclonal antibody:	CallCo
ovarian and breast			immunostimulant	-
cancer; bispecific			-	
antibody 520C9x22;				
MDX 210				
daclizumab;	Marketed	immunoglobulin G1	biotechnology;	transplant rejection:
dacliximab; MAb,	-	(human-mouse	monoclonal antibody;	cancer; autoimmune
Tac; MAb,		monoclonal clone	immunosuppressant	disease; eye disease
humanized Tac;		1H4 gamma chain		•
MAb, SMART Tac;		anti-human antigen		
Ro 247375;		Tac), disulfide with		
ZENAPAX		human-mouse	-	
		monoclonal clone	774 w	
		1H4 light chain,		-
	-	dimer		
MAb, alpha-tubulin	Preclinical		biotechnology;	cancer; autoimmune
			monoclonal antibody;	disease; diagnosis
			immunosuppressant	•
gen	Preclinical		biotechnology;	cancer; Crohn
receptor; TM 29			monoclonal antibody;	disease
		-	immunosuppressant	
MAbs, B cells; migis	Discontinued		biotechnology;	autoimmune disease;
	-		monoclonal antibody;	cancer
- 1			immunosuppressant	
MAb, MHC class II	Preclinical,			autoimmune disease;
				transplant rejection;
		7	osuppressant;	graft versus host
			NSAID	disease; cancer
				,

MAb, 791T/36-ricin	Discontinued		biotechnology;	cancer
A immunotoxin;			monoclonal antibody;	
immunotoxin-			immunotoxin	
colorectal cancer;				
XOMAZYME 791		-		-
MAb, A7 mitomycin	Preclinical		biotechnology;	cancer
C-dextran conjugate;			monoclonal antibody:	
MAb, A7-MMCD;			immunotoxin	
MAb, colon cancer				
mitomycin C-dextran				
conjugate				
MAb, alpha CD80-	Preclinical		biotechnology;	cancer
gelonin			monoclonal antibody;	,
			immunotoxin	
MAb, alphaCD86-	Preclinical		biotechnology;	cancer
gelonin	-		monoclonal antibody;	
			immunotoxin	-
MAb; Anti-Tac	Discontinued		biotechnology;	cancer
Pseudomonas			monoclonal antibody;	
exotoxin;			immunotoxin	
immunotoxin, T cell				
cancers			-	-
	Phase I		biotechnology;	cancer
Pseudomonas			monoclonal antibody;	
exotoxin;			immunotoxin	
immunotoxin B3-PE				
38; LMB 1				
MAb, B4-blocked	Discontinued		biotechnology:	cancer
ricin; MAb, B4-bR;			monocional antibody:	
ONCOLYSIN B			immunotoxin	
MAb, B7-	Preclinical		biotechnology;	cancer
immunotoxin		F	monoclonal antibody;	
			immunotoxin	
				J

			-	
MAb, BACH 250-	Preclinical	iq	biotechnology;	cancer
gelonin conjugate;		Ŭ.	monoclonal antibody;	
immunotoxin, BACH		<u>ii</u>	immunotoxin	
250-gelonin				
MAb, basic fibroblast Preclinical	Preclinical	id	biotechnology;	cancer
growth factor		<u>H</u>	monoclonal antibody;	
receptor-saporin;		ui.	immunotoxin	
MAb, bFGF receptor-				
SAP; 11A8			-	
MAb, CD33-	Phase III	bid	biotechnology;	cancer
calicheamicin; CMA		<u> </u>	monoclonal antibody:	
676; CDP 771		mi.	immunotoxin	
MAb, CMB 401-	Phase II	bic	biotechnology;	cancer
calicheamicin; MAb,		<u>ŭ</u>	monoclonal antibody;	
ovarian cancer; CMB		ij	immunotoxin	
401; CDP 671	•			
MAb, CYT 103-	Preclinical	bic	biotechnology;	cancer
aminopterin; MAb,		<u></u>	monoclonal antibody;	
B72.3-aminopterin;		mi	immunotoxin	
ONCOTHER 130	_			
MAb, epidermal	Discontinued	oid	biotechnology;	cancer
growth factor receptor		mo	monoclonal antibody;	
immunotoxin;		iui!	immunotoxin	
immunotoxin, EGRF;				
OLX 103; TP 40; L				
691912		-3		

MAb, erbB-2-	Preclinical		biotechnology.	Cancer
Pseudomonas			monoclonal antibody:	Carloo
exotoxin;			immunotoxin	
immunotoxin, single				
chain erbB-2-				
rseudomonas				
exotoxin; OLX 209; AR 209				
MAb, F(ab')2 HRS-3	Discontinued		biotechnology:	cancer
deglycosylated ricin			monoclonal antihody	Tooling.
A; MAb, HRS-3			immunotoxin	
deglycosylated ricin				
A; MAb, F(ab')2			-	
HRS-3 dgA; Mab,			•	-
HRS-3				
deglycosylated ricin				
A; MAb, F(ab')2	-			
HRS-3 dgA; MAb,				
IRac dgA				
MAb, F(ab')2 IRac	Discontinued		biotechnology;	cancer
deglycosylated ricin			monoclonal antibody:	
A; MAb, IRac			immunotoxin	
deglycosylated ricin			-	
A; MAb, F(ab')2 IRac				
dgA		· · ·		
	Phase I		biotechnology;	cancer
Pseudomonas			monoclonal antibody:	
exotoxin;			immunotoxin	
immunotoxin Fv B3-				
PE 38; LMB 7; NSC 658931			-	

MAR E.DI	h		-	
Pseudomonas	riecumical		biotechnology;	cancer
exotoxin;			imminotoxin	
immunotoxin FvB1-				
ress				
MAb, LL2-	Preclinical		biotechnology;	cancer
Pseudomonas			monoclonal antibody;	
exotoxin			immunotoxin	
MAb, ME20-	Discontinued		biotechnology;	cancer
Pseudomonas			monoclonal antibody;	
exotoxin;			immunotoxin	
immunotoxin ME20- LysPF40				
MAb. N901-blocked	Phase II		hiotochaologu	
ricin; immunotoxin.			monoclonal antihody.	caricel
N901-bR;	•		imminotoxin	
ONCOLYSIN S				
MAb, N901-DM1:	Preclinical		hiotechnology.	
imminotoxin N901-			proceedings,	caricer
DM1			inonocionai annoody; imminotoxin	
MAb, OVB3-	Phase I		biotechnology:	Cancer
Pseudomonas		•	monoclonal antihody:	
exotoxin conjugate;			immunotoxin	
immunotoxin OVB3-		_		
PE				
MAb, RFB4(dsFv)-	Phase I		biotechnology;	cancer
PE38; immunotoxin,			monoclonal antibody:	
RFB4(dsFv)-PE38;			immunotoxin	
BL 22; NSC 691237				
MAb, RFT5-ricin A	Phase II		biotechnology;	cancer
(CD25)			monoclonal antibody;	
immunotoxin;			immunotoxin	
KFT5.dgA				

MAb, ricin A	Discontinued	q	biotechnology:	cancer
immunoconjugate;		Ħ	ionoclonal antibody;	
immunotoxin			immunotoxin	
melanoma;			ti i i	
XOMAZYME-MEL				
MAb, SN7-ricin A;	Preclinical	Įq.	biotechnology;	cancer
immunotoxin SN7-		<u>E</u>	monoclonal antibody;	
ricin A; SN7-RA		i	immunotoxin	
MAb, Tac(Fv)-PE38; Phase I	Phase I	Įq.	biotechnology;	cancer
immunotoxin		<u>u</u>	monoclonal antibody;	
Tac(Fv)-PE38; LMB		<u></u>	immunotoxin	
2				
MAb, Tac(Fv)-PE40 Preclinical	Preclinical	<u>io</u>	biotechnology;	cancer
ımmunotoxın		E.	monoclonal antibody;	
		ni	immunotoxin	
	Phase I	bi	biotechnology;	cancer
receptor targeted		<u>E</u>	monoclonal antibody;	
immunotoxin; MAb,		ii.	ımmunotoxin	
tfnR targeted				
ımmunotoxin;				
	Preclinical	bi	biotechnology;	cancer
immunotoxins,		Ē	monoclonal antibody;	
Menarini	-	ni	immunotoxin	
MAb, UV72	Preclinical	id	biotechnology;	cancer
immunotoxin		<u>.</u>	monoclonal antibody;	
		mi	mmunotoxin	
	Preclinical	piq	biotechnology;	cancer
receptor/ligand		:	monoclonal antibody;	
complex-dgA;			immunotoxin	
immunotoxin VEGF				
receptor/ligand		ere o une l'		
complex-dgA				

MAbs, CD22-saporin Phase II	Phase II		hiotechnolom.	20000
immunotoxin,			monoclonal antibody:	Calloci
bispecific, cancer; ITF 1265 + ITF 1269			immunotoxin	
MAb, doxorubicin	Discontinued		biotechnology;	cancer
conjugates; MAb,			monoclonal antibody;	
CC49-doxorubicin	-		immunotoxin;	
			anthracycline;	
-			antibiotic; DNA	
			intercalator	
MAb, anthracycline	Preclinical		biotechnology;	cancer
amine derivative			monoclonal antibody;	
			immunotoxin;	
			antibiotic	
MAb, CD5-	Phase II		biotechnology;	cancer; transplant
momordin;		_==_	tibody;	rejection
immunotoxin CD5-		· -	immunotoxin;	
momordin; ITF 1532		• •	immunosuppressant	
MAb, humanized,	Preclinical		biotechnology;	cancer
MRK 16; MRK 16		H	monoclonal antibody;	
		Į	MDR inhibitor	-
MAb, MRK 17;	Discontinued			cancer
MKK I7			monoclonal antibody;	
			MDR inhibitor	
MAb, humanized,	Phase II	,0	biotechnology;	rheumatoid arthritis;
leukemia; MAb,	_	H	onal antibody;	cancer; multiple
IgG2B; LDP 03; BW				sclerosis; transplant
7U; CAMPATH;		-		rejection
CAMPATH-1H				
iodine 131	Phase III	9	biotechnology;	cancer
tositumomab; MAb,		<u> </u>	monoclonal antibody;	
CD20-10dine 131; BEXXAR		<u>H</u> ;	radiotherapeutic	

MAK 16 00 -44	1.0			
MAN, 10.00-yunum	rnase I		biotechnology;	cancer
06			monoclonal antibody;	
			radiotherapeutic	
MAb, 35-67Cu;	Phase I		biotechnology;	cancer
MAb, murine colon			monoclonal antibody;	
carcinoma; MAb,			radiotherapeutic	
cancer			•	
MAb, 88BV59-	Phase I		biotechnology:	cancer
yttrium 90		- 1	monoclonal antibody;	
			radiotherapeutic	
MAb, B3-yttrium 90	Phase I		biotechnology;	cancer
			monoclonal antibody;	
			radiotherapeutic	
MAb, CC49-yttrium	Phase I		biotechnology;	cancer
			monoclonal antibody;	
		T	radiotherapeutic	
MAb, CD20-iodine	Phase II		biotechnology;	cancer
131			monoclonal antibody;	
		I	radiotherapeutic	
	Phase I	٠	biotechnology;	cancer
streptavidin + biotin-		_ 	monoclonal antibody;	
yttrium 90		H	radiotherapeutic	
MAb, CEA rhenium-	Phase II		biotechnology;	cancer
188; MAb, colorectal		_ 14	monoclonal antibody;	-
cancer; IMMURAIT-			radiotherapeutic	
Rhenium			•	
MAb, CG250-iodine	Phase II	.0	biotechnology;	cancer
131		H .	monoclonal antibody;	
		. Fa	radiotherapeutic	
MAb, chimeric L6-	Discontinued		biotechnology;	cancer
nodine 131; BMS		H	monoclonal antibody;	
180548		1	radiotherapeutic	

MAb, CYT 103-	Phase II		biotechnology:	Cancer
ottrium 90; MAb,		<u>' </u>	monoclonal antibody:	100100
B72.3-yttrium 90;		<u> </u>	radiotherapeutic	
ONCORAD OV 103;			- -	
ONCORAD CR103				
MAb, ERIC1 yttrium Discontinued	Discontinued	<u>.a.</u>	biotechnology;	cancer
06		H .	monoclonal antibody;	
			radiotherapeutic	
(MAb, F(ab)2	Discontinued	ُ مِ	biotechnology;	cancer
NRLU10-rhenium			nonoclonal antibody;	
186; MAb, F(ab)2		<u>.</u>	adiotherapeutic	
pancarcinoma; RHENEX				
MAK G250 joding	Dhone II			
121	riiase II	<u>ρ</u>	piotechnology;	cancer
151		E	nonoclonal antibody;	
		Ä	radiotherapeutic	
ed	Phase I	<u>, q</u>	biotechnology;	cancer
MN-14; MAb,		<u> </u>	monoclonal antibody;	
humanized		_ =	radiotherapeutic	
carcinoembryonic			•	
antigen; MN 14;			:	
CEA-Cide				
MAb, iodine-131,	Phase II	9	biotechnology:	cancer
DNA-associated		<u> </u>	monoclonal antibody:	<u> </u>
antigens; 1311-		_H	radiotherapeutic	
chTNT-1/B;			L	
COTARA; Tumor				
Necrosis Therapy;				
TNT			-	
	Phase II	9	biotechnology;	cancer
131; LymphoCide;		<u>. </u>	monoclonal antibody;	
ImmuRAIT-LL2		ra	radiotherapeutic	

MAb, LYM-1-iodine Phase III	Phase III	biotechnology;		cancer
131; LYM 1;		monoclo	monoclonal antibody;	
ONCOLYM		radiotherapeutic	rapeutic	
MAb, MAb fragment, Discontinued	Discontinued	biotechnology;		ancer
REC A33-TFM-		monoclo	ibody:	
nuclide; CDP 833		radiotherapeutic	apeutic	
MAB, NRLU13-	Phase II	biotechnology;		cancer
streptavidin + biotin-	1.	monoclo	ibody;	
yttrium 90;		radiotherapeutic	apeutic	
AVICIDIN				
7-iodine	Phase I	biotechnology;		cancer
131; OKB7		monoclo	ibody;	
		radiotherapeutic	apeutic	-
MAb, pan-B-yttrium; Phase III	Phase III	biotechnology;	Ť	cancer
MAb, B-cell radiation		monoclo	ibody:	
therapy; IDEC Y2B8	•	radiotherapeutic	apeutic	
MAb, PEM-antisense Preclinical	Preclinical	biotechnology:		cancer
oligonucleotide-		monoclo	tibody:	
radionuclide; AS 102		radiotherapeutic	apeutic	
MAb, PF1-A; MAb,	Preclinical	biotechnology;		cancer
squamous cell		monoclor	ibody:	•
carcinoma; AS 114		radiotherapeutic	apeutic	
MAb, UI13A yttrium Discontinued	Discontinued	biotechnology;		cancer
06		monoclor	ibody;	
	-	radiotherapeutic	apeutic	
	Phase II	biotechnology;		cancer
capromab; MAb,		monoclor	monoclonal antibody;	
CYT 356-yttrium 90;	•	radiotherapeutic	apeutic	•
MAb, 7E11C5-				
yttrium 90; MAb,				
prostate cancer;			×: ,	
OncoRad PR				

D-144110

MAK ABS. MAK	Droelinieel			
11110, 423, IMAB,	ricommoan	91010	biotechnology;	cancer
anti-CD2 anti-		nom	monoclonal antibody;	
idiotypic;		vaccine	ine	
ווארטע ארטיוויון				
MAb, BEC-2;	Phase III	biote	biotechnology;	cancer
vaccine, BEC-2;		nour	monoclonal antibody;	
EMD 60205; BEC2		vaccine	ine	
MAb, CA 125;	Phase III	biote	biotechnology;	cancer
vaccine, cancer;		Duoui	monoclonal antibody;	•
B43.13; OvaRex		vaccine	ine	
MAb, CA19.9; AR	Preclinical	biote	biotechnology;	cancer
44.6; GivaRex		monc	monoclonal antibody;	
		vaccine	ine	
MAb, idiotypic CEA; Phase II	Phase II	biote	tology;	cancer
vaccine, cancer;		ouom	ibody;	
cancer vaccine;	•	vaccine	ine	
CeaVac				
MAb, idiotypic GD2; Phase II	Phase II	biote	biotechnology;	cancer; psoriasis
vaccine, cancer;		ouom	monoclonal antibody:	1
cancer vaccine;		vaccine	ine	
TriGem			-	
MAb, idiotypic,	Phase II	biotec	biotechnology;	cancer
MUC1; vaccine,		ouom	monoclonal antibody;	
cancer; cancer		vaccine	ne	
vaccine; TriAb				
	Phase I	biotec	biotechnology;	cancer
vaccine, cancer; AR	:	ouom	monoclonal antibody;	
20.5; BrevaRex		vaccine	ne	
· 's	Preclinical	biotec	biotechnology;	cancer
ProstaRex		ouou	monoclonal antibody;	
		vaccine	ne	

monoclonal antibody Clinicals	Clinicale	100+0:4	hiotochan location	
bati idiotemio concer-	-			cancer
ann-iniotypic, cancer		conomi	monoclonal antibody;	
		vaccine	9	
antisense	Preclinical	biotech	biotechnology; mRNA cancer	cancer
oligonucleotide, B		transla	translation inhibitor;	
cell lymphoma		antisense;	ıse;	
		oligon	oligonucleotide	
antisense	Preclinical	biotech	biotechnology; mRNA cancer	cancer
oligonucleotide, c-		transla	translation inhibitor;	
. qku		antisense;	ıse;	
		oligon	oligonucleotide	
antisense	Discontinued	biotech	biotechnology; mRNA cancer	cancer
oligonucleotide,		translat	translation inhibitor;	
cancer		antisense;	ise;	
		oligon	oligonucleotide	
antisense	Preclinical	biotech	biotechnology; mRNA cancer	cancer
oligonucleotide,		translat	translation inhibitor;	
cancer; mRNA		antisense;	se;	
translation inhibitor,		oligonu	oligonucleotide	
cancer		,	=	
	Phase II	biotech	biotechnology; mRNA cancer	cancer
oligonucleotide, Ha-	-	translat	translation inhibitor;	
ras; ISIS 2503		antisense;	se;	
		oligonu	oligonucleotide	
antisense	Discontinued	biotech	biotechnology; mRNA cancer	ancer
oligonucleotide,		translat	translation inhibitor;	
Kaposi's sarcoma		antisense;	se;	
		oligonu	oligonucleotide	

antisense oligoniicleotide	Phase II		biotechnology; mRNA cancer	cancer
Philadelphia			translation inhibitor; antisense;	
chromosome; antisense			oligonucleotide	
oligonucleotide,				
chronic myelogenous				
antisense	Preclinical		hiotechnology: mPNA cancer	Concer
oligonucleotides, Ki-			translation inhibitor;	Callect
ras			antisense;	
			oligonucleotide	
GPs 0193; NAVIN	Discontinued		biotechnology; mRNA HIV infection;	HIV infection;
		,	translation inhibitor;	cancer
			antisense;	
			oligonucleotide	
LR 3523	Discontinued		biotechnology; mRNA cancer	cancer
-			translation inhibitor;	
	-		antisense;	
			oligonucleotide	
BCG A4	Preclinical		biotechnology;	cancer
			ongonucieonde	
LR 5165	Discontinued	بي	biotechnology;	cancer
			oligonucleotide	
_	Discontinued	<u></u>		cancer; genetic
directed DINA therapy		<u> </u>	oligonucleotide	disorder; viral
			_	infection; bacterial
				infection
	Preclinical	<u>.u.</u>	biotechnology;	cancer
en			oligonucleotide	
	Preclinical	<u>.u.</u>		cancer
chronic myelogenous leukemia. Kimeragen		0	oligonucleotide	
	T			

antisense	Preclinical		biotechnology:	cancer
oligonucleotide, bcl- 2; ODN 2009	·		oligonucleotide; antisense	
antisense	Preclinical		biotechnology:	Cancer
oligonucleotide,			oligonucleotide:	
cancer, GeneSense			antisense	
Technologies; GTI				
2040				
antișense	Preclinical		biotechnology	cancer
oligonucleotide,			oligonucleotide:	ionimo.
cancer, GeneSense			antisense	
Technologies; GTI 2501				
antisense	Preclinical		biotechnology;	cancer
oligonucleotide,			oligonucleotide:	
cancer,	•		antisense	
Isis/AstraZeneca				
antisense	Phase II	d(P-thio) (T-C-C-C-	biotechnology:	cancer
oligonucleotide, raf		G-C-T-G-T-G-A-	oligonucleotide:	
kinase; antisense			antisense	
oligonucleotide,				
cancer; ISIS 5132;				
CGP 69846A; CGP			-	
69846A; ODN 698				
antisense	Preclinical		biotechnology;	cancer
oligonucleotide, TAG			**	
0; IAG 6			antisense	
antisense	Preclinical		logy;	cancer
oligonucleotides, non-			.	
Hodgkins lymphoma, Fox Chase Cancer			antisense	
Center				

oligonucleotides, VimRx	Preclinical	- 1	biotechnology;	cancer; psoriasis
			oligonucleotide; ribozyme	
ribozyme, bcl-2,	Preclinical		biotechnology;	cancer
Kibozyme			oligonucleotide;	
	_		ribozyme	
ribozyme, europium-	Preclinical		biotechnology;	cancer; viral
rexaphyrin, cancer;			oligonucleotide;	infection
mbozyme, europium			nbozvme	
texaphyrin, viral infection			-	
ribozyme, K-ras	Preclinical		biotechnology;	cancer
			oligonucleotide;	
			ribozyme	
sense	Discontinued		biotechnology:	cancer: viral
oligonucleotides,			oligonucleotide;	infection
GenSet; transcription			transcription factor	
factor decoys, GenSet			regulator	
polyethylene glycol	Discontinued		biotechnology:	gout cancer
uricase; PEG-uricase;			oxidoreductase	ومدن مستوور
uricase macrogol			uricase	
class II restricted	Preclinical		biotechnology: peptide cancer	cancer
melanoma antigens,			1 1 60	
National Institutes of				
Health				
urokinase receptor	Preclinical		biotechnology: nentide cancer: inflammation	cancer inflammation
antagonists, Chiron			And (Co	omicot, minaminiamon
interferon-inducible	Preclinical	-	biotechnology.	Sucer
protein-10; IP-10		<u>.</u> _	peptide: chemokine	
ole	Preclinical		Γ	Cancer ave disease
protein-10; IP-10			kine	vancei, cyc discase

antibody-derived	Digoonting			
anticoay-delived	Dantining	DIO	biotechnology;	cancer; diagnosis
anticancer peptides,		ded	peptide; contrast	
Antisoma	·	mec	medium	
RecepTox-GnRH	Preclinical	biot	biotechnology;	cancer
		pep	peptide; fusion toxin	
chimeric peptides,	Preclinical	biot	biotechnology;	cancer; viral
National Institutes of		pen	peptide: vaccine	infection
Health		4 1		
plasminogen activator Phase II	Phase II	biot	biotechnology:	Cancer.
inhibitor; PAI-2		plas	tivator	inflammation skin
-		linhi		ulcer
matrix	Discontinued	biot		arthritis: cancer:
metalloproteinase		prot	proteinase inhibitor;	arthritis
inhibitor		matrix	ix	
		meta	metalloproteinase	-
		inhil	inhibitor; NSAID	
maspin; mammary	Preclinical	biote	biotechnology;	cancer
serine proteinase		prote	proteinase inhibitor;	
inhibitor; LXR 023;		serin	serine proteinase	
MEIAKEX	-	inhit	inhibitor	
neutral	Discontinued	biote	ogy;	cancer; migraine;
ciluopepiluase; NEF		prote		inflammatory bowel
	<u> </u>	meta	netalloproteinase	disease;
		***	• • •	inflammation;
				asthma; respiratory
				disease
	Preclinical	biote	ogy;	cancer
acute promyelocytic		hiboz	ribozyme;	
	-	oligo	oligonucleotide	
les,	Preclinical	biote	logy;	cancer
mumple arug		riboz	ribozyme;	
esistance		oligo	oligonucleotide	

ribozyme, ras, P. Ribozyme		:	
ras,		ribozyme; oligonucleotide	
	Preclinical	biotechnology;	cancer
		nbozyme; oligonucleotide	
	Phase I	biotechnology;	retinopathy; cancer
endothelial growth		ribozyme;	•
ractor receptor;		oligonucleotide	
receptor; RPI 4610; ANGIOZYME			
screening technology, Preclinical	reclinical	biotechnology; target	drug design
growth regulatory compounds		pased screening	technology; cancer
drug delivery system, Preclinical	reclinical	biotechnology; vaccinecancer	lecancer
verotoxin fusion			
protein cancer			
vaccine; vaccine,		-	
cancer			
growth F	Phase I	biotechnology; vaccinecancer	ecancer
MEDI 501	Phase I	biotechnology; vaccinecancer; viral	ecancer; viral
MEDI 503 Pr	Preclinical	hiotechnology, yaccinecancer	IIII CCIIOII
MEDI 504 Pr	Preclinical	biotechnology: vaccine cancer	Position
eq	Preclinical	biotechnology; vaccinecancer	ecancer
sociated CTAA 79	Preclinical	biotechnology; vaccine cancer	cancer
AV1017			

vaccine, B cell	Preclinical	19	hiotechnology: vaccine cancer	ancer
lymphoma specific			(6)	
idiotype-granulocyte				
macrophage colony				
stimulating factor;				
vaccine, Id/MoGM- CSF				
vaccine, breast	Preclinical	id	piotechnology: vaccinecancer	ancer
cancer;			(6)	
immunotherapy,		<u> </u>	varu.	
breast cancer;				
TWO VAC				
vaccine, breast cancer Preclinical	Preclinical	bi	biotechnology; vaccinecancer	ancer
vaccine, breast	Preclinical	id	biotechnology; vaccinecancer	ancer
cancer, CelSci				
vaccine, canarypox	Phase I	bio	biotechnology; vaccinecancer	ancer
CEA; vaccine, cancer;			· -	
ALVAC-CEA				
vaccine, cancer	Preclinical)io	biotechnology; vaccinecancer	ancer
vaccine, cancer	Preclinical)ĬĢ	biotechnology: vaccinecancer	ancer
vaccine, cancer,	Discontinued	id	hiofechnology: vaccinecancer	ancer
MedImmune		<u>. </u>	creamings), recuired	To a second
1	Phase I	bid	biotechnology; vaccinecancer	ancer
cancer; vaccine,	-		3	
Hsp65-HPV E7				
fusion protein;				
Hsp65E7; HspE7;				
ONCOCINE				
vaccine, colorectal	Phase II	bic	biotechnology: vaccinecancer	ancer
and lung cancers;			3	
colorectal and lung				
cancers vaccine;				
OncoVax-CL		-		•

vaccine, colorectal	Preclinical		hiotechnology, yearing	***************************************
cancer			greeningly, vaccinication	כמווכנו
vaccine, Epstein Barr	Preclinical		biotechnology: vaccineglandular fever	eglandular fever
viral coat protein;		·		cancer.
vaccine, EBV		,		
vaccine, Epstein-Barr	Clinicals		biotechnology: vaccinecancer	cancer
virus gp 220-340;			(6)	
vaccine, EBV				
vaccine, gp75	Preclinical		biotechnology: vaccine cancer	cancer
antigen; vaccine,				
cancer		_	-	
vaccine, hepatitis B	Preclinical	<u>.</u>	biotechnology: vaccinecancer	Cancer
core antigen fusion			0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Toolino.
proteins, National				
Institutes of Health;			-	
vaccine, cancer	•			
vaccine, HER/neu-2	Preclinical	2	biotechnology: vaccinecancer	cancer
oncogene; vaccine,				
breast cancer				
vaccine, human	Phase I	9	biotechnology: vaccinecancer	Cancer
			(6)	Tooling
vaccine, cervical			-	
cancer; vaccine, HPV	-			
	Phase II	10	biotechnology: vaccinecancer. viral	cancer. viral
papillomavirus;			(18)	infection
therapeutic antigen,				
cervical cancer;				
vaccine, HPV; TA-		-		
HPV		:		

papillomavirus;		PIOIC	dring way worden	ring infaction.
			ciccomicios, vaccino vita infection,	vital mitecuoli,
therapeutic antigen,				direct
genital warts;	-			
vaccine, HPV; TA-	-			
GW				
vaccine, mage-1;	Discontinued	biotec	biotechnology: vaccinecancer	ancer
vaccine, melanoma;			(6)	10010
TBC-Mage-1;		_		
MAGEVAC				
vaccine, MART-1;	Phase I	biotec	biotechnology: vaccinecancer	ancer
vaccine, melanoma			(6)	
vaccine, mutant p53	Phase I	biotec	biotechnology: vaccinecancer	ancer
and ras peptide				
activated monocytes				
vaccine, neu; vaccine, Preclinical	Preclinical	biotec	biotechnology: vaccine cancer	ancer
breast and ovarian			, (Garana	
cancer; TBC-NEU				
vaccine, papilloma	Discontinued	biotec	biotechnology: vaccinecancer	ancer
virus HPV 16;				alicol
vaccine, cervical		-		
cancer		21		
, prostate	Phase I	biotec	biotechnology: vaccinecancer	ancer
				Toolin .
immunotherapy,	,		-	
prostate cancer;				
PROSTVAC				
vaccine, prostate	Preclinical	hiotech	biotechnology: vaccinecancer	ncer
				7007
4)	Phase II	biotech	biotechnology; vaccinecancer	ancer
cancer; prostate	_	-	3	
cancer vaccine;				
NOKELIN		-		

vaccine, prostate cancer, CelSci	Preclinical		biotechnology; vaccinecancer	ecancer
vaccine, ras; vaccine, Discontinued colorectal cancer;	Discontinued		biotechnology; vaccinecancer	ecancer
אין פראי (פראי-טפי				
vaccine, recombinant Phase I dendritic cells, Duke University	Phase I		biotechnology; vaccinecancer	ecancer
vaccine, TBC-CEA; vaccine, cancer; TBC-CFA	Phase II		biotechnology; vaccinecancer	ecancer
1				
vaccine, tumor; tumor Discontinued vaccine	Discontinued		biotechnology; vaccinecancer	cancer
virus derived	Discontinued		hiotechnology, wooning	
particles, human			december, vaccine ancel	Calicel
papillomavirus;				
VDPs, HPV				
thymalfasin; thymosin alpha-1; Ta-	Marketed	(N-acetyl)-ser-asp- ala-ala-val-asp-thr-	biotechnology; vaccinecancer; viral	cancer; viral
I; ZADAXIN		ser-ser-glu-ile-thr-thr-immunostimulant;	immunostimulant;	10100
		lys-asp -leu-lys-glu-	peptide	
		lys-lys-glu-val-val-		
		glu-glu-ala-glu-asn- OH		
	Preclinical	,	biotechnology:	Cancer
antigen;			vaccine; biotechnology	cancol 1
vaccine, HPV;			3	
vaccine, cervical				-
cancer				
e, gene-based,	Preclinical		biotechnology;	cancer
cancer			vaccine; gene therapy	

vaccine, gene-based, non-Hodgkin's B cell	Phase II		biotechnology; vaccine; gene therapy	cancer
iyiiipiioiiia, vaxii				
vaccine, gene-based,	Preclinical		biotechnology;	cancer
T cell lymphoma;			vaccine; gene therapy	
APL 400020;				
GENEVAX			,	
vaccine, ALVAC-	Phase I		biotechnology:	Cancer
hB7.1; vaccine,		•	vaccine:	
ovarian carcinoma;			imminoetimulant	
AUT-OV-ALVAC-				
hB7.1		Vis.	- -	
vaccine, cervical	Preclinical		biotechnology:	cancer
intraepitheal		-1	vaccine:	
neoplasia; TA-CIN;		•	immunostimulant	
TA-CIN				
MAb, I-Mel-1; I-Mel-Discontinued	Discontinued		biotechnology;	cancer
1; MELIMIMUNE-1			vaccine: monoclonal	
			antibody	
MAb, I-Mel-1 +	Discontinued		biotechnology:	Cancer
MAb, I-Mel-2; MAb,			vaccine: monoclonal	· ·
I-Mel-2 + MAb, I-			antihody	
Mel-1;				
MELIMIMUNE				
MAb, idiotypic	Phase III		biotechnology;	cancer
105AD7; MAb, anti-	-		vaccine: monoclonal	
idiotypic gp72;			antibody	
MAh	Draclinical			
neuroblastoma/elioma	1001111041		biotechnology;	cancer
; MAb, NG 1; MAb,			vaccine, monocional	
cancer; NG 1;			airiocey	
MONOPHARM G				
			1	

vaccine, MAb, anti-	Preclinical		biotechnology;	cancer
idiotype, cancer;			vaccine; monoclonal	
vaccine, cancer;			antibody	
MAb, cancer			•	
vaccine, melanoma;	Phase II		biotechnology;	cancer
MAb, MK2-23		-	vaccine; monoclonal	
			antibody	-
minodronic acid; YM Phase II	Phase II	(1-hydroxy-2-	bisphosphonate	osteoporosis:
529; YH 529		(imidazo[1.2-		hypercalcemia;
		a]pyridin-3-		cancer
·		yl)ethylidene)bisphos	-	
		phonic acid	<u>.</u>	
neridronic acid;	Discontinued	(6-amino-1-	bisphosphonate	Paget disease:
aminohexane		hydroxyhexylidene)di		osteoporosis: cancer
diphosphonate;		phosphonic acid	•	
AHDP Na	٠	4		
pamidronic acid;	Marketed	(3-amino-1-	bisphosphonate	osteonorosis: cancer
pamidronate		ylidene)b		120111111111111111111111111111111111111
disodium; APD; CGP		isphosphonic acid		
23339AE; AREDIA;		•		
OSTEOKIT				•
	Marketed	[1-hydroxy-3-	bisphosphonate;	osteoporosis: cancer.
ibandronate sodium;		(methylpentylamino)posteoanagenetic		hypercalcemia
BM 210955;		ropylidene]bisphosph)	
BONDRONAT		onic acid		

2000	•			
RC 3093	Phase I		bombesin antagonist	cancer
			-	
		pyrido[3,4-b]indole-		
-t		3-carbonyl-L-		
		glutaminyl-L-		
		tryptophyl-L-alanyl-		-
		L-valylglycyl-N-	-	
_		[(1S)-1-[[[(1S)-1-		
		(aminocarbonyl)-3-		
		methylbutyl]amino]m		
		ethyl]-3-		
		methylbutyl]-L-		
		histidinamide		
D 22213	Phase I	R*)]]-	bombesin antagonist;	cancer
		N2-[(2,3,4,9-	peptide	
	•	tetrahydro-1H-		
	·	pyrido[3,4-b]indol-3-		
		yl)carbonyl]-L-		
		glutaminyl-L-		
		tryptophyl-L-alanyl-		
		L-valylglycyl-N-[1-		
		[[[1-(aminocarbonyl)-	-	
		3-		
		methylbutyl]amino]m		
_		ethyl]-3-		
		methylbutyl]-L-		
		histidinamide		
		monoacetate		

glucarolactam; ND	Discontinued	5-amino-5-deoxy-D-	chemoprotectant	cancer
2001	 , ,	glucosaccharic acid- delta-lactam	•	
myeloid progenitor inhibitory factor; MPIF-1; HG 00300	Phase II		chemoprotectant; biotechnology; hematoprotectant;	cancer
			inhibitor; stem cell division inhibitor; chemokine	
dexrazoxane; razoxane (+). (S):	Marketed	(+)-(S)-4,4'-	chemoprotectant;	cancer; heart failure
ICRF 187; NSC			eytopiotectant ≅	
109 / 80; ADK529; ICI 59118;	<u>.</u> .			
CARDIOXANE;		-		
RAZOXIN:				
ZINECORÉ;				
ANTRAGARD			, -	
gammalinolenic acid	Discontinued		chemoprotectant;	cancer
+ eicosapentaenoic		:	cytoprotectant	
AMELORAD:				
TARAGAM				
ICRF 197	Preclinical		chemoprotectant;	cancer; heart failure
2 t 10 f			cytoprotectant	
MG1 136	Discontinued	Discontinued diethyldithiocarbamat chemoprotectant;	hemoprotectant;	cancer
		X X	cytoprotectant	

WR 151327; NSC	Preclinical	3-[[3-	chemoprotectant;	cancer; HIV
70000		(metnylamino)propyi]cytoprotectant amino]-1-	cytoprotectant	ınfection
		propanethiol	_ •	
		dihydrogen phosphate ester		
amifostine; ethiofos;	Marketed	2-[(3-	chemoprotectant:	cancer
gammaphos; WR		propyl)amino]e	cytoprotectant;	
Z/Z1; NSC 296961; YM-08310: WR		thanethiol dihydrogen radioprotectant	radioprotectant	
2721C; ETHYOL		piiospiiaic		
hematopoietic growth Preclinical	Preclinical		chemoprotectant;	cancer
factor inhibitors,			hematopoiesis	.,,,
Ligand			inhibitor	
hematopoietic	Preclinical		chemoprotectant;	cancer
progenitor cell		-	hematoprotectant;	
inhibitor, University			hematopoiesis	
of Indiana			inhibitor; stem cell	
			division inhibitor	
stem-cell division	Discontinued		chemoprotectant; stem cancer	cancer
inhibitors, Terry Fox		<u>.</u>	cell division inhibitor;	
Laboratory			hematopoiesis	
11 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1			inhibitor	
stem cell innibitory	Discontinued	•	_	cancer
iactoi, ilatutai, SCIF		<u> </u>	cell division inhibitor;	
		.	nematoprotectant;	
		<u>r£i</u>	hematopoiesis	
		1.	inhibitor	
CRL 1095	Discontinued	Q	chemosensitizer	cancer
CRL 1605	Preclinical	9	chemosensitizer	cancer
glutathione-S-	Preclinical			cancer
tranferase inhibitors, Telik				

napavin	Preclinical	3-[[[2-[(4-azido-2-	chemosensitizer	cancer
		nitrophenyl)amino]et hyl]amino]carbonyl]-	. <u>1</u> 2-2-1	
		O4-deacetyl-3-		
		de(methoxycarbonyl)		
TER 199	Preclinical	(2R)-I,-gamma-	chemosensitizer	***************************************
		glutamyl-S-		ישווכנו ישווכנו
		(phenylmethyl)-L-	-	
		cysteinyl-2-		
declopramide; OXI	Phase II		chemosensitizer:	cancer
104			apoptosis inducer:	
			radiosensitizer	
CMDA; CJS 8	Preclinical	N-[4-[(2-		cancer
-			cylating	
			agent	
		ethyl]amino]benzoyl]		-
		-L-glutamic acid		
galamustine;	Discontinued	6-[bis(2-	chlormethine	cancer
galactose-6-mustard;		yl)amino]-6-	derivative; alkylating	-
C6 GLM; G 6 M		deoxy-D-	agent	
		galactopyranose		
SN 23862	Preclinical	5-[bis(2-	nethine	cancer
		chloroethyl)amino]- deriva	derivative; alkylating	
		2,4-dinitrobenzamide	agent	
spiromustine;	Phase II	3-[2-[bis(2-	nethine	cancer
spirohydantoin		amino]eth	lerivative; alkylating	
mustard; SHM;		yl]-1,3-	agent	
speratine; NSC		4.5]decane		
2112/1		-2,4-dione	-	

tallimustine; FCE	Discontinued	Discontinued N-[5-[[(3-amino-3-	chlormethine	cancer
24517		iminopropyl)amino]c	minopropyl)amino]c derivative; alkylating	
		arbonyl]-1-methyl-	agent	
		[1H-pyrrol-3-yl]-4-		
		[[[4-[[4-[bis(2-	-	
		chloroethyl)amino]be		
		nzoyl]amino]-1-		
		methyl-1H-pyrrol-2-		
		yl]carbonyl]amino]-1-		
		methyl-1H-pyrrole-2-		
veramine: RL 0017	Preclinical	(3heta 16heta 17heta	homothing	
			derivative: alkylating	cancer
			agent	
		dien-3-ol		
lintitript; SR 27897;	Phase II		cholecystokinin A	eating disorder:
SR 27897B		nyl)-2-	antagonist;	cancer
		carbo	cholecystokinin	
		dole-1-	antagonist	
4 4				
docosanol, n-;	Pre-	I-docosanol	cicatrizant	viral infection; skin
docosanol, 1-; behenyl registration	registration		-	ulcer; cancer
alcohol; LIDAKOL				
Myc/Max inhibitors,	Discontinued		cicatrizant	cancer: skin ulcer
Apoptosis				
Technology;				
Myc/Max inhibitors,				
ICRF				_
OLX 501	Discontinued		collagenase inhibitor;	septic shock; cancer;
				vascular leakage
		- b. -	metalloproteinase	
			inhibitor; proteinase	
		7	IUIIOIIOI	

OI V 51.4				
OLA 314	Discontinued		collagenase inhibitor; septic shock; cancer	septic shock; cancer
			matrix	
			metalloproteinase	
			inhibitor; proteinase	-
			inhibitor	
MAb,	Phase I		contrast medium;	cancer; diagnosis
carcinoembryonic			monoclonal antibody;	
antigen; PK1A3			biotechnology;	
			radiotherapeutic;	
			radiodiagnostic	
NLCQ 1	Preclinical	4-[3-(2-	contrast medium; MRI diagnosis; cancer	diagnosis; cancer
•		nitroimidazolyl)propylagent; imidazole	agent; imidazole	-
		lamino]-7-		
-		trifluoromethyl-	-	
	<u></u>	quinoline		
Lamitachai criticacour	11			
peptide-iodine 123;	rnase 11	· .	contrast medium; pentide	diagnosis; cancer
VIP-I 123				
cancer therapy,	Preclinical		contrast medium;	cancer
Angstrom/Diatide			radiotherapeutic;	
			radiodiagnostic	
fludarabine +	Discontinued		corticosteroid	cancer
prednisone;				
prednisone +				
fludarabine				
ORG 6632	Discontinued	a.	corticosteroid;	cancer; rheumatoid
		beta-	mmunosuppressant	arthritis
		hydroxy-		
		16alfa, 17alfa-		
-		dimethylpregna-1,4-		
		giene-3,20-dione		

HX 0836	Preclinical	(E)-3-(3.4-	COX inhibitor: 5	Cancer
•		dihydroxyphenyl)-1-	dihydroxyphenyl)-1- lipoxygenase inhibitor	
		(2,5-		
		dimethoxyphenyl)-2-		
		propen-1-one		
celecoxib; SC 58635; Marketed	Marketed	4-[5-(4-	COX inhibitor; COX 2 arthritis; pain; cancer	arthritis; pain; cancer
YM 177;		methylphenyl)-3-		
CELEBREX;		(trifluoromethyl)-1H-	NSAID	
CELEBRA		pyrazol-1-		
		yl]benzenesulfo		
		namide		
cyclocreatine; AM	Discontinued	2-amino-4,5-dihydro- creatine kinase		cancer; viral
. 687		1H-imidazole-1-	modulator	infection
cdk2 inhibitors	Preclinical			
Molecum eties	i recillical		=	cancer
ivolecuments			kinase inhibitor	
cyclin-dependent	Preclinical		cyclin dependent	cancer
kinase inhibitor,			kinase inhibitor	
Agouron; cancer				
therapy, Agouron			-	
lent	Preclinical		cyclin dependent	cancer
kinase/cyclin				
inhibitors, Mitotix;				
Cdk/cyclin inhibitors,	-		-	
Mitotix				
	Preclinical		cyclin dependent	cancer
kinase4 modulators,		- -		
Pharmacopeia; cdk4				
modulator,				_
Pharmacopeia			-	

flavopiridol; NSC	Phase II	cis-2-(2-	cvelin denendent	Concor
649890; HMR 1275		enyl)-5,7- :y-8-(3-	kinase inhibitor	
	•	hydroxy-1-methyl-4-		
		pipendinyl)-4H-1-	-	
		benzopyran-4-one		
CYC 202	Preclinical		cvclin dependent	cancer
			kinase inhibitor;	
tumor necrosis factor	Pre-		cytokine	Cancer
alpha, natural; TNF	registration			
alpha, natural;	I .			
tonermin; MHR 24			· .	
granulocyte-colony stimulating factor	Preclinical		cytokine agonist	cancer
agonists,				
Pharmacopeia;				
granulocyte-colony				
stimulating factor				
agonists, Regeneron				
interferon agonists,	Preclinical		cytokine agonist;	cancer; viral
Ligand				infection; infectious
				disease; multiple
				sclerosis
ap,	Preclinical		cytokine antagonist	cancer; asthma;
wegeneron				rheumatoid arthritis;
			Ī	allergy
antagonist Pentor	Preclinical	0	nist;	cancer
Podd Thomas			pepude; NSAID	

CNI 1403	Dhasa T			
	r liase 1	I'V,IV -DIS[3, 2-DIS[1- CYTOKINE] [(aminoiminomethyl) inhibitor	cytokine synthesis inhibitor	cancer
		hydrazono]ethyl]phen		
		yij-uecanediamide tetrahydrochloride	-	
drug delivery system, Preclinical	Preclinical		cytokine;	cancer
Therapeutics			biotechnology	
delivery system, gene Preclinical	Preclinical		cytokine:	cancer
therapy, IL-2,			biotechnology: gene	Tooling
Biovector			therapy:	
Therapeutics; gene			immunostimulant	
therapy, IL-2,				
Biovector				
Therapeutics				
cytotoxic lymphocyte Discontinued	Discontinued		cytokine:	cancer
maturation factor;	_	-: -	immunostimulant	
CLMF				
501; ILX	Phase I	N-[[(3,4-	diarylsulfonylurea	cancer
295501		henyl)amino		
		carbonyl]-2,3-		
		dihydro-5-		
		benzofuransulfonami		
7 17 10// 11				
sulorenur; LY 186641 Discontinued	Discontinued	N-[[(4-	diarylsulfonylurea	cancer
_		chlorophenyl)amino]c		
		arbonyl]-2,3-dihydro-		
		1H-indene-5-		
		sulfonamide		
AN 9; PIVANEX	Phase II	id (2,2-	differentiation inducer	cancer
		oxopropoxy)methyl		
		csier		

SD-144110

СВНА	Preclinical	N-hvdroxv-3-f3-	differentiation inducer Lancer	00000
		(hydroxyamino)-3-		
		oxo-1-propenyl]-		
		benzamide		
EMBA	Preclinical	diethyl bis-	differentiation inducer	cancer
		(pentamethylene-		
		Z,Z		
		dimethylcarboxamide		
)malonate		
hexamethylene	Phase II	N,N'-1,6-	differentiation inducer cancer	cancer
bisacetamide;		hexanediylbisacetami		
HMBA; NSC 95580; HEXABID		qe		
NF 036	Preclinical	8-[(7-chloro-4-	differentiation inducer cancer	cancer
		l -[ou		
		1,3,5-		
		naphthalenetrisulfonic		
		acid trisodium salt		
SAHA; SW 064652	Preclinical		differentiation inducer cancer	cancer
		hydroxamic acid		
TI 66	Preclinical		differentiation inducer cancer	cancer
		-		
		bis(phenylmethyl)-		
		2,4-		
		diazabicyclo[4.2.0]oct		
		ane-3,5-dione	-	
CDDO	Preclinical	2-cyano-3,12-	differentiation inducer; cancer	cancer
		(11)	untiproliferative agent	
		dien-28-oic acid		

alitretinoin; LGD 1057; LG 1057; LGN 1057; ALRT 1057; NSC 659772; PANRETIN	Marketed	9-cis-retinoic acid	differentiation inducer; cancer; psoriasis retinoid agonist; RAR agonist	cancer; psoriasis
AG 187	Discontinued	2,4-diamino-6-(N-(4- dihydrofolate (phenylsulfonyl)benz reductase inhibitor yl)methylamino)quina zoline	dihydrofolate reductase inhibitor	cancer
LY 298207	Preclinical	4-(2,4-diamino-diny])butyl]ben	dihydrofolate reductase inhibitor	cancer
LY 316373	Preclinical	N-[4-[3-(2,4-diamino-dihydrofolate 5- pyrimidinyl)propyl]be nzoyl]-L-glutamic acid	bitor	cancer
trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898; NeuTrexin	Marketed	5-methyl-6-[[(3,4,5- dihydrofolate trimethoxyphenyl)amireductase inhibitor; no]methyl]-2,4- antifolate; NSAID quinazolinediam ine		cancer; psoriasis; rheumatoid arthritis; pneumocystis
drug delivery system, Discontinued methotrexate; methotrexate Therapeutic Implant; MPI 5004; IntraDose-MTX; INTRADOSE-MTX	Discontinued	9 2 8	dihydrofolate reductase inhibitor; antimetabolite	cancer

MDAM	Dhace I	N 1 1 1 10 00 4 3:5	11:1	
	T TIMBE T	14-[4-[4-4-diamino-dinydrololate	oinyoroioiate	cancer; transplant
-		-0	reductase inhibitor;	rejection;
		pteridinyl)ethyl]benzolNSAID;	NSAID;	rheumatoid arthritis;
		yij-4-methylene-DL- immunosuppressant	immunosuppressant	asthma
eniluracil: 5-	Phase III		dihydronyrimidine	10000
ethynyluracil; 5-EU;			dehydrogenase	Calloci
776C85; BW 776C85	••	ione	inhibitor;	
			antimetabolite	
spirogermanium;	Discontinued		DMARD; NSAID	malaria; multiple
192903; SPIKU-		dimethyl-2-aza-8-		sclerosis; rheumatoid
75		germaspiro[4.5]decan		arthritis; cancer
acridine-derived	Preclinical		DMA intercolotor	
bisintercalators, NIH			ביים	calicel
anticancer agents,	Discontinued		DNA intercalator	cancer
kko				
BBR 2778	Phase I	6,9-bis[(2-	DNA intercalator	cancer
]be		
	-	nz[g]isoquinoline-		
		5,10-dione (Z)-2-		
		butenedioate (1:2)		
bisnafide; DMP 840	Phase II		DNA intercalator	cancer
		ethanediylbis[imino(1]		
		-methyl-2,1-		
		ethanediyl)]]bis[5-		
		nitro-1H-		
		benz[de]isoquinoline-		
		1,3-(2H)dione]		
BW 7U85	Discontinued	dilliculariesullonare T	DMA internalistan	
			DIAM IIICICAIAIOI	cancer
502U83	Discontinued		DNA intercalator	cancer

crisnatol; crisnatol	Discontinued [2-[(6-	7-[(6-	DNA intercalator	cancer
mesilate; BW 770U82; BWA 770U		chrysenylmethyl)ami no]-2-methyl-1,3-		
D 1411	Discontinued	proparection	DNA intercalator	Cancer
DMP 315	Preclinical	[R-(R*,R*)]-5-[1-	DNA intercalator	cancer
		methyl-2-[[2-[[2-(5-	-	
		nitro-1,3-dioxo-1H-		
		benz[de]isoquinolin-	. <u>.</u> .	
		z(3n)-		
		yl)propyl]amino]ethyl		
		January Jeuny 1-411-		
		benzo[de]pyrido[3,4-		
		g]isoquinoline-		
		4,6(5H)dione		
		dimethanesulfonate		
ledoxantrone; CI 958	Phase II	5-[(2-	DNA intercalator	cancer
isomer; PD 121373		aminoethyl)amino]-2-		
		[2-		
		(diethylamino)ethyl]-		
		2H-		
		[1]benzothiopyrano[4]		
		,3,2-cd]indazol-8-ol		
de; NSC	Phase II	2-[2-	DNA intercalator	cancer
3002888		(dimethylamino)ethyl		
]-5-nitro-1H-		
		benz[de]isoquinoline-		
		1,3(2H)-dione		

S 160202; S 16020-2; Phase II	Phase II	N-f2-	DNA intercalator	cancer
S 16020; NSC		hylamino)ethyl		
659687; NSC D659687]-9-hydroxy-5,6-		
		pyrido[4,3-		
		b]carbazole-1-		
		carboxamide dihydrochloride		
cyclopentanthraquino Preclinical	Preclinical		DNA intercalator;	cancer
nes, Sloan Kettering Institute			anthraquinone	
OC 4845	Preclinical	1,1a,2,2a,5,10-	DNA intercalator;	cancer
			anthraquinone	
		3[[[methylamino]car		
		bonyl]oxy]methyl]-az		
		irino[2',3':3,4]cyclope		
		nta[1,2-a]anthracene-		
		5,10-dione		
C 1311	Phase I	5-[[2-	DNA intercalator;	cancer
		(diethylamino)ethyl]a DNA topoisomerase	DNA topoisomerase	
		mino]-8-hydroxy-6H- inhibitor	inhibitor	
		imidazo[4,5,1-	-	
		de acridin-6-one		
NLP.1	Preclinical	5-1H-	DNA intercalator;	cancer
		imidazol-1-	radiosensitizer	
		yl)propyl]phenanthrid		
		inium bromide		
			7	

aphidicolin glycinate; Preclinical	Preclinical	glycine,	DNA polymerase	cancer
NSC 303812		(3alfa,4alfa,5alfa,17al inhibitor fa)-3,17-dihydroxy-4-	inhibitor	
		methyl-9,15-cyclo-		
		C,18-dinor-14,15-		-
		secoandrostane-4,17-		
		dimethanol ester		
		hydrochloride		
DNA polymerase betaDiscontinued	Discontinued		DNA polymerase	cancer
inhibitors, Agouron			inhibitor;	
		-	radiosensitizer;	
			chemosensitizer	
NU/ICRF 505	Discontinued		DNA topoisomerase	cancer
11011 40 110110			inducei	
UCI 4B; UCIB 4	Discontinued		DNA topoisomerase	bacterial infection;
		[1,2,3,4,4a,7,8,8a-	inducer; antibiotic	cancer
	• ,	octahydro-3-hydroxy-		
		5-(hydroxymethyl)-		
		1,2,4a-trimethyl-4-	-	
		oxo-1-		
		naphthalenyl]ethyl]-		
		alpha-oxo-		
		oxiraneacetaldehyde		
-6	Phase II	(S)-10-amino-4-ethyl-DNA topoisomerase		cancer
aminocamptothecin;		4-hydroxy-1H-		
9-AC; NSC 603071		pyrano[3',4':6,7]indoli		
(S); NSC 629971 (+,-		zino[1,2-b]quinoline-		
); FCE 28044		3,14(4H,12H)-dione		
AMP 53; azonafide	Discontinued		DNA topoisomerase	cancer
		1	IIIIIDIIOI	

SC 343499; [(methylsulfonyl)aminolphenyl]aminol-N,5-dimethyl-4-acridinecarboxamide NSC Preclinical (5R-cis)-5,6,11,11a-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-1H,3H-oxazolo[3,4*!1,6]pyrido[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7-dihydro-1-methyl-4,7-dioxo-1H-indol-3-yl)-4-thiazolecarboxamide C Discontinued 12,13-dihydro-1,11-dihydroxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione Discontinued dione Discontinued indolo[2,3-a]phase I ii Phase I	asulacrine; amsalog;	Phase I	9-[[2-methoxy-4-	DNA topoisomerase	cancer
No.5-dimethyl-4- acridinecarboxamide No.5-dimethyl-4- acridinecarboxamide No.5-6,11,11a- tetrahydro-5-(4- hydroxy-3,5- dimethoxyphenyl)- 1H,3H- oxazolo[3',4':1,6]pyri do[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide thiazolecarboxamide 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- alpyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Discontinued Phase I	OI 921; NSC 343499;		[(methylsulfonyl)ami	inhibitor	
NSC Preclinical (5R-cis)-5,6,11,11a-tetrahydro-5-(4-hydroxy-3,5-dimethoxphenyl)-1H,3H-oxazolo[3',4" 1,6]pyrido[3,4-b]indol-3-one 2-(5-amino-4,7-dihydro-1-methyl-4,7-dioxo-1H-indol-3-yl)-4-thiazolecarboxamide 12,13-dihydro-1,11-dihydroxy-5H-indol0[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione Discontinued dione Discontinued linguage I in Phase I	SN 21407		no]phenyl]amino]-		
acridinecarboxamide NSC Preclinical (5R-cis)-5,6,11,11a- tetrahydro-5-(4- hydroxy-3,5- dimethoxyphenyl)- 1H,3H- oxazolo[3',4',1,6]pyri do[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide C Discontinued 12,13-dihydro-1,11- dihydro-1,11- dindolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Discontinued Phase I Phase I			N,5-dimethyl-4-		
NSC Preclinical (5R-cis)-5,6,11,11a- tetrahydro-5-(4- hydroxy-3,5- dimethoxyphenyl)- 1H,3H- oxazolo[3',4' 1,6]pyri do[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide C Discontinued 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Discontinued Phase I Phase I Phase I			acridinecarboxamide		
tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)- 1H,3H-oxazolo[3',4':l,6]pyri do[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7-dihydro-1-methyl-4,7-dioxo-1H-indol-3-yl)-4-thiazolecarboxamide C Discontinued 12,13-dihydro-1,11-dihydroxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione Discontinued dione Discontinued dione Discontinued dione Discontinued dione Discontinued dione Discontinued dione Discontinued dione Discontinued dione	zatoxin; NSC	Preclinical	(5R-cis)-5,6,11,11a-	DNA topoisomerase	cancer
hydroxy-3,5- dimethoxyphenyl)- 1H,3H- oxazolo[3',4"l,6]pyri do[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide L2,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued dione Discontinued Fhase I Phase I Phase I	40737		tetrahydro-5-(4-	inhibitor	
dimethoxyphenyl)- 1H,3H- oxazolo[3',4"il,6]pyri do[3,4-b]indol-3-one 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide Discontinued 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued dione Discontinued Phase I Phase I Phase I			hydroxy-3,5-		
1H,3H- oxazolo[3',4']t,6]pyri do[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide Discontinued 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued dione Discontinued Fhase I Phase I Phase I	_		dimethoxyphenyl)-		
oxazolo[3',4"],6]pyri do[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide Discontinued 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued in Phase I		,	1H,3H-		
do[3,4-b]indol-3-one Discontinued 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide thiazolecarboxamide 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued in Phase I Phase I	•		oxazolo[3',4':1,6]pyri		
Discontinued 2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide thiazolecarboxamide Discontinued 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Preclinical			do[3,4-b]indol-3-one		
dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide thiazolecarboxamide 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued dione Phase I Phase I Phase I Phase I Phase I	3E 10988	Discontinued	2-(5-amino-4,7-	DNA topoisomerase	cancer
4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide thiazolecarboxamide 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- alpyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Phase I			dihydro-1-methyl-	inhibitor	
13-yl)-4- thiazolecarboxamide Discontinued 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Phase I			4,7-dioxo-1H-indol-	-	
thiazolecarboxamide Discontinued 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Preclinical			3-yl)-4-		
C Discontinued 12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Preclinical			thiazolecarboxamide		
dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Phase I Phase I	E 13793C			DNA topoisomerase	cancer
indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Phase I			dihydroxy-5H-	inhibitor	
alpyrrolo[3,4- c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Preclinical			indolo[2,3-	-	
c]carbazole-5,7(6H)- dione Discontinued Phase I Phase I Preclinical			a]pyrrolo[3,4-		
Discontinued Phase I Phase I Preclinical			c]carbazole-5,7(6H)-	-	
Phase I Phase I Phase I Phase I		- 1			
Phase I Phase I Preclinical		Uscontinued		UNA topoisomerase	cancer
Phase I Phase I Preclinical				nhibitor	
Phase I Preclinical		Phase I		DNA topoisomerase	cancer
Phase I Preclinical				nhibitor	
Preclinical		Phase I		DNA topoisomerase	cancer
Preclinical				nhibitor	-
inhibitor		Preclinical		DNA topoisomerase	cancer
				inhibitor	

BO 2367	Discontinued	Discontinued (-)-7-[1R* 2R* 6R*)- DNA tonoisomerase	DNA tonoisomerase	cancer
		2-amino-8-	inhibitor	
-		azabicyclo[4.3.0.]-		
		non-3-en-8-yl]-1-		
		cyclopropyl-6,8-		
		difluoro-1,4-dihydro-		
		4-0xo-3-		
		quinolinecarboxylic acid		
camptothecin	Preclinical		DNA topoisomerase	cancer
analogues, Research			inhibitor	
Triangle mounting				
camptothecin derivatives, Daiichi	Discontinued		DNA topoisomerase inhibitor	cancer
CKD 602	Phase I	4-ethyl-4-hydroxy-	DNA topoisomerase	cancer
			inhibitor	
		methylethyl)amino]et		
-		hyl]-1H-		
	_	pyrano[3',4':6,7]indoli		
		zino[1,2-b]quinoline- 3.14(4H.12H)-dione		
DM II 33	Preclinical		DNA topoisomerase inhibitor	cancer
DNA topoisomerase	Preclinical		DNA topoisomerase	cancer
inhibitor, second		•••	inhibitor	
generation, Xenova;				
AK 3942 Senes; AK 5942				
DRF 1042	Preclinical		DNA topoisomerase	cancer
		• •	inhibitor	

camptothecin; camptothecin delivery system; MPI 5019 drug delivery system, Phase I liposome lurtotecan; lurtotecan liposome; NX 211	II.	inhibitor DNA topoisomerase inhibitor	
camptothecin delivery system; MPI 5019 drug delivery system, Phase I liposome lurtotecan; lurtotecan liposome; NX 211	-10	DNA topoisomerase inhibitor	
drug delivery system, Phase I liposome lurtotecan; lurtotecan liposome; NX 211	18	DNA topoisomerase inhibitor	
drug delivery system, Phase I liposome lurtotecan; lurtotecan liposome; NX 211	Ī	DNA topoisomerase inhibitor	
liposome lurtotecan; lurtotecan liposome; NX 211	a]	inhibitor	cancer
lurtotecan liposome; NX 211	31		
Amic delinen enotem Dreelinies	31	_	
und denvery system, precimical		DNA topoisomerase	cancer
microsphere 10-		inhibitor	
hydroxycamptothecin	_		
:10-			
hydroxycamptothecin		_	
microsphere			-
DX 8951; DX 8951f Phase II	(1S-trans)-1-amino-9-DNA topoisomerase	DNA topoisomerase	cancer
	ethyl-5-fluoro-	inhibitor	
	1,2,3,9,12,15-		
	hexahydro-9-		
	hydroxy-4-methyl-		
	10H,13H-		
	benzo[de]pyrano[3',4'		
	:6,7]indolizino[1,2-	-	
	b]quinoline-10,13-	<i>1</i> t	
	dione		
	monomethanesulfonat		
	O		

ED 110	Discontinued	12-beta-D-	DNA topoisomerase	cancer
			inhibitor	
		12,13-dihydro-1,11-		
		dihydroxy-5H-		
		indolo[2,3-		
		a]pyrrolo[3,4-		
		c]carbazole-5,7(6H)-		
		dione		
ER 37328	Preclinical	12,13-dihydro-5-[2-	DNA topoisomerase	cancer
		thylamino)ethyl	inhibitor	
]-4H-		
		benzo[c]pyrimido[5,6		
		,1-jk]carbazole-		
		4,6,10(5H,11H)-		• • •
		trione		
F 11782; F 1267; L	Preclinical	[SR-	DNA topoisomerase	cancer
0084		1		
		a,9beta(R*)]]-5-[3,5-	-	
		dimethoxy-4-	-	-
		(phosphonooxy)phen		
		yl]-9-[[4,6-0-		
		ethylidene-2,3-bis-O-		
-		[(pentafluorophenoxy		
		acetyl]-beta-D-		
		glucopyranosyl]oxy]-		
		5,8,829-	-	
	· ·	tetrahydrofuro[3',4':6,		
		7]naphtho[2,3-d]-1,3-		
	Ų	dioxol-6(5aH)-one		

fostriecin; NSC	Phase I	5,6-dihydro-6-	DNA topoisomerase	cancer
339638; CI 920; CL		[3,6,13-trihydroxy-3- inhibitor	inhibitor	
1565A		methyl-4-		
		(phosphonooxy)-		
		1,7,9,11-		
		tridecatetraenyl]-2H-		
		pyran-2-one		
		monosodium salt		-
HAR 7	Preclinical		DNA topoisomerase	cancer
			inhibitor	
₽ Pa	Phase I		DNA topoisomerase	cancer
60475; NSC		(dimethylamino)prop	inhibitor	
D645008		nino]-8-methyl-		
		7H-		
		benzo[e]pyrido[4,3-		
	-	b]indol-3-ol		
irinotecan; irinotecan Marketed	Marketed	(1,4'-bipiperidine)-1'- DNA topoisomerase	DNA topoisomerase	cancer
hydrochloride;		carboxylic acid (S)-	inhibitor	
camptothecin 11;		4,11-diethyl-		
CPT 11; DQ 2805;		3,4,12,14-tetrahydro-	-	
SN 3811; U 101440E;		4-hydroxy-3,14-		
CPT 11; CAMPTO;		dioxo-1H-		
TOPOTECIN;		pyrano(3',4':6,7)indoli		
CAMPTOSAR;		zino(1,2-b)quinolin-		
IRKAN		9-yl ester,		
		monohydrochloride		

lurtotecan; lurtotecan dihydrochloride; GG 211; GI 147211; GI	Suspended	(S)-8-ethyl-2,3- dihydro-8-hydroxy- 15-[(4-methyl-1-	DNA topoisomerase inhibitor	cancer
147211A; GI 147211C		piperazinyl)methyl]- 11H-1,4-dioxino[2,3- glovrano[3,4'6,7]ind		
	·	olizino[1,2-b]quinoline-		
		9,12(8H,14H)-dione		•
MPI 6003	Discontinued		DNA topoisomerase inhibitor	cancer
NB 506	Phase I	_	DNA topoisomerase	cancer
		glucopyranosyl-	inhibitor	
		2,,',12,13-lettanyaro-		
		dioxo-6H-indolo[2,3-		
		a]pyrrolo[3,4-		
		c]carbazol-6-yl)-		
		formamide		
NC 190; NCU 190	Discontinued	6-[[[2-	DNA topoisomerase	cancer
•		$\overline{}$	inhibitor	
		Jamino]carbonyl]-5-		
		hydroxy-10-		
		methoxybenzo[a]phen		
		azine-9-carboxylic		
NCA 0465	Preclinical	→-	DNA topoisomerase	cancer
		1	inhibitor	
NK 109; NK 106	Phase I		oisomerase	cancer
			inhibitor	
		[1,3]benzodioxolo[5,6]	-	
		-c]phenanthridinium,		
		suffate (1:1) (saft)		
			_	

NU/ICRF 500	Discontinued		DNA topoisomerase	cancer
NU/ICRF 506	Discontinued		DNA topoisomerase inhibitor	cancer
polyethylene glycol-	Preclinical		DNA topoisomerase	cancer
camptothecin; PEG-			inhibitor	
camptothecin;		•	-	
camptothecin		-		
macrogol;				
PROTHECAN				
rubitecan; 9-	Phase III		DNA topoisomerase	cancer
nitrocamptothecin;			inhibitor	
RFS 2000				
sobuzoxane; MST 16; Marketed	Marketed	1,2-	DNA topoisomerase	cancer
PERAZOLIN		ethanediylbis[(2,6-	inhibitor	
	-	dioxo-4,1-		
		piperazinediyl)methyl		
		ene]bis(2-		
		methylpropyl)		
		carbonic acid ester		
TAN 1496	Discontinued		oisomerase	cancer
			inhibitor	

TAN 1518A	Discontinued	Discontinued 2-hydroxybenzoic	DNA tonoisomerase	Concor
		acid 3-	inhibitor	
		(aminocarbonyl)-8-		
		[2,6-dideoxy-4-O-(2-		-
		methyl-1-oxo-2-		
		butenyl)hexopyranosy		
		<u></u>		
		1,4,4a,6,11,11a,12,12		
		a-octahydro-2,4a,5,7-		
		tetrahydroxy-11-		
		methoxy-11-methyl-		
		4,6-dioxo-1-		
		naphthacenyl ester		•
TAS 103	Phase I	6-[[2-	DNA topoisomerase	cancer
	-	(dimethylamino)ethyl inhibitor	inhibitor	
	·	Jamino]-3-hydroxy-	·	
		7H-indeno[2,1-		
		c]quinolin-7-one		
teniposide; VM 26;	Marketed		DNA topoisomerase	cancer
NSC 122819;			inhibitor	
VUMON; BEKNOS;		9beta(R*)]]-5,8,8a,9-		
VEHEM SANDOZ		tetrahydro-5-(4-		
		hydroxy-3,5-		
		dimethoxyphenyl)-9-		
		[[4,6-0-(2-		
		thienylmethylene)-		
		beta-D-	•-	
		glucopyranosyl]oxy]f		-
		uro[3',4':6,7]naphtho[
		2,3-d]-1,3-dioxol-		
		6(5aH)-one		
			J	

TOP 53	Phase I	[5R-	DNA topoisomerase	cancer
		(5alpha,5abeta,8aalph inhibitor a,9beta)]-9-[2-[72-	inhibitor	
		(dimethylamino)ethyl		
		[methylamino]ethyl]-		
		5,8,8a,9-tetrahydro-5-		
		(4-hydroxy-3,5-		
		dimethoxyphenyl)fur		
		o[3',4':6,7]naphtho[2,		
		3-d]-1,3-dioxol-		
tonoisomorphism to the		o(Jan)-one		
inhibitor, Biota	ricomical		DNA topoisomerase	cancer
topotecan:	Marketed	(2)-10-	DNIA 400000	
hycamptamine: SKF		(dimethylamino)met	piva topoisomerase	cancer
104864; SKF		hv11-4-ethv1-4 9-	ionomin.	
104864A;		dihydroxy-1H-		
HYCAMTIN		pyrano[3',4':6,7]indoli		
		zino[1,2-b]quinoline-		
		3,14(4H,12H)-dione		
WIN 63320	Discontinued		DNA topoisomerase	cancer
WIN 64593	Discontinued		DNA topoisomerase	cancer
			inhibitor	
	Phase I	N-[2-	DNA topoisomerase	cancer
601316; DACA		(dimethylamino)ethyl inhibitor	inhibitor	
]-4-		
		acridinecarboxamide		

Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-DNA topoisomerase Cos-cis/-o-acetyl-10-Cis/-o-	AD:312	Dreatings!	(1) 0 1:110		
chloroethyl)nitrosoamanthracycline; ino]carbonyl]amino]- alkylating agent; 2,3,6-trideoxy-alfa-L- antibiotic lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- maphthacenedione Discontinued 10-[[2-O-(2-amino- 2,6-dideoxy-3-O- methyl-alfa-D- galactopyranosyl]oxy beta-D- galactopyranosyl]oxy l-6-hydroxy-1- methylbenzo[h][1]ben zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione Preclinical brase I 2,2'-[1,3- propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator liH- benz[de]isoquinolone -1,3(2H)-dione	716	riccimical	(85-cls)-8-acetyl-10- [[3-[[[(2-	DNA topoisomerase inhibitor;	cancer
ino]carbony]amino]- alkylating agent; 2,3,6-trideoxy-alfa-L- antibiotic]yxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione Discontinued 10-[[2-O-(2-amino- 2,6-dideoxy-3-O- imhibitor; antibiotic methyl-alfa-D- galactopyranosyl]oxy J-6-hydroxy-1- methylbenzopyran- beta-D- galactopyranosyl]oxy J-6-hydroxy-1- methylbenzopyran- 5,12-dione Preclinical phase I 2,2'-[1,3- propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione	·		chloroethyl)nitrosoam	anthracycline;	
L,3,0-trideoxy-alfa-L- antibiotic lyxo- hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione Discontinued 10-[[2-O-(2-amino- 2,6-dideoxy-3-O- deoxy-3-C-methyl- beta-D- galactopyranosyl]oxy]-6-hydroxy-1- methylbenzohl[1]ben zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione Preclinical phase I 2,2'-[1,3- propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione -1,3(2H)-dione			ino]carbonyl]amino]-	alkylating agent;	
hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione Discontinued 10-[[2-O-(2-amino- 2,6-dideoxy-3-O- methyl-alfa-D- galactopyranosyl]-6- deoxy-3-C-methyl- beta-D- galactopyranosyl]oxy]-6-hydroxy-1- methylbenzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; antifungal 2,2'-[1,3- propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione			2,3,6-trideoxy-alfa-L-	antibiotic	
hexopyranosyl]oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione Discontinued 10-[[2-0-(2-amino- 2,6-dideoxy-3-0- methyl-alfa-D- galactopyranosyl)-6- deoxy-3-C-methyl- beta-D- galactopyranosyl]oxy]-6-hydroxy-1- methylbenzopyran- zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione			lyxo-		
7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione Discontinued 10-[[2-O-(2-amino- 2,6-dideoxy-3-O- methyl-alfa-D- galactopyranosyl]-6- deoxy-3-C-methyl- beta-D- galactopyranosyl]oxy J-6-hydroxy-1- methylbenzopyran- 5,12-dione Preclinical propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl]bis- intercalator 1,3(2H)-dione -1,3(2H)-dione			hexopyranosyi]oxy]-	·	
6,8,11-trihydroxy-1- methoxy-5,12- naphthacenedione Discontinued 10-[[2-O-(2-amino-DNA topoisomerase 2,6-dideoxy-3-O-inhibitor; antibiotic methyl-alfa-D-galactopyranosyl]-6-deoxy-3-C-methyl-beta-D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzopyran-5,12-dione DNA topoisomerase cde][1]benzopyran-5,12-dione DNA topoisomerase inhibitor; DNA topoisomerase propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl]bis-intercalator 1.3(2H)-dione 1.3(2H)-dione			7,8,9,10-tetrahydro-		
methoxy-5,12- naphthacenedione Discontinued 10-[[2-O-(2-amino-DNA topoisomerase 2,6-dideoxy-3-O-inhibitor; antibiotic methyl-alfa-D-galactopyranosyl]-6-deoxy-3-C-methyl-beta-D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzopyran-5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis-intercalator 1H. biscontinued 10-[[2-O-(2-amino-inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis-intercalator 1H. benz[de]isoquinolone -1,3(2H)-dione	•		6,8,11-trihydroxy-1-		
haphthacenedione Discontinued 10-[[2-O-(2-amino-DNA topoisomerase 2,6-dideoxy-3-O-inhibitor; antibiotic methyl-alfa-D-galactopyranosyl]-6-deoxy-3-C-methyl-beta-D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzopyran-cde][1]benzopyran-5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis-intercalator 1 H-benz[de]isoquinolone -1,3(2H)-dione			methoxy-5,12-		
Discontinued 10-[[2-O-(2-amino- DNA topoisomerase 2,6-dideoxy-3-O- inhibitor; antibiotic methyl-alfa-D- galactopyranosyl]-6-deoxy-3-C-methyl-beta-D- galactopyranosyl]oxy]-6-hydroxy-1- methylbenzopyran- sopyrano[5,4,3-cde][1]benzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione			naphthacenedione		
2,6-dideoxy-3-O- inhibitor; antibiotic methyl-alfa-D- galactopyranosyl)-6- deoxy-3-C-methyl- beta-D- galactopyranosyl]oxy J-6-hydroxy-1- methylbenzo[h][1]ben zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA topoisomerase propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione	elsamitrucin;	Discontinued	10-[[2-0-(2-amino-	DNA topoisomerase	cancer
methyl-alfa-D- galactopyranosyl)-6- deoxy-3-C-methyl- beta-D- galactopyranosyl]oxy]-6-hydroxy-1- methylbenzo[h][1]ben zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione	elsamicin A; BMY		2,6-dideoxy-3-0-	inhibitor; antibiotic	
galactopyranosyl)-6- deoxy-3-C-methyl- beta-D- galactopyranosyl]oxy]-6-hydroxy-1- methylbenzo[5,4,3- cde][1]benzopyran- 5,12-dione Preclinical Phase I 2,2'-[1,3- propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione	28090; NSC 369327;		methyl-alfa-D-	-	
deoxy-3-C-methyl- beta-D- galactopyranosyl]oxy]-6-hydroxy-1- methylbenzo[h][1]ben zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator i H- benz[de]isoquinolone -1,3(2H)-dione	BMS 181171		galactopyranosyl)-6-		
beta-D- galactopyranosyl]oxy]-6-hydroxy-1- methylbenzo[h][1]ben zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione			deoxy-3-C-methyl-		
galactopyranosyl]oxy]-6-hydroxy-1- methylbenzo[h][1]ben zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal Phase I 2,2'-[1,3- propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione			beta-D-		
-6-hydroxy-1-methylbenzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA topoisomerase propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis-intercalator 1H-benz[de]isoquinolone 1,3(2H)-dione -1,3(2H)-dione			galactopyranosyl]oxy		
methylbenzo[h][1]ben zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- benz[de]isoquinolone -1,3(2H)-dione]-6-hydroxy-1-		
zopyrano[5,4,3- cde][1]benzopyran- 5,12-dione Preclinical Phase I 2,2'-[1,3- propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- benz[de]isoquinolone -1,3(2H)-dione			methylbenzo[h][1]ben		
Preclinical DNA topoisomerase inhibitor; antifungal propanediylbis(imino-inhibitor; DNA topoisomerase propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis-intercalator 1H-benz[de]isoquinolone -1,3(2H)-dione			zopyrano[5,4,3-		
Preclinical DNA topoisomerase inhibitor; antifungal phase I 2,2'-[1,3- DNA topoisomerase propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione			cde][1]benzopyran- 5,12-dione		
Phase I 2,2'-[1,3- Phase I DNA topoisomerase propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator benz[de]isoquinolone -1,3(2H)-dione	DNA topoisomerase	Preclinical		DNA topoisomerase	cancer mycoeie.
Phase I 2,2'-[1,3- DNA topoisomerase propanediylbis(imino-inhibitor; DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione	inhibitors, AVAX			nhibitor; antifungal	parasitic infection
Phase I 2,2'-[1,3- DNA topoisomerase propanediylbis(imino-inhibitor, DNA 2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione	Technologies				
		Phase I		ONA topoisomerase	cancer
2,1-ethanediyl)]bis- intercalator 1H- benz[de]isoquinolone -1,3(2H)-dione			propanediylbis(imino-li	nhibitor; DNA	
1H- benz[de]isoquinolone -1,3(2H)-dione			2,1-ethanediyl)]bis- i	ntercalator	
benz[de]isoquinolone -1,3(2H)-dione			1H.		
-1,3(2H)-dione		_	benz[de]isoquinolone		
			-1,3(2H)-dione	-	

LU 55446	Discontinued		DNA topoisomerase	cancer
			inhibitor; DNA	
			intercalator	
dosergoside; AF 1	Discontinued	[8beta(1S,2R,3E)]-N- dopamine agonist	dopamine agonist	cancer; infertility
		(hydroxymethyl)-3-		
		heptadecenyl]-6-		
		methylergoline-8-		
drug delivery system, Pre-	Pre-		donamine agonist	disheter oberity
bromocriptine;	registration			cancer, oucaily,
bromocriptine	·			TOO!
delivery system;				
ERGOSET				
ST 557	Discontinued			cancer
			immunostimulant	
21.5/0	Discontinued		dopamine agonist;	cancer
T			immunostimulant	
Fan-Her inhibitors, SUGEN; Her2	Preclinical		EGF receptor inhibitor cancer	cancer
inhibitors, SUGEN				
LFM A12	Preclinical	(Z)-2-cyano-3-		cancer
		hydroxy-N-[4- ii	Je	
)phe	inase inhibitor	
		ny]-2-butenamide		

ABT 627. A 127722. Dhase II	· Dhace II	178	12 - 1 - 1 - 1 - 1	
A 147677	, F 11455 11	[23-	endothelin antagonist; cancer; restenosis;	cancer; restenosis;
/20/+1		(2alpha, 3beta, 4alpha)	endothelin A	myocardial
]-4-(1,3-benzodioxol- antagonist	antagonist	infarction
		(5-y1)-1-[2-) 	
		(dibutylamino)-2-		
		oxoethyl]-2-(4-		
		methoxyphenyl)-3-		
		pyrrolidinecarboxylic		
		acid		
BE 14348B	Discontinued	2(S),3(S)-3-methyl-	estrogen agonist	cancer
-		4',5,7-trihydroxy-)	
		flavanone		
GW 5638	Preclinical	(E,Z)-3-[4-(1,2-	estrogen agonist;	osteoporosis; cancer:
		diphenyl-1-	antiestrogen	coronary artery
		butenyl)phenyl]-2-		disease
		propenoic acid		
CP 336156	Phase II	(5R,6S)-5,6,7,8-	estrogen partial	osteonorosis: cancer
		ıyı-	agonist	
		5-[4-[2-(1-)	
		pyrrolidinyl)ethoxy]p		
		henyl]-2-naphthalenol	•	
		(28,38)-2,3-		
		dihydroxybutanedioat		
2-methoxvestradiol	Dreclinical	C(1.1)(Salt)		
2-ME			estrogen; angiogenesis cancer inhibitor	cancer
estrogen receptor	Preclinical		estrogen; hormone	hormone deficiency:
therapy,				contracention:
Ligand/Wyeth Ayerst	·			cancer; osteoporosis
EMATE	Discontinued	3-	estrone sulfatase	cancer
		[(aminosulfonyl)oxy]-linhibitor	nhibitor	
		estra-1,3,5(10)trien-		
		21.014		

						T
cancer		cancer		cancer	cancer	cancer
ether lipid	1. 1.	ether lipid		ether lipid	ether lipid	ether lipid
4-amino-1-[5-O-[1,3- ether lipid dihydroxy-6-[(1- oxohexyadecyl)oxy]-2,4-dioxa-8-thia-1,3-diphosphahexacos-1-yl]-beta-D-	စ္ခ	M,N,N- 3,5,9-	ntoxa-4- phosphaheptacosan-1- aminium hydroxide	=	ara-CDP-rac-1-S- e tetradecy1-2-0-	loxy)-3- butyl
Preclinical	Pre-	registration		Preclinical	Preclinical	Preclinical
ara-CDP-DL-PTBA; Preclinical CYTOROS	edelfosine: ET 18-	OCH3; ALP		9 Da	ether lipid, Roswell Park	ether lipid, Vancouver University

ilmofosine; BM	Discontinued	Discontinued 4-hydroxy-7-	other linid	
41440; BM 21440		(methoxymethyl)-	מנוליו היווס	cancel
		N,N,N-trimethyl-3,5-		
		dioxa-9-thia-4-		
		phosphapentacosan-1-		
		aminium hydroxide,		
		inner salt, 4-oxide		
miterosine;	Marketed	2	ether lipid	cancer; leishmaniasis
hexadecylphonylcholi		[[(hexadecyloxy)hydr	·	
ne; HPC; D 18506;		oxyphosphinyl]oxy]-		
MILIEX		Z,Z,Z		
		trimethylethanaminiu		
		m, hydroxide, inner		
		salt		
perifosine; D 21266;	Phase I	-4-	ether lipid	Cancer
NKA 17		[[hydroxy(octadecylo	1	
		xy)phosphinyl]oxy]-		
		1,1-	-	
		dimethylpiperidinium		
		inner salt		
SRI 34234	Discontinued		ether lipid	cancer
SRI 62834	Discontinued	(+,-)-2-	ether lipid	cancer: multiple
		[[hydroxy[[tetrahydro	•	sclerosis
		-2-		
		[(octadecyloxy)methy		
		1]-2-		
		furanyl]methoxy]phos		
		phinyl]oxy]-N,N,N-		
		trimethyl-		
		ethanamium, inner		
FI C ET 1 12. ET 1 124				
1 - C - C - C - C - C - C - C - C - C -	rnase 1	9	ether lipid	cancer

SDZ 62826	Discontinued		ether lipid;	cancer
			immunostimulant	
etoposide phosphate; Marketed	Marketed	(5R,5aR,8aR,9S)-5-	etoposide analogue	cancer
BMY 40481;		[3,5-dimethoxy-4-		
ETOPOPHOS		(phosphonooxy)phen		
		yl]-9-[(4,6-0-(1R)-		
		ethylidene-beta-D-	•	
		glucopyranosyl)oxy]-		
		5,8,8a,9-		
		tetrahydrofuro[3',4':6,		
	٠	7]naphtho[2,3-d]-1,3-		
		dioxol-6(5aH)-one		
IGT 13	Preclinical		etoposide analogue	cancer
NK 611; VP 19; 2'-	Phase II	[5R-[5alpha,5a-	etoposide analogue	cancer
tethylamino)etopo		beta,8a-		
side	-	alpha,9beta(R*)]]-9-		
		[[2-deoxy-2-		
		(dimethylamino)-4,6-		
		O-ethylidene-beta-D-		
		glucopyranosyl]oxy]-		
		5,8,8a,9-tetrahydro-5-		
		(4-hydroxy-3,5-		
	•	dimethoxyphenyl)fur		
•		o[3',4':6,7]naphtho[2,		
		3-d]-1,3-dioxol-		
		6(5aH)-one		
		hydrochloride		

GL 331	Phase II	ISB-	otonopido carolo	
		->10	croposine analogue;	cancer
		(5alpha,5abeta,8aalph DNA topoisomerase	DNA topoisomerase	
		a,9beta)]-5,8,8a,9-	finhibitor	
-	•	tetrahydro-5-(4-		
		hydroxy-3,5-		
		dimethoxyphenyl)-9-		
		[(4-		
		nitrophenyl)amino]fur		
		o[3',4':6,7]naphtho[2,		
		3-d]-1,3-dioxol-		
		6(5aH)-one		
ARGLABIN	Registered		farnesyl protein	cancer
			transferase inhibitor	
B 956	Preclinical	[2S-	farnesyl protein	cancer
		,8S*)	transferase inhibitor	
]-N-[8-amino-9-		
		mercapto-5-(1-		
		methylethyl)-1-0xo-2-		
		(phenylmethyl)-3,6-		
		nonadienyl]-L-		
famesyl transferen				
iatiicsyi ualisiciase	Discontinued			cancer
rinioltors			transferase inhibitor	
L 639749	Preclinical		farnesyl protein	cancer
			transferase inhibitor	

cancer	cancer	cancer	cancer	cancer	cancer	cancer	
farnesyl protein 1[R*(R*)],2R*(S),3 transferase inhibitor 2*]]-2-[[2-[[2-amino- nercaptopropyl)amin]-3- nethylpentyl]oxy]-1- xo-3- henylpropyl]amino]- (methylsulfonyl)- utanoic acid, 1- nethylsulfonyl)- nethylsulfonyl)- nethylsulfonyl)- nethylsulfonyl)- nethylsulfonyl)- nethylsulfonyl)- nethylsulfonyl)-	farnesyl protein	famesyl protein	farnesyl protein transferase inhibitor	farnesyl protein transferase inhibitor	farnesyl protein transferase inhibitor	farnesyl protein transferase inhibitor	יייייייייייייייייייייייייייייייייייייי
[2S- [1[R*(R*)],2R*(S),3 R*]]-2-[[2-[[2-amino-3- mercaptopropyl)amin o]-3- methylpentyl]oxy]-1- oxo-3- phenylpropyl]amino]- 4-(methylsulfonyl)- butanoic acid, 1-			4-(1-methylethenyl)- f 1-cyclohexene-1- methanol		# ##	fa fa	
Preclinical	Phase I	Preclinical	Phase II	Preclinical	Preclinical	Preclinical	1
L 744832	L 778123	PD 169451	perillyl alcohol; NSC Phase II 641066	ras famesyl protein transferase inhibitors, Parke Davis	ras farnesyl protein transferase inhibitors, University of Pittsburgh	35	

SCH 50228	Droglinion	1 (2 12.00 0 21.12		
0776	riccillical	1-(3-oromo-s-cnioro- iramesyi protein	ramesyi protein	cancer
		6,11-dihydro-5H-	transferase inhibitor	
		benzo[5,6]cyclohepta[
		1,2-b]pyridin-11-yl)-		
		4-[(1-oxido-4-		
		pyridinyl)acetyl]piper		
L 731734	Discontinued	73C_	formount mention	
	2000	[3D*[3D*[3D*/C*) 2	tancsyl protein	calicel
		[]	nantido	
		-7)]-7]]-7-[[[\10'[\2	pepude	
		amino-3-		
		mercaptopropyl)amin		
		0]-3-		
		methylpentyl]amino]-		
		3-methyl-N-		
	•	(tetrahydro-2-oxo-3-	-	
		furanyl)pentanamide		
L 731735	Discontinued	[2S-[2R*(S*),3S*]]- famesyl protein	famesyl protein	cancer
		-C-011111112-7)]-7]-11]-11	nausiciase illilloitoi,	
		mercaptopropyl)amin peptide	peptide	
		o]-3-methylpentyl]-L-		
		isoleucyl]-L-	v • ₹° min	
R 115777	Phase II		farnesvi protein	cancer
			transferase inhibitor:	
			signal transduction	
		•••	inhibitor	
SCH 66336	Phase II	,	farnesyl protein	cancer
			transferase inhibitor;	
			signal transduction	
			nnibitor	

TOP 53	Phase I	[5R-	DNA topoisomerase	cancer
		(Salpha, Sabeta, 8aalph inhibitor	inhibitor	
		a,>ucta)]->-[4-1[4- (dimethylamino)ethyl		,
]methylamino]ethyl]-		
		5,8,8a,9-tetrahydro-5-		
		(4-hydroxy-3,5-		
•	·	dimethoxyphenyl)fur		
		3-d]-1,3-dioxol-		
		6(5aH)-one		
topoisomerase	Preclinical		DNA topoisomerase	cancer
inhibitor, Biota			inhibitor	
topotecan;	Marketed	(S)-10-	DNA topoisomerase	cancer
hycamptamine; SKF		[(dimethylamino)met	inhibitor	
104864; SKF		hyl]-4-ethyl-4,9-		
104864A;		dihydroxy-1H-		
HYCAMTIN		pyrano[3',4':6,7]indoli		
		zino[1,2-b]quinoline- 3,14(4H,12H)-dione		
WIN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
WIN 64593	Discontinued		DNA topoisomerase	cancer
			inhibitor	
	Phase I	N-[2-	DNA topoisomerase	cancer
601316; DACA		(dimethylamino)ethyl inhibitor	inhibitor	
]-4-		
		acridinecarboxamide		

BIM 26028	Discontinued	÷	gastrin antagonist; bombesin antagonist	cancer; cachexia;
CDP 845	Discontinued		gelatinase inhibitor;	cancer
			matrix	
			metalloproteinase	
			inhibitor; proteinase	
			inhibitor; angiogenesis	
CT 1746	Discontinued		manoucoinhibitori	
	nontininostr		getatitiase innibitor;	cancer
			metalloproteinase	
			inhibitor; proteinase	
			inhibitor	
gelatinase inhibitors,	Preclinical		gelatinase inhibitor;	cancer
Celitech			matrix	
			metalloproteinase	
			inhibitor; proteinase	
			inhibitor	
basal cell carcinoma	Preclinical		gene	cancer; skin disease
therapy, Ontogeny;				`
patched gene; ptc				
gene				
ocl-6-based non-	Preclinical		gene	cancer
Hodgkin's lymphoma)	
cancer therapy cancer Preclinical	Preclinical			
cell growth genes			Selle	cancer
CDK4 based therapy, Preclinical	Preclinical		gene	Cancer
Axys; melanoma		-		
herapy, Axys	-			
HFE-based therapies, Preclinical Progenitor	Preclinical		gene	iron overload; cancer
	7			

immune system	Preclinical		gene	autoimmune disease;
modulators, Chiroscience		<u>.</u>		rheumatoid arthritis; cancer; HIV infection
melanoma differentiation- associated genes	Discontinued		gene	cancer
MMAC1 based therapy, Myriad	Preclinical		gene	cancer
MTS2 based therapy, Myriad	Preclinical		gene	cancer
MTS3 based therapy, Preclinical Myriad; cancer therapy, Myriad	Preclinical		gene	cancer
mum-1-based cancer therapy	Preclinical		gene	cancer
P-TEN-based cancer therapy, Amplicon	Preclinical		gene	cancer
prostate tumor- inducing genes	Discontinued		gene	cancer; diagnosis
gene therapy, ATase	Preclinical		gene therapy; biotechnology	cancer
gene therapy, C-CAM, Introgen; adenoviral C-CAM, Introgen: INGN 231	Preclinical		gene therapy; biotechnology	cancer
L .	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer; SMART GENETIC CONSTRUCTS	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer

gene therapy cancer	Drootinian			
gone are apy, cancer			gene therapy;	cancer
41.			olotecnnology	
gene merapy, cancer,	Preclinical		gene therapy;	cancer
Cobra Therapeutics;			biotechnology	
CTL 102; TXS 0202			(9)	
gene therapy, cancer,	Preclinical		gene therapy:	Cancer, rechiratory
pulmonary disease			hiotechnology	disease
gene therapy,	Preclinical		gene theream	discase
hepatocellular			Bene merapy, biotochaele	cancer
carcinoma; HepXia			ororectimology	
gene therapy, ovarian Preclinical	Preclinical		gene therany:	cancer
and pancreatic cancer			biotechnology	Tooling
gene therapy, ovarian Preclinical	Preclinical		gene therany:	cancer
cancer; gene therapy,			biotechnology	iooi no
brca1, MB 700			(9)	
gene therapy, p16,	Preclinical		gene therany:	rectenosis: cancer
p27; gene therapy,			biotechnology	coronosis, cancon
restenosis; gene			6	
therapy, cancer		-		
	Phase I	3	gene therapy:	cancer
gene therapy, cancer			biotechnology	
gene therapy,	Preclinical		gene therapy:	cancer
scFV/gamma G250;		يد	biotechnology	
gene therapy, renal			6	
carcinoma				
gene therapy, stress	Preclinical	01)	gene therapy;	cancer
		٩	biotechnology	
	Phase I	01)	gene therapy;	cancer
thymidine kinase;		<u>.</u>	biotechnology	
gene therapy, cancer;			3	
gene therapy, HS-tk				

gene therapy,	Preclinical		gene therapy;	cancer
thymidine kinase;			oiotechnology	
gene therapy, glioma			3	
gene therapy, tumor	Preclinical		gene therapy;	cancer
antigens; gene			biotechnology	
therapy, cancer			3.	
gene therapy, ATF	Preclinical	Gil	gene therapy;	cancer
BTPI; gene			biotechnology;	-
1			angiogenesis inhibitor	
	Preclinical	- Cary	gene therapy;	cancer
colorectal cancer,			biotechnology:	
Oxford BioMedica;			angiogenesis inhihitor	
CoRectoGen				
la,	Preclinical	Q	gene therapy:	cancer
Oxford Biomedica;		<u>, e</u>	biotechnology:	
GlioStat	-		angiogenesis inhibitor	
gene therapy, ovarian Preclinical	Preclinical	8	gene therapy;	cancer
cancer, Oxtord		<u>Q</u>	iotechnology;	
BioMedica; BetOvaC			angiogenesis inhibitor	
gene therapy, prostate Preclinical	Preclinical	9	gene therapy:	cancer
cancer; ProCaStat		<u> </u>	biotechnology;	
		a	angiogenesis inhibitor	
	Phase I	50	gene therapy;	cancer
interleukin-2,			biotechnology;	
Transgene; gene		_6.	cytokine;	
therapy, cancer			immunostimulant	
gene therapy, wt p53; Preclinical	Preclinical	80		cancer
gene therapy, cancer		<u> </u>		
-		13	radiosensitizer;	
		to.	chemosensitizer	

vaccine, gene-based,	Phase I		gene therapy;	cancer
colorectal cancer;		· · · · · · · · · · · · · · · · · · ·	biotechnology; vaccine	4)
CO17-A/GA733; AV		:		
GA 7332				
vaccine, gene-based,	Preclinical		gene therapy;	cancer
numan papilioma virus	- -		biotechnology; vaccine	
progression elevated genes	Discontinued		gene; angiogenesis	cancer
glutathione inhibitors, Discontinued Telik	Discontinued,		glutathione inhibitor	cancer
AG 2026	Discontinued		glycinamide ribotide	cancer
			formyltransferase inhibitor	
AG 2032	Discontinued		glycinamide ribotide	cancer
			formyltransferase inhibitor	
AG 2034	Phase I	(S)-N-[[5-[2-(2-	glycinamide ribotide	cancer
		amino-4,6,7,8-	formyltransferase	
		tetrahydro-4-oxo-1H- inhibitor	inhibitor	
		pyrimido[5,4- h][1_4]thiazin_6		•
		yl)ethyl]-2-		
		thienyl]carbonyl]-L-		•
AG 2037	Preclinical		glycinamide ribotide	cancer
			formyltransferase	
П			inhibitor	•
contortrostatin; CN	Preclinical		ein IIb/IIIa	cancer; thrombosis
2,			antagonist; platelet	
			antiaggregant; biotechnology	
			79	

mannostatin A	Preclinical	[1R-	glycosidase inhibitor	cancer
		(1alpha,2alpha,3alpha		
		,4aipiia,30eia)]-4- amino-5-		
		(methylthio)-1,2,3-		
glycosidase inhibitor, Preclinical	Preclinical		glycosidase inhibitor. cancer: rhenmatoid	cancer rhenmatoid
Oxford			NSAID	arthritis
GlycoSciences				en min
	Preclinical		gonadorelin agonist	cancer
ATRIGEL sustained		•		
release leuprorelin;	•			
leuprorelin ATRIGEL			-	
drug delivery system,	Phase III		gonadorelin agonist	cancer.
microparticle	_			endometriosis
buserelin; buserelin		•		
microparticle delivery				
system				
drug delivery system,	Clinicals		gonadorelin agonist	cancer
sustained release				
LHRH analogue;				
LHRH analogue				
delivery system;		,		
ProMaxx, LHRH				
analogue; ProMaxx				
100				

goserelin; goserelin	Marketed	6-FO-(1.1-	gonadorelin agonist	Concor.
acetate; ICI 118630;		dimethylethyl)-D-	100000000000000000000000000000000000000	endometriosis:
ZOLADEX		serine]-1-9-		infertility
		luteinizing hormone-		•
		releasing factor		
		(swine) 2-		
		(aminocarbonyl)hydra		
		zide		
leuprorelin;	Marketed	6-D-leucine-9-(N-	gonadorelin agonist	cancer;
leuprorelin acetate;		ethyl-L-prolinamide)-	1	endometriosis
leuprolide; TAP 144;		10-deglycinamide		
TAP 144SR;		luteinizing hormone-	-	
ABBOTT 43818;		releasing factor	***	
LUPRON; CARCIN;		(swine)		
LEUPLIN; LUPRON				
DEPOT; PROSTAP				
ST; PROSTAP SR;	-			
ENANTONE		- •	. <u>.</u>	
nafarelin; nafarelin	Marketed	6-[3-(2-	gonadorelin agonist	cancer:
acetate; D-NaI(2)6		naphthalenyl)-D-		endometriosis:
LHRH; RS 94991;		alanine]-luteinizing		infertility
RS 94991 298;		hormone-releasing		f
SAMYNAREL;		factor (swine)		
SYNAREL;				
NASANYL			-	
RL 0903	Phase II		gonadorelin agonist	cancer
triptorelin; BN	Marketed		gonadorelin agonist	cancer; precocious
52014; BIM 21003;		luteinizing hormone-		puberty;
AY 25650; CL	_	releasing factor		endometriosis
118532; WY 42462;		(swine)		
AKVECAP;				
DECAPEP I YL				

estrogen; progestogen gonadorelin agonist; yptophyl- rosyl-2- yptophyl- ruginyl-N- inamide gonadorelin agonist; peptide gonadorelin agonist; peptide gonadorelin antagonist 2- gonadorelin antagonist -3-(3alanyl- ethyl-LL-N6-(1L-Nsyl-	leuprolide + estrogen Phase I	Phase I		gonadorelin agonist;	contraception; cancer
delivery system, Phase I ant, histrelin ogel implant Bit; PPI 149; R Phase II Nacetyl-JNoro-D. alaniyl-DNoro-D. aparaginyl-L. gonadorelin agonist; gonadorelin agonist; peptide L-seryl-Norosyl-D. alaniyl-D- alaniyl-D- alaniyl-L-yroinamide gonadorelin agonist; peptide gonadorelin agonist; peptide gonadorelin antagonist peptide gonadorelin antagonist peptide gonadorelin antagonist peptide gonadorelin antagonist peptide gonadorelin antagonist peptide gonadorelin antagonist peptide gonadorelin antagonist peptide pridinyl)-D- alaniyl-L-N6-(1- phenylalanyl-L-N6-(1- phenylethyl)-L-lysyl- L-prolyl-D- alaninamide	+ progesterone			estrogen; progestogen	
sting hormone Subset, conjugated; H analogue Hymer conjugate Elin El	gonadotropin	Preclinical		gonadorelin agonist;	cancer
ogue, conjugated; H analogue elin Phase II 5-oxo-L-prolyl-L- inistidyl-L-tryptophyl- peptide L-seryl-L-tryptophyl- L-leucyl-L-arginyl-N- ethyl-L-prolinamide ant; histrelin ogel implant B61 Phase I S61 Phase I N-acetyl-3-(2- alanyl-4-chloro-D- phenylalanyl-3-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	releasing hormone			gonadorelin antagonist	
H analogue lymer conjugate Phase II 5-oxo-L-prolyl-L- ponadorelin agonist; histidyl-L-tryptophyl- L-seryl-L-tryptophyl- methyl-D-tryptophyl- logel implant Bé1 Phase I Phase I Phase I Rethyl-L-prolinamide ethyl-L-prolinamide gonadorelin agonist; peptide peptide L-seryl-L-prolinamide gonadorelin antagonist gonadorelin antagonist phenylalanyl-D- alanyl-4-chloro-D- phenylalanyl-1- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	analogue, conjugated;) 	
elin Phase II 5-oxo-L-prolyl-L- gonadorelin agonist; histidyl-L-tryptophyl-peptide L-seryl-L-tryptophyl- methyl-D-tryptophyl- E-seryl-L-prolinamide gonadorelin agonist; pelin hydrogel ant; histrelin ant; histrelin ant; per 149; R Phase I gonadorelin antagonist naphthalenyl)-D- alanyl-L-chloro-D-phenylalanyl-C-phenylalanyl-L-lysyl-L-tyrosyl-D-asparaginyl-L-lysyl-L-tysyl-L-tysyl-D-alaninamide	GnRH analogue				
elin Phase II 5-oxo-L-prolyl-L- instidyl-L-tryptophyl- E-seryl-L-tryptophyl- E-leucyl-L-arginyl-N- ethyl-L-prolinamide delivery system, Phase I ethyl-L-prolinamide ant; histrelin ogel implant 861 Bhase II N-acetyl-3-(2- alanyl-A-chloro-D- phenylalanyl-1- E-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	copolymer conjugate				
histidyl-L-tryptophyl-peptide L-seryl-L-tyrosyl-2- methyl-D-tryptophyl- L-leucyl-L-arginyl-N- ethyl-L-prolinamide gonadorelin agonist; elin hydrogel ant; histrelin ogel implant 861 Rhase I N-acetyl-3-(2- gonadorelin antagonist naphthalenyl)-D- alanyl-4-chloro-D- phenylalanyl-2- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-Nsyl- L-prolyl-D- alaninamide	avorelin	Phase II	5-oxo-L-prolyl-L-	gonadorelin agonist;	cancer; precocious
L-seryl-L-tyrosyl-2- methyl-D-tryptophyl- L-leucyl-L-arginyl-N- ethyl-L-prolinamide ant; histrelin ogel implant 861 Phase I N-acetyl-3-(2- alanyl-4-chloro-D- phenylalanyl-3-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			histidyl-L-tryptophyl-	peptide	puberty;
methyl-D-tryptophyl- L-leucyl-L-arginyl-N- ethyl-L-prolinamide gonadorelin agonist; elin hydrogel ant; histrelin ogel implant 861 Phase I slix; PPI 149; R Phase II N-acetyl-3-(2- alanyl-4-chloro-D- phenylalanyl-2-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			L-seryl-L-tyrosyl-2-		endometriosis
L-leucyl-L-arginyl-N- ethyl-L-prolinamide delivery system, Phase I elin hydrogel ant; histrelin ogel implant 861 Phase I N-acetyl-3-(2- alanyl-4-chloro-D- phenylalanyl-1- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			methyl-D-tryptophyl-		
delivery system, Phase I elin hydrogel ant; histrelin ogel implant 861 Phase I Sonadorelin antagonist naphthalenyl)-D- alanyl-4-chloro-D- phenylalanyl-3-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	;		L-leucyl-L-arginyl-N-		
elin hydrogel ant; histrelin ogel implant 861	J		emyi-L-prolinamide		
ant; histrelin ogel implant 861 Rhase I lix; PPI 149; R Phase III naphthalenyl)-D- alanyl-4-chloro-D- phenylalanyl-3-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	arug delivery system,			gonadorelin agonist;	precocious puberty;
ant; histrelin 9gel implant 861 Phase I In Acctyl-3-(2- alanyl-4-chloro-D- phenylalanyl-3-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	nistrelin hydrogei			peptide	cancer
861 Phase I slix; PPI 149; R Phase III N-acetyl-3-(2- naphthalenyl)-D- alanyl-4-chloro-D- phenylalanyl-3-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	implant; histrelin				
esting phase I lix; PPI 149; R Phase III N-acetyl-3-(2- naphthalenyl)-D- alanyl-4-chloro-D- phenylalanyl-3-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	hydrogel implant				
slix; PPI 149; R Phase III N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	A 84861	Phase I		gonadorelin antagonist	cancer
naphthalenyl)-D- alanyl-4-chloro-D- phenylalanyl-3-(3- pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	abarelix; PPI 149; R	Phase III	N-acetyl-3-(2-	gonadorelin antagonist	cancer; benign
oro-D1-3-(3alanylethyl-LL-N6-(1L-Iysyl-	3827		naphthalenyl)-D-		prostate
1-3-(3- -alanyl- nethyl-L- -L-N6-(1-)-L-lysyl-			alanyl-4-chloro-D-	. 2	hypertrophy;
pyridinyl)-D-alanyl- L-seryl-N-methyl-L- tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			phenylalanyl-3-(3-		endometriosis
L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide			pyridinyl)-D-alanyl-		
tyrosyl-D- asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			L-seryl-N-methyl-L-		
asparaginyl-L-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			tyrosyl-D-		
methylethyl)-L-lysyl- L-prolyl-D- alaninamide			asparaginyl-L-N6-(1-		
L-prolyl-D- alaninamide			methylethyl)-L-lysyl-		
alaninamide			L-prolyl-D-		***************************************
A. A. OUR UND THE CO. L. C. C. C. C. C. C. C. C. C. C. C. C. C.			alaninamide		

cetrorelix: SB 75: SB Registered	Registered	N-Acetv1-3-(7-	consdorelin antagonist infamilite:	in Contiliture Concount
075. CETROTINE)	Lone 1-1-1-1	Bornes on annagonist	michinity, cancer,
10/2, CELINO 11DE		naphrhalenyi)-U-		endometriosis;
		alanyl-4-chloro-D-		benign prostate
		phenylalanyl-3-(3-		hypertrophy:
		pyridinyl)-D-alanyl-	_	confracention
		L-seryl-L-tyrosyl-N5-	-	Total donnarios
		(aminocarbonyl)-D-	-	
	<u> </u>	omithyl-L-leucyl-L-		
	-	arginyl-L-prolyl-D-		
		alaninamide		
D 20453	Discontinued		gonadorelin antagonist cancer	Cancer
D 21775; T 148	Discontinued	N-acetyl-3-(2-	gonadorelin antagonist cancer	cancer
		٥	,	
		alanyl-4-chloro-D-		•
		phenylalanyl-3-(3-		
		pyridinyl)-D-alanyl-	-	
		L-seryl-L-tyrosyl-N6-		
		[N-acetyl-3-		
		(acetylamino)-L-		
		alanyl]-D-lysyl-L-		
		leucyl-L-arginyl-L-		_
		prolyl-D-alaninamide		
D 23487	Discontinued	Unspecified	gonadorelin antagonist cancer	ancer
D 26344	Preclinical	3	gonadorelin antagonist cancer: infartility	ancer infertility
		8	Jarry Comments	outcot, tittottitly

detirelix; RS 68439	Discontinued	Discontinued N-acetyl-3-(2-	gonadorelin antagonist contracention: cancer	contracention. cancer
		4		
		Phenylalanyl-D-		
		tryptophyl-L-seryl-L-		
		tyrosyl-N6-		
		[bis(ethylamino)meth		
		ylene]-D-lysyl-L-		
		leucyl-L-arginyl-L-		
drug delivery system,	Discontinued		gonadorelin antagonist cancer	cancer.
ATRIGEL sustained				endometriosis
release ganirelix;				ereor normania
ganirelix ATRIGEL				
drug delivery system,	Discontinued		gonadorelin antagonist endometriosis:	endometriosis:
ATRIGEL sustained))	cancer
release GnRH		-		
antagonists				
drug delivery system,	Preclinical	3,	gonadorelin antagonist cancer: contracention	cancer: contracention
microcapsule SB 75;			•	
SB 75 microcapsule				
gonadotropin	Preclinical		gonadorelin antagonist contracention: cancer	contracention: cancer
releasing hormone		.		
antagonists, Alanex				
gonadotropin-	Preclinical	. :	gonadorelin antagonist cancer	ancer
releasing hormone)	
antagonist, Agouron;				
GnRH antagonist,				
Agouron				
HOE 2013	Suspended	CAU .	gonadorelin antagonist cancer;	ancer;
			<u> </u>	endometriosis

A 76154 Preclinical N-[3-(4-choro.D- phenylalanyl-D-tr pytophyl-L-seryl-L- phenylalanyl-D- phenylalanyl-D- phenylalanyl-D- precoriou. arginyl-L-proline, 2- (aminocarbonyl)hydra zide A 76154 Preclinical N-[3-(4- fluorophenyl)-1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6-(1- methylethyl)-L-lysyl- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide	ramorelix; HOE 013 Phase II	Phase II	N-acetyl-3-(2-	gonadorelin antagonist cancer	cancer
alanyl-4-chloro-D- phenylalanyl-D-tr yptophyl-L-seryl-L- tyrosyl-O-(6-deoxy- alpha-L- mannopyranosyl)-D- seryl-L-leucyl-L- arginyl-L-proline, 2- (aminocarbonyl)hydra zide Preclinical N-[3-(4- fluorophenyl)-1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide)	
phenylalanyl-D-tr yptophyl-L-seryl-L- tyrosyl-O-(6-deoxy- alpha-L- mannopyranosyl)-D- seryl-L-leucyl-L- arginyl-L-proline, 2- (aminocarbonyl)hydra zide Preclinical N-[3-(4- nophenyl)-1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			alanyi-4-chioro-D-		
yptophyl-L-seryl-L- tyrosyl-O-(6-deoxy- alpha-L- mannopyranosyl)-D- seryl-L-leucyl-L- arginyl-L-proline, 2- (aminocarbonyl)hydra zide Preclinical N-[3-(4- fluorophenyl)-1- oxopropyl]-3-(1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			phenylalanyl-D-tr		
tyrosyl-O-(6-deoxy- alpha-L- mannopyranosyl)-D- seryl-L-leucyl-L- arginyl-L-proline, 2- (aminocarbonyl)hydra zide Zide N-[3-(4- fluorophenyl)-1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			yptophyl-L-seryl-L-		
alpha-L- mannopyranosyl)-D- seryl-L-leucyl-L- arginyl-L-proline, 2- (aminocarbonyl)hydra zide Preclinical N-[3-(4- fluorophenyl)-1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			tyrosyl-O-(6-deoxy-		
mannopyranosyl)-D- seryl-L-leucyl-L- arginyl-L-proline, 2- (aminocarbonyl)hydra zide Preclinical N-[3-(4- fluorophenyl)-1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			alpha-L-		
seryl-L-leucyl-L- arginyl-L-proline, 2- (aminocarbonyl)hydra zide Preclinical N-[3-(4- fluorophenyl)-1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			mannopyranosyl)-D-		
arginyl-L-proline, 2- (aminocarbonyl)hydra zide Preclinical N-[3-(4- gonadorelin fluorophenyl)-1- antagonist; peptide oxopropyl]-3-(1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			seryl-L-leucyl-L-		
(aminocarbonyl)hydra zide Preclinical N-[3-(4- gonadorelin fluorophenyl)-1- antagonist; peptide oxopropyl]-3-(1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			arginyl-L-proline, 2-		
Preclinical N-[3-(4- gonadorelin fluorophenyl)-1- antagonist; peptide oxopropyl]-3-(1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			(aminocarbonyl)hydra		•
Preclinical N-[3-(4- gonadorelin fluorophenyl)-1- antagonist; peptide oxopropyl]-3-(1- naphthalenyl)-D- alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			zide		
ntagonist; peptide	A 76154	Preclinical		gonadorelin	cancer;
· ·			fluorophenyl)-1-	antagonist; peptide	endometriosis;
·		-	oxopropyl]-3-(1-		precocious puberty
alanyl-L-seryl-N- methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			naphthalenyi)-D-		
methyl-L-tyrosyl-N6- (3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			alanyl-L-seryl-N-		
(3- pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			methyl-L-tyrosyl-N6-		
pyridinylcarbonyl)-D- lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			(3-		
lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl- L-prolyl-D- alaninamide			pyridinylcarbonyl)-D-		
methylethyl)-L-lysyl- L-prolyl-D- alaninamide			lysyl-L-leucyl-N6-(1-		
L-prolyl-D- alaninamide			methylethyl)-L-lysyl-		
alaninamide			L-prolyl-D-		
			alaninamide		

teverelix;	Phase I	N-acetyl-3-(2-	gonadorelin	cancer.
ANTARELIX		naphthalenyl)-D-	antagonist; peptide	endométriosis;
		phenylalanyl-3-(3-		infertility
		pyridinyl)-D-alanyl-		
		L-seryl-L-tyrosyl-N6-		
		(aminocarbonyl)-D-		
		lysyl-L-leucyl-N6-(1-		
		methylethyl)-L-lysyl-		
-		L-prolyl-D- alaninamide		
deslorelin; BACHEM Marketed	1 Marketed	5-oxo-L-prolyl-L-	gonadorelin	cancer; precocious
9022; SOMAGARD		histidyl-L-tryptophyl-superagonist	superagonist	puberty
		L-seryl-L-tyrosyl-D-		
		tryptophyl-L-leucyl-		
		L-arginyl-N-ethyl-L-		·
drup delivery eyetem	Dreclinical	prominaminge	1	
declaratin implant:		~	gonadorelin	cancer;
deslorelin implant			superagonist	gynecological;
hometel a				intertility
nematology	Discontinued		growth factor	cancer
cytokines, AIMIKAD;				-
hematology cytokines Chugai				
hematonoietic grounth Dreelinies	Drootinion			
factor mimetics			growth tactor	cancer; bacterial
Ligand				infection; anemia
GM 1306	Preclinical	3	growth factor	diabetes:
		E		retinopathy; cancer
GM 1474	Preclinical	Unspecified	tor	cancer
		E .	modulator	
keratinocyte growth factor antagonist	Preclinical	<u>au</u> E	growth factor modulator; nentide	cancer
			anudad (vamman	

henstockte growth	Drootinioo1		0 ,	
forter related	r recimical		growth factor;	cancer
lactor related			biotechnology;	
proteins; HGF-related			chemoprotectant:	
proteins			cytoprotectant	
CMI SAF9	Preclinical		growth factor:	Concer
			hematopoietic factor	Carroo
thrombopoietin; TPO Phase II	Phase II		growth factor;	cancer;
-		· · · · · · · · · · · · · · · · · · ·	hematopoietic factor;	thrombocytopenia
			biotechnology	
Tie-2 ligands,	Preclinical		growth factor;	cancer; restenosis;
Regeneron;			hematopoietic factor;	retinopathy; skin
angiogenesis ligands,			cicatrizant;	ulcer;
Kegeneron			angiogenesis inhibitor; atherosclerosis;	atherosclerosis;
			angiogenesis inducer	peripheral vascular
				disease
SB 251353	Preclinical		growth factor;	cancer
			hematopoietic factor;	
			immunostimulant	
goralatide;	Phase II	1-[N2-[N-(N-acetyl-	hematoprotectant:	cancer
seraspenide; BN		L-seryl)-L-alpha-	chemoprotectant;	
52040; BIM 32001		aspartyl]-L-lysyl]-L-	peptide	
		proline		
pentosan polysulfate	Marketed	u u	heparinoid;	arthritis; angina;
sodium; SP 54; PZ		2,3-bis(hydrogen	vasodilator; NSAID	hyperlipidemia;
OS, CARI ROFHEN;		sulfate), sodium salt		rheumatoid arthritis;
ELMIRON:				cancer; cystitis
LELONG MOUSSE				
MAXAMINE	Phase III		histamine agonist;	cancer; viral
			ist	infection; hepatitis

inhibitor HMG CoA reductase inhibitor hormone hormone hormone hormone hormone	MAP 30	Preclinical	N2-[N-[N-IN-IN2-	HIV integrase	HIV infection:
isoleucyl)-L-lysyl]-L- threonyl]-L-threonyl]- L-threonyl]-L-tysine (S)-2-methylbutyric HMG CoA reductase acid, 8-ester with inhibitor (4R,6R)-6-[2- [(1S,2S,6R,8S,8aR)- 1,2,6,7,8,8a- hexahydro-8- hydroxy-2,6- dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one hormone hormone hormone hormone hormone				inhibitor	cancer
threonyl]-L-threonyl]- L-threonyl]-L-lysine (S)-2-methylbutyric HMG CoA reductase acid, 8-ester with inhibitor (4R,6R)-6-[2- [(1S,2S,6R,8S,8aR)- 1,2,6,7,8,8a- hexahydro-8- hydroxy-2,6- dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one hormone hormone hormone hormone hormone			isoleucyl)-L-lysyl]-L-		
L-threonyl]-L-lysine (S)-2-methylbutyric HMG CoA reductase acid, 8-ester with inhibitor (4R,6R)-6-[2- [(1S,2S,6R,8S,8aR)- 1,2,6,7,8,8a- hexahydro-8- hydroxy-2,6- dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one hormone			threonyl]-L-threonyl]-		
(S)-2-methylbutyric HMG CoA reductase acid, 8-ester with inhibitor (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]tetrahy dro-4-hydroxy-2H-pyran-2-one hormone			L-threonyl]-L-lysine		
acid, 8-ester with inhibitor (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydroxy-2H-pyran-2-onehormo	lovastatin; mevinolin;	Marketed	ric	HMG CoA reductase	hyperlipidemia;
(4R,6R)-6-[2- [(1S,2S,6R,8S,8aR)- 1,2,6,7,8,8a- hexahydro-8- hydroxy-2,6- dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one hormone	monakolin K; MK			inhibitor	cancer
[(1S,2S,6R,8S,8aR)- 1,2,6,7,8,8a- hexahydro-8- hydroxy-2,6- dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one hormone hormone hormone hormone	803; MSD 803; MB		(4R,6R)-6-[2-		
1,2,6,7,8,8a- hexahydro-8- hydroxy-2,6- dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one hormone hormone hormone hormone	530B; L 154803;		[(1S,2S,6R,8S,8aR)-		
hexahydro-8- hydroxy-2,6- dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one hormone hormone hormone hormone	MEVACOR;		1,2,6,7,8,8a-		
hydroxy-2,6- dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one l hormone l hormone l hormone hormone	MEVLOR;		hexahydro-8-		
dimethyl-1- naphthyl]ethyl]tetrahy dro-4-hydroxy-2H- pyran-2-one hormone hormone hormone hormone hormone	LOVACOL;		hydroxy-2,6-		
naphthyl]etrahy dro-4-hydroxy-2H- pyran-2-one hormone hormone hormone hormone hormone	HIPOVASTIN;		dimethyl-1-		
dro-4-hydroxy-2H- pyran-2-one hormone hormone hormone hormone hormone	DISLIPIN;		naphthyllethylltetrahy		
pyran-2-one hormone hormone hormone hormone hormone	LOVASTEROL;		dro-4-hvdroxv-7H-		
hormone hormone hormone hormone hormone	LINCIL		pyran-2-one		
hormone hormone hormone		Preclinical			cancer
hormone		Preclinical			Osteonorosis. Daget
I hormone hormone	PEPTITROL				disease. cancer
l hormone hormone	calcitonin; calcitonin				discase, caricei
hormone	PEPTITROL				
hormone	drug delivery system, F	Preclinical			nrecocions amberty.
hormone	subcutaneous		<u> </u>		precedents publicly,
hormone	gonadotropin				Cancer: contracention
	releasing hormone;				wiver, contraception
	gonadotropin				
	releasing hormone				
	subcutaneous				
	implant; GnRH				
	subcutaneous implant				
superagonists, NIH	glycoprotein hormone P	reclinical	Щ		nfertility; cancer
	superagonists, NIH		-		

numan cnomonic gonadotropin beta; beta hCG	Precimical		hormone	cancer
NV 06	Preclinical		hormone; apoptosis inhibitor; antiproliferative agent;	cancer
gallium nitrate; NSC 15200; CALSTAT; GANITE	Marketed	gallium nitrate nonahydrate	hypocalcemic; nitric oxide synthase inhibitor	hypercalcemia; cancer
AS 101; IVXQ 101; OSSIRENE	Phase II	(SP-5-22)-ammonium immunostimulant trichloro(1,2-ethanediolato(2-)-0,0")-teilurate	immunostimulant	HIV infection; cancer
BCH 1393	Suspended	N2-[[[5-[6- (dimethylamino)-9H- purin-9- yl]pentyl]oxy]carbon	immunostimulant	cancer
beta-alethine; BETATHINE	Phase II	3-amino-N-(2- mercaptoethyl)- propanamide	immunostimulant	cancer
bropirimine; ABPP; U 54461; U 54461S; NSC 149027; REMISAR	Pre- registration	2-amino-5-bromo-6- phenyl-4(1H)- pyrimidinone	immunostimulant i	cancer; viral infection
CL 246738	Phase II	3,6-bis(2- piperidinoethoxy)acri dine trihydrochloride	inmunostimulant h	viral infection; HIV infection; cancer
CL 870420	Discontinued	+	mmunostimulant	cancer
conagenin	Preclinical	N-(3,5-dideoxy-3- methyl-D-xylonoyl)- 2-methyl-L-serine	mmunostimulant	cancer

DNA repair enhancers, OXiGENE	Preclinical		immunostimulant	cancer
drug delivery system, Phase III liposome muramyl	, Phase III		immunostimulant	cancer
unpepude- phosphatidylethanola				
mine; drug delivery				
system, liposome MTP-PE; MTP-PE				
liposome				
FCE 24578	Discontinued	alpha-cyano-1,4- dihydro-beta-oxo-	immunostimulant	cancer; bacterial infection
		N,1- diphenyl[1]benzothio		
		pyrano[4,3-c]pyrazole-3-		
100	ł	propanamide		
FCE 25276	Suspended		immunostimulant	cancer; bacterial
FCE 25648	Suspended		immunostimulant	cancer: bacterial
				infection
	Suspended		immunostimulant	cancer; bacterial
FR 901235	Discontinued	T	immunostimulant	cancer
		6-methoxy-7-methyl-	.,	
		phenalene-1,3(2H)-		
HAB 430	_			
	Discontinued	(4,5-dihydro-3- fi phenyl-5-	immunostimulant	cancer; bacterial
		isoxazolyl)phosphoni c acid		

icadamines, Cornell Research Foundation	Preclinical		immunostimulant	viral infection;
idramantone:	Phase I	7.	100000000000000000000000000000000000000	cancer
kemantane		hydroxytricyclo[3.3.1].1(3.7)]decanone	rinitatios cimuratio	cancer
imiquimod; R 837; S	Marketed	1-(2-methylpropyl)-	immunostimulant	viral infection;
26308; DZ 2636; ALDARA; ZARTRA		1H-imadazo[4,5- claninolin-4-amine		cancer
immunostimulant,	Preclinical		immunostimulant	cancer infections
Repligen;				disease
immunostimulant, Pfizer	,			
immunostimulants,	Preclinical		immunostimulant	cancer, autoimmine
Massachusetts			-	disease
General Hospital	-			
JT 3002; CGP 40774 Preclinical	Preclinical		immunostimulant	cancer
KRN 7000	Phase I	[1S-(1R*,2R*,3S*)]-	immunostimulant	cancer
			. C	
		galactopyranosyloxy)		
		methyl]-2,3-		
		dihydroxyheptadecyl] hexacosanamide		
large multivalent immunogen; LMI	Preclinical		mmunostimulant	cancer
	Pre-		immunostimulant	cancer: HIV
DP 2202; PS PG;	registration			infection
LEMONAL,				
lentinan sulfate;	Marketed		immunostimulant	HIV infection;
TV 400				cancer
LK 409	Freclinical	N-(1,7-dioxooctyl)-L-jimmunostimulant		cancer
		glutamine		

loxonoine; KwJ	Discontinued 7-allyl-8-	7-allyl-8-	immunostimulant	cancer
21/3/		oxoguanosine	-	
mirimostim; human	Marketed	1-214-colony-	immunostimulant	cancer
urine derived		stimulating factor 1		
stimulating factor		(human clone		
inducer; CSF-HU; P		p3ACSF-69 protein		
100; LEUKOPROL; COSTILATE		moiety reduced)	,	
MMS 2	Preclinical		immunostimulant	cancer
Nocardia-CWS; N-	Discontinued		imminostimulant	Concor
CWS; rubratine; RUBRATIN				calicel
OM 163	Preclinical	Inchedified	imminoatimiloset	
OM 174	100		minimiosiminani	cancer
OIM 1/4	Fhase I		immunostimulant	cancer
KG 003; KG 136	Discontinued	7.	immunostimulant	HIV infection;
2000				cancer
KM 06	Discontinued		immunostimulant	cancer; transplant
		dihydro-6-oxo-9H-		rejection
		-6-uund		
		yl)pentyl]oxy]carbon		
		yl]-L-leucyl]-L-		
		methionine		
romurtide;	Marketed	2-acetamido-3-0- ji	immunostimulant	cancer: bacterial
muroctasin; MDP-				infection
Lys (L18); MDP-Lys;		1-carbamoyl-3-[((S)-		
DJ 7041; NOPIA		1-carboxy-5-	-	
-		stearamidopentyl)carb		
		amoyl]propyl]carbam		
		oyl]ethyl]carbamoyl]e		
		thyl]-2-deoxy-D-		
		glucopyranose		

RS 0481 S 0481	Discontinued	[D (D* D*)] 2		
1000	Donining Co.	-C-[('A',A)-A]	liminosumulant	cancer
<u>.</u>		oenzoyl-N-(1- phenylethyl)-4-		
		thiazolidinecarboxami		·.
S 27609	Discontinued	4-omino		
)))	naniminasi	1-allIII0-	nnmunosumulant	cancer
		aipha,alpha,2-		
		imidazo[4,5-	•	
		c]quinoline-1-ethanol	i	
SRL 172	Phase III		immunostimulant	tuberculosis; cancer;
				asthma; bacterial
				infection; leprosy;
QT 780. PCF 30	Dhace T	NI FE CL.		rmmus
	ו וומסב ו	14-15-(hypoxaninin-9-immunostimulant	ımmunostımulant	cancer; bacterial
		VI)pentyloxycarbonyl] -I -aroinine		infection
thymotrinan.	Suchended	T Lines		
thymnomorphism 22 24	panindena		unimmosumulant	cancer
unymopoleum 32-34; RGH 0205: TP3		iysyl)-L-aspartic acid		
vaccine, malienant	Phace II			
melanoma; LP 2307		-		cancer
vaccine, Maruyama;	Pre-		mmunostimulant	cancer
Maruyama vaccine;	registration	-		
SSM				
vaccine, melanoma,	Phase I		immunostimulant	cancer
University of				
Pittsburgh; melanoma				
vaccine				
tiprotimod; HBW 538 Discontinued		2-[(3-	immunostimulant;	mycosis; cancer
		oy])thio]-	antifungal	
		4-methyl-5-	-	
		thiazoleacetic acid		

MGN 3	Phase I	Unspecified	immunostimulant;	cancer
			biological response modifier	
NSC 631570; E	Pre-	5,5',5"-	immunostimulant;	cancer
B238865; UKSR 222;	registration;	Lphospanotaloyadya biological response etris(imino-2.1-	biologicai response modifier	
W 122; UKRAIN		ethanediyl)tris[5-		
		methylchelidoninium]	•	
1	Phase I	-	immunostimulant;	cancer
Immunex; CD40LT			biotechnology	
prolactin	Preclinical		immunostimulant;	cancer; infectious
			biotechnology;	disease
			hormone; vaccine	
			adjuvant	
pentoxifylline:	Discontinued	-	immunostimulant;	cancer
ciprofloxacin;			chemoprotectant;	
ciprofloxacin:		-	cytoprotectant	
pentoxifylline; CT		-		
1500				
acemannan; CARN	Marketed	(1->4),(1->6)-alpha-	immunostimulant;	inflammatory bowel
1000; CARN 750;		D-galacto-beta-D-		disease; skin ulcer;
CARRASYN;		mannan acetate		inflammation: cancer
ALIMINASE;	,			
VORALEX;			-	
CARRAVEX				
tetrachlorodecaoxide; Marketed	Marketed		immunostimulant	skin ulcer. HIV
TCDO; WF 10;				infection: cancer
OXOFERIN				

granulocyte colony stimulating factor mimetic, Ligand/SmithKline Beecham; G-CSF mimetic, Ligand/SmithKline Beecham	Preclinical		immunostimulant; cytokine agonist	cancer; viral infection; bacterial infection
thiethazole Preclinical rabilautide; RP 56142 Discontinued	Preclinical Discontinued	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid threo-6-carbamoyl-N2-[N-(N-lauroyl-1alanyl)-D-gamma-	immunostimulant; immunosuppressant; antioxidant immunostimulant; lipopeptide	cancer; rheumatoid arthritis; infectious disease; transplant rejection bacterial infection;
hemoregulatory peptide, Nycomed immunostimulant peptides, BioChem Pharma	Preclinical Discontinued	glutamyl]-L-lysine	immunostimulant; peptide immunostimulant; peptide	bacterial infection; cancer cancer; viral infection
interleukin-2 receptor Preclinical agonist; IL-2R agonist SUIS-gonadorelin; Phase I SUIS-LHRH	Preclinical Phase I		immunostimulant; peptide immunostimulant;	cancer; HIV infection cancer
thymopoietin receptorPreclinical agonist ubenimex; bestatin; Marketed NK 421; BESTATIN		(-)-N-[(2S,3R)-3- amino-2-hydroxy-4- phenylbutyryl)]-L- leucine	stimulant;	cancer; HIV infection cancer

TOTAL COLUMN				
HEKAMIDE	Suspended		immunostimulant;	cancer; infections
			peptide; oligosaccharide	disease
monophosphoryl lipid Phase III	Phase III	-	immunostimulant;	cancer
A + myobacterium			vaccine adjuvant	
cell wall sk;				
myobacterium cell				
wall skeleton +	-			
monophosphoryl 1;		,		
MPL + CWS;			-	
DETOX				
D5; PM 92114	Discontinued		immunosuppressant	cancer
dehydrodidemnin B;	Preclinical	N-[1-(1,2-	immunosuppressant	viral infection;
DDB		dioxopropyl)-L-	<i>,-</i>	cancer
		prolyl]didemnin A		
dinaline; GOE 1734;	Discontinued	4-amino-N-(2-	immunosuppressant	cancer
NSC 328786;		aminophenyl)benzami		
AAPBA		de		
fluasterone	Phase I		immunosuppressant	cancer; diabetes;
				systemic lupus
				erythematosus
gusperimus;	Marketed	/-(-,+)	immunosuppressant	transplant rejection;
gusperimus		[(aminoiminomethyl)	4	multiple sclerosis;
hydrochloride;		amino]-N-[2-[[4-[(3-		cancer
deoxyspergualin, 15-;		aminopropy!)amino]b		
desoxyspergualin;		utyl]amino]-1-		
DSG; NKT 01; NSC		hydroxy-2-		
356894; BMS		oxoethyl]heptanamide		
181173; BMY 42215-	•-			
1; SPANIDIN; SUPANIDIN				
promedulan;	Discontinued		immunosuppressant	cancer
TERICIMUS				

XENOJECT	Preclinical		immunosuppressant	cancer; autoimmune disease
protein A-based	Preclinical		immunosuppressant;	autoimmune disease;
initialic modulator	 - -		Immunosumulant	cancer
signal transduction	Preclinical		immunosuppressant;	autoimmune disease;
Inodulators, Inanonal Tewish Center for			immunostimulant;	cancer; inflammation
Immunology and			The Carrier	
Respiratory Medicine				
CI 972	Discontinued	2,6-diamino-1,5-	immunosuppressant;	rheumatoid arthritis;
		dihydro-7-(3-	NSAID	cancer; psoriasis
		thienylmethyl)-4H-		•
-		pyrrolo[3,2-		
	. •	d]pyrimidin-4-one		
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		monohydrochlonde		
Ciaumonne, 2-CuA;	Marketed	z-cnioro-z-	immunosuppressant;	cancer; multiple
NSC 105014F; RWJ		deoxyadenosine	nucleoside analogue;	sclerosis; rheumatoid
26251; LEUSTATIN;			NSAID	arthritis
LEUSTAT;				
MYLINAX				
T cell peptide,	Preclinical		immunosuppressant;	autoimmune disease;
University of Illinois			peptide	cancer; bacterial
				infection
	Phase I		immunotoxin;	cancer
PE40; SGN 10; BMS			biotechnology	
191352				
MAb, TES-23-	Discontinued		immunotoxin;	cancer
neocarzinostatin;			biotechnology	
1 ES-23-INCS				

MAN TOO TOLETTO				
MAD, 173-pokeweed Preclinical	Frechnical		immunotoxin;	cancer
viral protein			biotechnology;	
conjugate;			monoclonal antibody	
immunotoxin, TP3-		-		
pokeweed viral				
protein conjugate;				
TP3-PAP				
MAb, doxorubicin-	Preclinical		immunotoxin;	cancer
CEA; DOX-CEA			biotechnology;	
			monoclonal antibody;	
			anthracycline;	
			antibiotic; DNA	
			intercalator	
drug delivery system, Preclinical	Preclinical		integrin antagonist;	cancer
ANCHOR angiostatic			angiogenesis inhibitor;	
agent	-		cell adhesion inhibitor	
S 836	Discontinued		integrin antagonist;	cancer
		-	angiogenesis inhibitor;	
			cell adhesion inhibitor;	
			alpha5 beta3 integrin	
			antagonist	
CDP 850	Preclinical		integrin antagonist;	cancer
			biotechnology; cell	•
			adhesion inhibitor;	
			immunosuppressant;	
			monoclonal antibody;	
			E selectin antagonist	

<u>.</u>		hydroxy-1,5-	cell adhesion inhibitor	
		(phosphonooxy)-		
		7,9,11-tridecatrienyl]-		
		5-methyl-2H-pyran-2-		
		one		
SB 223245 Pre	Preclinical	(S)-7-[[(1H-	ntegrin antagonist;	osteoporosis;
		benzimidazol-2-	cell adhesion inhibitor restenosis; cancer	restenosis; cancer
		ylmethyl)methylamin		
		o]carbonyl]-2,3,4,5-		
		tetrahydro-4-methyl-		
		3-oxo-1H-1,4-		
		benzodiazepine-2-		
-		acetic acid	•••	
	Preclinical		integrin antagonist;	osteoporosis; cancer;
antagonists, DuPont			cell adhesion inhibitor; restenosis	restenosis
-			alpha5 beta3 integrin	
-		CS.	antagonist	

IC 101	Preclinical .	(alphaS,2R,5S,6R)-6- integrin antagonist; ethyltetrahydro-alpha-cell adhesion inhibi 2-dihydroxy-alpha-cell adhesion inhibi 2-dihydroxy-alpha-cell adhesion inhibi 2-dihydroxy-1-leucyl-hex ahydroxy-L-leucyl-hexahyd ro-3-pyridazinecarbonyl-hexahyd ro-3-pyridazinecarbonyl-N-hydroxy-D-Alanine (7->2)-lactone	(alphaS,2R,5S,6R)-6- integrin antagonist; cancer; b ethyltetrahydro-alpha-cell adhesion inhibitor; infection 2-dihydroxy-alpha-immunostimulant; methyl 1-5-(3-byran-2-acetyl-(3S)-byran-2-acetyl-(3S)-byridazinecarbonyl-N-hydroxy-L-laucyl-hexahyd ro-3-byridazinecarbonyl-hydroxy-D-Alanine (7->2)-lactone	cancer; bacterial infection
anti-inflammatory agents, Chiroscience/Trega	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
cell adhesion inhibitor, GlycoTech/Novartis	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
drug delivery system, STEALTH cell adhesion inhibitors			integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
GM 7050	Discontinued		integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
RGD-based angiogenesis antagonists	Preclinical		integrin antagonist; NSAID; cell adhesion inhibitor	cancer, rheumatoid arthritis; eye disease

drug delivery system, Discontinued	Discontinued	interferon	cancer
interferon alfa;		 	
interferon alfa depot delivery; MPI 7057			
drug delivery system, Preclinical	Preclinical	interferon	cancer; viral
transdermal			infection
BIPHASIX interferon			
alfa; interferon alfa		-	-
transdermal			
interferon alfa;	Marketed	interferon	cancer; viral
BALL-1; MR 22;			infection; mucositis;
BALL 1; OIF; IFN	-	•	musculoskeletal
ALPHA MOCHIDA			disorder
interferon alfa;	Marketed	interferon	cancer; viral
Interferon Alfanative			infection
interferon alfa-n3;	Marketed	interferon	viral infection;
KEMRON;	•		cancer
ALFERON;			
ALFERON N;			
ALFERON LDO;			
ALTEMOL;			
REFERON			
n beta;	Marketed	interferon	multiple sclerosis;
			cancer; eye disease
	Marketed	interferon	cancer
natural; IFN gamma,		 -	
natural; OH 6000;			
OGAMMA 100			
interferon-alpha; IFN-Preclinical	Preclinical	interferon;	cancer; viral
\neg		 biotechnology	infection
ron, modified,	Preclinical	interferon;	cancer
Lanox		biotechnology;	
		immunosuppressant	

leukocyte alpha	Marketed		interferon;	viral infection;
interteron; ALFAFERONE; CILIFERON			immunostimulant	cancer
doretinel; BASF 47011; RWJ 20257; ORF 20257	Discontinued	(E)-1,2,3,4- tetrahydro-7-[2-[4- (hydroxymethyl)phen yl]-1-methylethenyl]- 1,1,4,4- tetramethylnaphthalen ol	keratolytic	cancer
U 74389	Preclinical	Unspecified	lazaroid	cancer
U 74500A	Preclinical	21-[4-[3,6-	lazaroid	cerebrovascular
		ois(dietnylamino)-2- pyrindinyl]-1-		disease; cancer
		piperazinyl]-16-	-	
		methylpregna-		
	,	dione hydrochloride		
lysofylline;	Phase III		lysophosphatidate	cancer;
Isofylline; CT			acyltransferase	cardiovascular
1501R; ProTec		dimethylxanthine	inhibitor; xanthine	disease; respiratory
breflate; NSC	Preclinical	N.N-dimethyl-	macrolide: antibiotic	Cancer
656202; NAS 656202				
		(1R*,2E,6S*,10E,11a		
		S*,13S*,14aR*)]-	-	
		1,6,7,8,11a,12,13,14,1		
	-	4a-decahydro-1-	-	
		hydroxy-6-methyl-4-		
		cyclopent[f]oxacyclot		
	_=	ridecin-13-yl ester		

duocarmycin SA; DC Discontinued	Discontinued	(7bR)-1,2,4,5,8,8a-	macrolide; antibiotic	bacterial infection;
1113		hexahydro-4-oxo-2-		cancer
		[(5,6,7-trimethoxy-1H-indol-2-		
· · · · · ·		yl)carbonyl]cycloprop		
		a[c]pyrrolo[3,2-		
		e]indole-6-carboxylic		
rhizoxin; lizoxine	Phase II	Ī	macrolide: antibiotic	cancer
drug delivery system,	Discontinued		macrophage	cancer
liposome CGP 31362;			stimulator;	
CGP 31362 liposome; MLV-CGP 31362		:	immunostimulant	
GPX 325	Preclinical		MAO inhibitor;	cancer
		· · · · · · · · · · · · · · · · · · ·	chemoprotectant;	
		e de la composición della comp	cytoprotectant;	
			radioprotectant	
matrilysin inhibitors, Preclinical	Preclinical		matrilysin inhibitor;	cancer
Affymax			matrix	
-			metalloproteinase	
		·	inhibitor; proteinase	-
			inhibitor	
matrix	Discontinued	- F -	matrix	arthritis; periodontal
metalloproteinase				disease; skin ulcer;
inhibitors,			inhibitor; cicatrizant;	cancer
Osteo Arthritis;		•	proteinase inhibitor;	
cartilage degrading			NSAID	
enzyme inhibitors,		· =		
Osteo Artuntus;				
TORS		10.70		

anticancer matrix	Preclinical		matrix	cancer
metalloproteinase inhibitors			metalloproteinase	
	-		inhibitor	
CMT 3; COL 3; NSC Phase I	Phase I	(4aS,5aR,12aS)-		cancer
683551; METASTAT		1,4,4a,5,5a,6,11,12a-	_	
		octahydro-	inhibitor; proteinase	
		3,10,12,12a-	inhibitor	
		tetrahydroxy-1,11-		
		dioxo-2-		·
		naphthacenecarboxam		
		ide		
D 1927	Preclinical		matrix	cancer
•••			metalloproteinase	
	•		inhibitor; proteinase	-
			inhibitor	
D 2163	Phase I		matrix	cancer
	•		metalloproteinase	
			inhibitor; proteinase	
ilomastat; GM 6001; Phase III	Phase III	-I]-IN		retinopathy;
CS 610;				diabetes; cancer
GALARDIN;			se	
GALARDIN MPI		(methylamino)-2-	inhibitor	
		oxoethyl]-2-(2-		-
		methylpropyl)-		
		OutailCutailiuc		

marimastat; BB 2516; Phase III TA 2516	; Phase III	(2S,3R)-N4-[(1R)- 2.2-dimethyl-1-	matrix metallonroteinase	cancer
		9	inhibitor; proteinase	
			inhibitor	
		methylpropyl)butaned iamide		
matrix	Preclinical		matrix	cancer
metalloproteinase			metalloproteinase	
inhibitors, Agouron			inhibitor; proteinase	
S 3304	Phase I		-	cancer inflammation
			inhibitor; proteinase	
			inhibitor	
prinomastat; AG 3340Phase III	Phase III	Unspecified		cancer; retinopathy
			metalloproteinase	•
			inhibitor; proteinase	
			inhibitor; angiogenesis	
			inhibitor	
CH 104	Discontinued			cancer; inflammation
		<u> </u>	metalloproteinase	
			inhibitor; proteinase	
			inhibitor; NSAID	
CH 715	Discontinued			cancer; inflammation
		-	metalloproteinase	
		· —	inhibitor; proteinase	•
			inhibitor; NSAID	
matrix	Preclinical			periodontal disease;
metalloproteinase		- 1-3		kidney disease;
inhibitor, State		- p-4	ase	cancer; arthritis;
University of New		· · · · ·		osteoporosis
TOIL				

matrix	Preclinical		matrix	cancer; arthritis
metalloproteinase			metalloproteinase	
inhibitors, ProScript			inhibitor; proteinase	
00.14	,		itilibitor, INSAID	
F1 88	Phase I		matrix	inflammation; cancer
			metalloproteinase	
			inhibitor; proteinase	
			inhibitor; NSAID	
solimastat; BB 3644 Phase l	Phase I	(2S,3R)-3-[[)1S)-2,2- matrix	matrix	multiple sclerosis;
		dimethyl-1-(2-	metalloproteinase	rheumatoid arthritis;
		pro	inhibitor; TNF	inflammatory bowel
		oyl]-2-	inhibitor; proteinase	disease; cancer
		methoxy-5-	inhibitor	
		methylhexanohydroxa		
		mic acid		
BIBW 22; BIBW 22BS	Discontinued		MDR inhibitor	cancer
biricodar; biricodar	Phase II	(S)-1-[oxo(3,4,5-	MDR inhibitor	cancer
dicitrate; VX 710;		trimethoxyphenyl)ace		
INCEL		tyl]-2-		
		piperidinecarboxylic	-	
		acid 4-(3-pyridinyl)-		
		1-[3-(3-	;	
		pyridinyl)propyl]buty		
		l ester		•
buthionine	Phase I	(2S)-2-amino-4-(S-	MDR inhibitor	cancer
sulfoximine; BSO;		butylsulfonimidoyl)b		
NSC 326231		utanoic acid		

dexniguldipine; (+)- niguldipine; (R)- niguldipine; niguldipine, (R)-; B 8509035; BY 935	Discontinued	(R)-1,4-dihydro-2,6- MDR inhibitor dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid 3-(4,4-diphenyl-1-piperidinyl)propyl methyl ester	MDR inhibitor	cancer
drug delivery system, liposome ciclosporin; ciclosporin liposome; CYCLOXOME	Discontinued		MDR inhibitor	cancer
flezelastine; D 18024 Preclinical	Preclinical	4-((4- fluorophenyl)methyl) 2-(hexahydro-1- (phenylethyl)-1H- azepin-4-yl)-1(2H)- phthalazinone monohydrochloride	MDR inhibitor	cancer
н 85	Preclinical	N-[2-[[3-(4- chlorophenyl)-2- propenyl]formylamin o]ethyl]-5- isoquinolinesulfonam ide	MDR inhibitor	cancer
LU 49667	Discontinued		MDR inhibitor	cancer
LU 51903	Discontinued		MDR inhibitor	cancer
MDR inhibitor, BioNumerik	Preclinical		MDR inhibitor	cancer
MDR inhibitor, Xenova	Preclinical		MDR inhibitor	cancer
MDR inhibitors, Fox Chase Cancer Center	Preclinical		MDR inhibitor	cancer

MS 209	Phase II	4-(diphenylacetyl)-	MDR inhibitor	cancer
		alpha-[(5-		
		quinolinyloxy)methyl		-
]-1-piperazineethanol,		
		(E)-2-butenedioate		
		(2:3)		
NA 382	Preclinical	,	MDR inhibitor	cancer
		7-oxostaurosporine	•	
PAK 104P	Preclinical	trans-5-(4,6-dimethyl-MDR inhibitor	MDR inhibitor	cancer
-		2-oxido-1,3,2-		
		dioxaphosphorinan-2-		
	•	yl)-2,6-dimethyl-4-(3-		
		nitrophenyl)-3-		
		pyridinecarboxylic		
		acid 2-[4-		
		(diphenylmethyl)-1-	-	
		piperazinyl]ethyl	-	-
		ester trihydrochloride		
propyl bis-acridone	Preclinical	cridin-	MDR inhibitor	cancer
		10-y1)propane		
R 101933	Phase I		MDR inhibitor	cancer
Ro 112933	Discontinued N-[2-(3,4-	-		cancer
		dimethoxyphenyl)eth		
		yl]-N-methyl-2-(2-		
		naphthalenyl)-1,3-		
		dithiane-2-		•
		propanamine		
		nyarochloride		

2 16200	Descriptor 1			
(0701)	r recuiricai		MUK innibitor	cancer
		dichlorophenyl)-1,4-		
		dihydro-2-methyl-6-		
		[[2-[2-[[(4-		
		nitrophenyl)methyl]a		
		mino]ethoxy]ethoxy]	· ÷.	
-		methyl]-3,5-		
		pyridinedicarboxylic		
		acid 5-ethyl 3-methyl		
		ester		
S 16317	Preclinical		MDR inhibitor	cancer
		dihydro-2-methyl-6-		
		[[2-[2-[(4-		
		pyridinylmethyl)amin		
		o]ethoxy]ethoxy]meth		
		yl]-3,5-		
		pyridinedicarboxylic		
		acid 5-ethyl 3-methyl		-
		ester		
S 16324	Preclinical	(+)-4-(2,3-	MDR inhibitor	cancer
		dichlorophenyl)-1,4-		
		dihydro-2-methyl-6-		
		[[2-[2-[(3-		
		thienylmethyl)amino]		
_		ethoxy]ethoxy]methyl		
]-3,5-		
		pyridinedicarboxylic		
		acid 5-ethyl 3-methyl		
		ester		

0000				
88/62	Discontinued	Discontinued 6-[4-[[2,2-bis(4-	MDR inhibitor	cancer
		fluorophenyl)ethyl]a		-
		mino]-1-piperidinyl]-		
		N,N'-di-2-propenyl-		
		1,3,5-triazine-2,4-		
		diamine		
SB RA 31012	Preclinical		MDR inhibitor	cancer
SDZ 214103	Discontinued	2-(3-methyl-D-2-	MDR inhibitor	Cancer
		hydroxybutanoic		
	-	acid)-4-L-leucine-7-	.	
		L-threonine-10-L-		-
		leucinecyclosporin A		
XR 1500	Suspended	Γ-	MDR inhibitor	Concor
CRL 1336	Discontinued		MDR inhibitor;	cancer
			chemosensitizer	
valspodar; SDZ	Phase III		MDR inhibitor;	cancer
FSC833; FSC 833;			chemosensitizer; P	
SDZ PSC 833;			glycoprotein inhibitor	
AMUKAY		oic acid]-		
		7-L-valine-	-	
		cyclosponn A		
elacridar; GF 120918; Suspended		N-[4-[2-(3,4-dihydro-MDR inhibitor; P	MDR inhibitor; P	cancer
81600		6,7-dimethoxy-2(1H)-glycoprotein inhibitor	glycoprotein inhibitor	
		isoquinolinyl)ethyl]p		-
		henyl]-9,10-dihydro-		
		5-methoxy-9-oxo-4-	-	
		acridinecarboxamide		
				_

dimesylate; VX 853				
		alpha-	glycoprotein inhibitor	
		[methyl[oxo(3,4,5-		
		trimethoxyphenyl)ace		
		tyl Jamino]-N-		
		(phenylmethyl)-N-[3-		
		(4-pyridinyl)-1-[2-(4-	-	
		pyridinyl)eth		
		yl]propyl]benzenepro panamide		
XR 9051 Su	Suspended	2-(3,4-	MDR inhibitor; P	cancer
_		dihydro-6,7-	glycoprotein inhibitor	
		dimethoxy-2(1H)-	•	
		isoquinolinyl)ethyl]p		
		henyl]-4-[[4-methyl-		
		3,6-dioxo-5-		
		(phenylmethylene)pip		
		erazinylidene]methyl]		
		benzamide		
SDZ 280446 Dia	Discontinued	cyclo[N-methyl-L-	hibitor;	cancer
		alpha-Asp-N-methyl- peptide	peptide	
		L-Ile-N-methyl-L-Ile-		
		Gly-N-methyl-L-Val-	-	
		O-methyl-L-Tyr-(2S)-		
		2-hydroxypropanoyl-		
-		(2S)-2-		
		piperidinecarbonyl-N-	•	
		methyl-L-Val-L-Val],	-	
		1,1-dimethylethyl	-	
		ester		

melanostatin; BMY 28566; BU 3619E	Discontinued	(S)-3-[[1-carboxy-2-(1H-imidazol-4-yl)ethyl]amino]-N-(N-methyl-L-phenylalanyl)-L-	melanin synthesis inhibitor	cancer
lithium gammalinolenate; EF 13; GLAMOLEC	Discontinued	alanine	metalloproteinase inhibitor; proteinase	cancer; HIV infection
PGE 2946979	Preclinical	3- metalloproteinase [(hydroxyamino)carb inhibitor; proteinase onyl]-4-[(4- inhibitor methoxyphenyl)sulfo nyl]-1- piperazinecarboxylic acid phenylmethyl	metalloproteinase inhibitor; proteinase inhibitor	inflammation; cancer
metalloproteinase inhibitors, Syntem	Preclinical		metalloproteinase inhibitor; proteinase inhibitor: NSAID	cancer; arthritis
BW 1069C85	Suspended		nbly	cancer
cryptophycin 52; LY Phase I 355703	Phase I		ule assembly	cancer
		nydroxy-1-0x0-6- [(2R,3R)-3- phenyloxiranyl]-2- heptenyl]-O-methyl-		
		tyrosyl-2,2-dimethyl- beta-alanyl-2- hydroxy-4-methyl-		
		pentanoic acid (3fwdarw1)-lactone		

cryptophycin 8	Preclinical	(2S)-3-chloro-N-	microtubule assembly cancer	cancer
		[(2E,5S,6R,7R,8S)-8- inhibitor	inhibitor	
		chloro-5,7-dihydroxy-	-	
		6-methyl-1-oxo-8-	-	-
	•	phenyl-2-octenyl]-O-		
		methyl-D-tyrosyl-		
		(2R)-2-methyl-beta-		
		alanyl-2-hydroxy-4-		
		methylpentanoic acid		
		(3->15)-lactone		
cryptophycin A	Preclinical	•	microtubule assembly cancer	cancer
derivatives, Wayne			inhibitor	
State University				
D 24851	Preclinical	1-[(4-	microtubule assembly cancer	cancer
		chlorophenyl)methyl] inhibitor	inhibitor	
		-alpha-oxo-N-4-		
		pyridinyl-1H-indole-		
		3-acetamide	•	
pothilone	Preclinical		microtubule assembly cancer	cancer
			inhibitor	

SD-14411

j(i,j)

Preclinical	N-acetyl-N-methyl-L- alanine [1S- (1R*,2S*,3R*,5R*,6 R*,16E,18E,20S*,21	N-acetyl-N-methyl-L-microtubule assembly cancer alanine [1S-inhibitor (1R*,2S*,3R*,5R*,6 R*,16E,18E,20S*,21	cancer
	hydroxy-12,20- dimethoxy-2,5,9,16- tetramethyl-8,23- dioxo-4,24-dioxa- 9,22-		
	orazatetracycio 19.3.1 110,14.03.5]hexacos a-10,12,14(26),16,18- pentaen-6-yl ester		
Phase I	2-fluoro-1-methyl-4- microtub pentafluorophenylsulfinhibitor	ule assembly	cancer
Preclinical		microtubule assembly cancer inhibitor	cancer
Preclinical		ule assembly ; angiogenesis	cancer
Preclinical	8.2	ule assembly ; antibiotic	cancer
	thyl-L- liyl-N- valyl-L-	microtubule assembly inhibitor; peptide	cancer
	prolyl-N- (phenylmethyl)-L- prolinamide		

1

(3)

valy1-L-valy1-N- methy1-L-valy1-N- methy1-L-valy1-L- proly1-L-valy1-L- proly1-L-valy1-L- proly1-L-valy1-L- proly1-L-valy1-L- proly1-L-valy1-N- linky1-N-N- s,11R*,12R*,16S*]- 7,11-dihydroxy- 8,8,10,12- tetramethy1-2-(2-methy1- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methy1]) Preclinical (B is [1S-, 16-methy1]) Preclinical (B is [1S-, 16-methy1])	LU 223651	Preclinical	N.N-dimethyl-1.	microfinhine assembly cancer	Cancer
methyl-L-valyl-L- prolyl-L-prolin-Tert. butylamide [1R*,3R*(E),7R*,10Smicrotubule assembly *,11R*,12R*,16S*]- promoter 7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical [2S-N,N-dimethyl-L- walyl-N-[2-methoxy- 4-[2-[1-methoxy methyl-3-oxo-3-[(2- phenethyl]amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- cycbutyl]-N-methyl- lvalinamide [S)-(5-amino-1,2- dihydro-2-methyl-3- phenylpyrido(3,4- b)pyrazin-7- yl)carbamic acid ethyl ester			valyl-L-valyl-N-	inhibitor; peptide	
proly1-L-prolin-Tert. butylamide Preclinical [IR*,3R*(E),7R*,10Smicrotubule assembly *,11R*,12R*,16S*]- 7,11-dihydroxy- 8,8,10,12- tetramethy1-3-[1- methy1-2-(2-methy1- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methy1)] Preclinical Ris [1S-, 16-methy1]- A-[2-Inethoxy- methy1-3-oxo-3-[(2- methy1-3-oxo-3-[(2- phenethy1)amino]prop y]-1-pyrrolidiny1]-1- (1-methy1propy1)-4- oxobuty1]-N-methy1- L-valinamide Phase II (S)-(5-amino-1,2- dihydro-2-methy1-3- phenylpyrido(3,4- phenylpyrido(3,4- phenylpyrazin-7- yl)carbamic acid ethy1 ester			methyl-L-valyl-L-	• •	
Preclinical [IR*,3R*(E),7R*,10Smicrotubule assembly *,11R*,12R*,16S*]- 7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl)] Preclinical Preclinical Bis [1S-, 16-methyl] Preclinical Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy- 4-[2-[1-methyx-2- methyl-3-oxo-3-[(2-bhenethyl)amino]propyl]-1-(1-methylpamino]propyl]-1-(1-methylpynidolyl-1- oxobutyl]-N-methyl- (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor byzarin-7- yl)carbamic acid ethyl ester			prolyl-L-prolin-Tert.		
Preclinical [1R*,3R*(E),7R*,10Smicrotubule assembly *,11R*,12R*,16S*]- promoter 7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl]) Preclinical Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy- 4-[2-[1-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- oxobutyl]-N-methyl- chase II (S)-(5-amino-1,2- dihydro-2-methyl-3- phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			butylamide		
,11R,12R*,16S*]- 7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl)- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl)] Preclinical Phase I [2S-N,N-dimethyl-L- valyl-N-[2-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- oxobutyl]-N-methyl- dihydro-2-methyl-3- phenylpyrido(3,4- phenyl	epothilones	Preclinical	[1R*,3R*(E),7R*,10S	microtubule assembly	cancer
7,11-dihydroxy- 8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl)] Preclinical Phase I [2S-N,N-dimethyl-L- valyl-N-[2-methoxy-2- methyl-N-[2-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- oxobutyl]-N-methyl- dihydro-2-methyl-3- phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			*,11R*,12R*,16S*]-	promoter	-
8,8,10,12- tetramethyl-3-[1- methyl-2-(2-methyl- 4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl)] Preclinical Rais [1S-, 16-methyl] Preclinical Rais [1S-, 16-methyl] Phase I [2S-N,N-dimethyl-L- mitosis inhibitor of valyl-N-[2-methoxy-2- methyl-3-oxo-3-[(2-phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- oxobutyl]-N-methyl- chase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			7,11-dihydroxy-		
tetramethyl-3-[1- methyl-2-(2-methyl- 4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical Ris [1S-, 16-methyl- valyl-N-[2-methoxy- 4-[2-[1-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- oxobutyl]-N-methyl- dihydro-2-methyl-3- phenylpyrido(3,4- b)pyrazin-7- yl)carbamic acid ethyl ester			8,8,10,12-		
methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2-dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor) hyprazin-7-yl)carbamic acid ethylester			tetramethyl-3-[1-		
4-thiazolyl)ethenyl]- 4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S., 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-4-[2-[n-methyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- cxobutyl]-N-methyl- dihydro-2-methyl-3-mitosis inhibitor; dihydro-2-methyl-3-mitosis inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			methyl-2-(2-methyl-		
4,17- dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7-yl)carbamic acid ethyl			4-thiazolyl)ethenyl]-		-
dioxabicyclo[14.1.0]h eptadecane-5,9-dione (B is [1S-, 16-methyl) Preclinical Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4- oxobutyl]-N-inethyl- cyobutyl]-N-inethyl- dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl			4,17-		
Preclinical mitosis inhibitor Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-4-[2-l1-methoxy-2-methyl]amino]prop yl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor b)pyrazin-7-yl)carbamic acid ethyl			dioxabicyclo[14.1.0]h		-
Preclinical mitosis inhibitor Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]prop yl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-dinyl-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-3-dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor b)pyrazin-7-yl)carbamic acid ethyl			eptadecane-5,9-dione		
Preclinical mitosis inhibitor Phase I [2S-N,N-dimethyl-L-mitosis inhibitor valyl-N-[2-methoxy-4-[2-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]prop yl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-1-L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor b)pyrazin-7-yl)carbamic acid ethyl			(B is [1S-, 16-methyl)		
Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy-4-[2-l-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-D-methyl-1-L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor) b)pyrazin-7-yl)carbamic acid ethyl ester	antimitotics,	Preclinical		mitosis inhibitor	cancer
Phase I [2S-N,N-dimethyl-L- mitosis inhibitor valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-D-methyl-1-L-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor) b)pyrazin-7-yl)carbamic acid ethyl ester	Nanodesign				-
valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-valinamide Phase II (S)-(5-amino-1,2-mitosis inhibitor; dihydro-2-methyl-3-tubulin polymerase phenylpyrido(3,4-inhibitor)lyl)carbamic acid ethylester	TZT 1027	Phase I	[2S-N,N-dimethyl-L-	mitosis inhibitor	cancer
4-[2-[1-methoxy-2- methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- dihydro-2-methyl-3- phenylpyrido(3,4- b)pyrazin-7- yl)carbamic acid ethyl ester			valyl-N-[2-methoxy-		
methyl-3-oxo-3-[(2- phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- dihydro-2-methyl-3- phenylpyrido(3,4- b)pyrazin-7- yl)carbamic acid ethyl ester			4-[2-[1-methoxy-2-		
phenethyl)amino]prop yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			methyl-3-oxo-3-[(2-		
yl]-1-pyrrolidinyl]-1- (1-methylpropyl)-4- oxobutyl]-N-imethyl- L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			phenethyl)amino]prop		
(1-methylpropyl)-4- oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester		,	yl]-1-pyrrolidinyl]-1-		
oxobutyl]-N-methyl- L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			(1-methylpropyl)-4-		
L-valinamide Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl			oxobutyl]-N-methyl-		
Phase II (S)-(5-amino-1,2- mitosis inhibitor; dihydro-2-methyl-3- tubulin polymerase phenylpyrido(3,4- inhibitor b)pyrazin-7- yl)carbamic acid ethyl ester			L-valinamide		
dihydro-2-methyl-3- phenylpyrido(3,4- b)pyrazin-7- yl)carbamic acid ethyl ester	mivobulin; CI 980;	Phase II			cancer
- ethyl	NSC 613862(-)			tubulin polymerase	
b)pyrazin-7- y1)carbamic acid ethy1 ester				inhibitor	
yl)carbamic acid ethyl ester			b)pyrazin-7-		
ester			yl)carbamic acid ethyl		
			ester		